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Abstract 
Background and Purpose: In 2014, a multidisciplinary breast cancer group developed and 
disseminated a clinical practice guideline to assist surgeons in choosing eligible patients, 
with locally advanced or inflammatory breast cancer, for whom a referral should be sent 
to medical oncology for consideration of neoadjuvant treatment. However, it was unclear 
whether surgeons had been adhering to this guideline. The purpose of this practicum was 
to compare the neoadjuvant referral rates pre- and post-guideline dissemination and 
evaluate the effects of patient/tumor/facility-related factors on surgeons’ decision to refer. 
Methods: (1) literature review; (2) consultation with key stakeholders; (3) chart review; 
and (4) recommendations. 
Results: The factors of interest and methods were informed by the literature review and 
the consultations. During the chart review process, data were collected on 47 and 54 
patient cases from 2013 (pre-guideline) and from 2016 (post-guideline), respectively. All 
patient cases of inflammatory breast cancer were referred for both study years. In contrast, 
the referral rates for all cases of locally advanced breast cancer was 23.3% and 26.9%. In 
2016, patients were more likely to be referred if they had positive lymph node 
involvement, AJCC stages of IIIA and IIIC, triple negative subtypes, or received 
definitive surgery at university-affiliated hospitals.   
Conclusion: There has been little to no improvement for guideline adherence between the 
study years and the referral rates for eligible patients were poor. Future efforts to clarify 
the guideline and improve referral appear to be warranted.    
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Introduction 
The Eastern Health Breast Disease Site Group (BDSG) has been developing and 
disseminating clinical practice guidelines for the screening, diagnosis and management of 
breast cancer within Eastern Health and for the provincial Cancer Care Program of 
Newfoundland and Labrador for several years. However, limited resources had prevented 
any meaningful measurement of outcomes from the development of these clinical practice 
guidelines. At a recent monthly BDSG meeting, the concern was raised that some eligible 
patients with newly diagnosed, locally advanced breast cancer were not being referred by 
surgeons to the discipline of medical oncology for a discussion regarding neoadjuvant 
therapy. This is contradictory to the recommendations of a BDSG guideline entitled 
“Neoadjuvant Treatment of Primary Breast Cancer” approved on July 4, 2014 by the 
Cancer Care Program and which had been disseminated to all surgeons in the province of 
Newfoundland and Labrador (NL). The group suggested that this practicum project would 
be an excellent opportunity to determine whether this guideline was having any impact on 
the number of patient referrals from surgeons for consideration of neoadjuvant therapy 
within the province of Newfoundland and Labrador.  
Background 
The 2010 American Joint Committee on Cancer (AJCC) staging manual, 7th ed., 
describes the staging of cancer as being based on the TNM system, where T denotes the 
size of the tumor, N as the extent of lymph node invasion, and M as the presence (or 
absence) of metastatic spread of disease (Edge et al., 2010). According to the Eastern 
Health BDSG guideline, locally advanced breast cancers are defined as having disease 
with either a “…primary tumor greater than 5 cm in diameter or that involves the skin or 
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chest wall” (represents a T3 or T4 tumor size), or “… (those) with fixed axillary lymph 
nodes or ipsilateral supraclavicular, infraclavicular, or internal mammary nodal 
involvement” (representing a N2 or greater), or both without evidence of distant 
metastatic spread (Eastern Health, 2014, p.10). According to Singletary et al. (2002), the 
AJCC staging system also recognizes locally advanced breast cancer to be any stage III 
(e.g., T3N1M0, T1N2M0) or one subset of stage IIB (i.e., T3N0M only). A copy of the 7th 
edition of the AJCC breast cancer staging guide, located in Appendix A, outlines the T 
sizes, nodal (N) and metastases (M) classifications. Inflammatory breast cancer, a T4 
disease, is also a subtype of locally advanced breast cancer however due to its distinct 
biology and clinical presentation, it is typically always considered separately. The Eastern 
Health neoadjuvant guideline describes inflammatory breast cancer as a rare and 
particularly aggressive type of disease characterized by erythema and edema of the breast 
which gives the breast a peau d’orange or orange peel appearance (2014).   
 Neoadjuvant therapy is antineoplastic therapy (e.g., chemotherapy, hormonal 
therapy, monoclonal antibodies, or occasionally, radiation therapy) which is administered 
prior to definitive surgery (e.g., lumpectomy, partial mastectomy, total mastectomy), in an 
effort to reduce tumor burden and produce an improved surgical result. Adjuvant therapy, 
on the other hand, is the use of antineoplastic therapy after the definitive surgery has 
taken place. Neoadjuvant therapy has been used for many years to treat patients with 
inflammatory breast cancer or those who are not surgical candidates due to extensive 
local disease.  
Early research has indicated that there has been no survival advantage (disease-free 
survival or overall survival) for the use of neoadjuvant therapy over that of adjuvant 
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therapy however, neoadjuvant therapy has been found to offer other advantages which 
adjuvant treatment cannot (Mauri, Pavlidis, & Ioannidis, 2005; Mieog, van der Hage, & 
van de Velde, 2007). Neoadjuvant therapy has the potential to shrink tumor size; improve 
the cosmetic surgical result; allow for in vitro assessment of tumor response to treatment; 
provide individualized treatment at a systemic level earlier; and downstage the axilla to 
allow sentinel node biopsy in select cases (Buzdar et al, 2005; Gianni et al, 2010; 
Teshome & Hunt, 2014; Zhang & Hurvitz, 2016).  
There have been many developments in the diagnosis and treatment of breast cancer 
in last forty years with the discovery of predictive tumor biomarkers and molecular 
subtyping, and the introduction of targeted therapy agents. Recent evidence from two 
meta-analyses has suggested that neoadjuvant therapy can offer some survival advantage 
for patients diagnosed with breast cancers having a human epidermal growth receptor 
(HER2) positive or triple negative subtype (Broglio et al., 2016; Houssami, Macaskill, 
von Minckwitz, Marinovich, & Mamounas, 2012). Specialized pathology testing can 
detect the presence/absence of hormonal and tyrosine kinase receptors on the surface of 
breast cancer cells which allow the identification of HER2 positive and triple negative 
breast cancers. HER2 positive subtypes would be breast cancers that are negative for 
estrogen (ER) and progesterone receptors (PR) but over-express the HER2 receptor, while 
a triple negative subtype does not express ER, PR or HER2 receptors. These two 
molecular subtypes tend to be associated with poorer prognostic outcomes than breast 
cancers with luminal subtypes which express high levels of hormonal receptors (ER 
and/or PR).     
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Traditionally, surgeons are often the patient’s first contact within the oncology 
realm which allows them (surgeons) full control over the sequence of treatment offered. 
Though neoadjuvant therapy is the standard of care for locally advanced and 
inflammatory breast cancers, research has found that a substantial number of these 
patients proceed with primary surgery as the first-line treatment option. The reasons for 
this are varied or not clearly understood (Mamounas et al., 2016; Read, Flitcroft, Snook, 
Boyle, & Spillane, 2015). Therefore, it was important to determine what patient-, tumor- 
or facility-related factors were likely to motivate the surgeon to refer. Eligible patients 
should, at least, be offered the opportunity to discuss the option of neoadjuvant therapy 
with a medical oncologist. 
Goals and Objectives 
The primary goal of this practicum project was to evaluate whether surgeons were 
utilizing the referral process for patients with breast cancer to see a medical oncologist as 
intended, and in accordance with the recommendations of an Eastern Health BDSG 
evidence-based clinical practice guideline. The objectives of this practicum project were: 
1. To establish the rates of surgeons’ adherence to evidence-based clinical practice 
guidelines which recommend neoadjuvant therapy for the treatment of locally 
advanced and inflammatory breast cancers;  
2. To determine which, if any, common factors or variables influence the surgeons’ 
decision-making on the sequence of treatment modalities for patients newly diagnosed 
with locally advanced or inflammatory breast cancer; and 
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3. To demonstrate the advanced nursing practice (ANP) competencies of research and 
leadership required in this role as investigator of a program evaluation for clinical 
practice guideline adherence in the management of breast cancer.  
Overview of Methods 
The development of this evaluation project employed three different methods 
which included a comprehensive literature review, consultations/interviews with 
individuals having expertise in their fields, and a retrospective chart review. The initial 
intent in conducting this study was always to use an observational retrospective study 
design. Though retrospective chart reviews are an excellent pre-existing data source for 
research, they are also notorious for missing and incomplete data, lack of consistent 
reporting, and inability to verify certain reported information (Gregory & Radovinsky, 
2012). These types of studies can also compromise the internal validity of a study by 
being particularly vulnerable to selection bias, misclassification bias, and information 
bias. In addition, the rigor of a study can be compromised by fallacies such as poor data 
collection techniques and lack of control for confounding factors. This study was 
conducted using strategies to control for bias and confounding while maintaining, and 
even strengthening, its rigor where possible.  
The most integral components of any study’s methodology are its study design, its 
sampling criteria, data collection process, and analysis of the study results. The methods 
utilized in developing these components for this evaluation project were a review of the 
research evidence which indicated the most common and effective study design for this 
type of project; consultations with experts to narrow the choice of inclusion and exclusion 
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criteria for the study; the use of effective tools to conduct a thorough and consistent 
collection of the necessary data; and an appropriate statistical analysis and interpretation 
of the study’s final results.  
Literature Review Summary 
For this evaluation project, three separate literature searches were conducted in the 
databases of PubMed, Embase, CINAHL, and the Cochrane Library using MeSH terms 
and Boolean operators of “AND” and “OR” as best suited. The searches were limited to 
the time period of January 1, 2010 and January 31, 2018, inclusive. The searches also 
utilized additional filters or limiters which consisted of English language only, full-text 
and human-based studies. The keywords of the first of two literature searches consisted of 
“guideline adherence” (major heading), “cancer”, “oncology”, “audit”, “research 
methods”, and “breast” while the second search included all of the previous terms (except 
“audit” and “research methods”) in addition to the terms “clinical audit”, “medical audit”, 
“quality of healthcare”. The third search utilized the keywords of “surgeon clinical 
decision making”, “neoadjuvant therapy”, and “breast cancer”. The first two searches 
yielded a total of 373 literature research articles, with 39 studies being chosen due to 
relevance to the topic at hand. Four of the studies focused on neoadjuvant therapy while 
the remaining 35 were general breast cancer-related studies, all of which measured 
adherence to a specific oncology clinical practice guideline. The third literature search, in 
addition to a hand search of the available studies, produced 11 research articles from 
which five were suitable for use in this evaluation. Refer to Appendix B for a copy of the 
literature review report.    
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The purpose of the first search had been to isolate research studies which measured 
adherence to a specific clinical practice guideline on the use of neoadjuvant therapy in the 
treatment of non-metastatic invasive breast cancer. The four neoadjuvant research studies 
were all rated as medium for quality as per the Public Health of Canada’s (PHAC) critical 
appraisal tool kit (2014). Therefore, it was appropriate to consider emulating certain 
features of the methodology used in these research studies, such as type of study design, 
various patient/tumor/facility characteristics examined, and similarities in results for use 
in this evaluation project. Two of these research studies focused on the locally advanced 
breast cancer cohort only (Killelea et al., 2015; Spronk et al., 2017), one focused on an 
inflammatory breast cancer cohort only (Lin et al., 2017), while the remaining study 
included both the locally advanced and the inflammatory breast cancer cohorts 
(Mohiuddin et al., 2016).  
Three of the four studies mentioned above were helpful in providing an expected 
rate for guideline adherence for both cohorts of interest. The range of surgeon adherence 
rates to neoadjuvant treatment guidelines for patients diagnosed with stage III locally 
advanced breast cancer was 44% to 79%, while the range of adherence was 
approximately 72% to 93% for those diagnosed with inflammatory breast cancer (Lin et 
al., 2017; Mohiuddin et al., 2016; Spronk et al., 2017). For all stage III locally advanced 
breast cancers, Mohiuddin and colleagues (2016) reported an adherence rate of 44% to 
79% to a neoadjuvant guideline while Spronk and associates (2017) found a rate of 79%. 
For the inflammatory breast cancer cohort, Mohiuddin et al. identified an adherence rate 
of 93% while Lin and colleagues (2017) reported an adherence rate of 72% using tri-
modality therapy (surgery, chemotherapy/endocrine therapy, radiation therapy). Killelea 
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and associates (2015) did not analyze their study results according to AJCC stage as did 
the others. Rather, these authors used the T stage and N status as the means by which to 
conduct their analysis and reported that 25% of the breast cancers referred for 
neoadjuvant treatment had a T2 tumor size (> 2cm but ≤ 5cm) while 58% had a T3 tumor 
size (> 5cm). Killelea et al. found that overall, 16.7% of all patients with T3 or smaller 
tumors who were categorized as having locally advanced breast cancer (either before or 
after definitive surgery) received neoadjuvant therapy.   
Three of these studies were American and the results of all three found an increase 
in utilization of guideline-recommended therapy over the study period (Killelea et al., 
2015; Lin et al., 2017; Mohiuddin et al., 2016). Killelea and associates found 
approximately a 7% increase in guideline adherence while Lin and colleagues found an 
8% increase. Mohiuddin et al. used an adjusted risk ratio of 1.20 with a 95% CI (1.15-
1.25) to support a modestly higher rate of neoadjuvant therapy utilization over the 
timespan of this study. The remaining study was of Dutch origin which reported no 
change at all over the period of the study (Spronk et al., 2017). The country of origin of 
the study has often been of importance to the Canadian oncology community, as there is a 
general understanding that the patterns of oncology treatment in Canada are most closely 
aligned with that of the United States, as compared to European countries. The type of 
facility where patients received treatment in these studies was categorized in terms of 
whether the facility was academically or university-affiliated, a teaching or 
comprehensive community hospital, or a general hospital. The results of two of these 
studies suggested that patients with locally advanced disease who received treatment at 
academically-affiliated healthcare centers were statistically more likely to receive 
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neoadjuvant therapy compared to general hospitals (Mohiuddin et al., 2016; Spronk et al., 
2017).  
During the literature search, it became apparent that there was a lack of research 
evidence available on the topic of clinical practice guideline adherence to neoadjuvant 
therapy with a result of only four research studies being found. The additional 35 studies 
had been chosen to obtain more information on the assessment of guideline adherence in 
other general breast cancer-related studies. All 39 studies utilized a retrospective cohort 
research design and measured guideline adherence over a pre-determined period of time. 
This was yet another strong justification for choosing a retrospective study design for use 
in this evaluation project. The 35 general studies included a variety of breast cancer-
related topics such as breast cancer treatment and the elderly, survival using first-line 
adjuvant treatment regimens, and the survival outcomes between molecular subtypes. The 
results highlighted from these topics indicated that the rate of guideline adherent 
treatment decreased with advanced age; lowered survival outcomes when deviations 
occurred in the recommended first-line treatment choice; and lowered survival outcomes 
for those having triple negative and HER2 positive breast cancers whose treatment 
deviated from the recommended first-line treatment choice. All 39 studies were critically 
appraised using the Public Health Agency of Canada Critical Appraisal Tool Kit (2014). 
The majority were given a medium-quality rating and three studies received a low-quality 
rating.  
Some of these studies were helpful in outlining aspects of the study design related 
to the inclusion and exclusion criteria, use of age stratification, the study time period of 
choice, and the selection of some variables of interest. Most importantly, these studies 
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were helpful in highlighting important strategies to aid in reducing the threat to the 
internal validity of a research study. One such strategy involved availing of the services of 
a cancer registrar in helping to minimize the risk of selection bias, misclassification bias 
and information bias which had often been inherent in several of these retrospective 
studies. These studies were also helpful in pointing out some disadvantages encountered 
in performing retrospective studies such as using data extractors unfamiliar with oncology 
data collection as well as inconsistent data collection results when the services of more 
than one data collector are being used. Having one investigator, with extensive breast 
cancer experience, who was solely responsible for data collection and able to ensure data 
accuracy was a distinct advantage in helping to control for misclassification bias. Another 
strategy of note was the use of a subgroup analysis to investigate multiple independent 
variables in a limited, stratified manner which was useful in controlling for the risk of 
confounding on the study outcomes.  
The third search provided some additional insight into some of the most important 
patient/tumor/facility-related characteristics which the surgeon might take into 
consideration prior to making the decision to refer or to proceed to definitive surgery.  
Consultations Summary 
The consultation process involved face-to-face or telephone interviews with experts 
in the field of breast cancer, two medical oncologists and one general surgeon. In 
addition, a consultation had been arranged with the director of the provincial cancer 
registry and the ARIA computer clinical support person at the Dr. H. Bliss Murphy 
Cancer Center (DHBMCC), both of whom have specialty training and expertise within 
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their job classifications. A copy of the consultations report can be reviewed in Appendix 
C.  
Medical Oncology 
 The two medical oncologists were interviewed face-to-face together, in order to 
form a consensus of opinion regarding the development of the eligibility criteria to be 
used for this study. Collaboration with the oncologists resulted in the development of the 
inclusion and exclusion criteria for the study population of two cohorts of patient cases 
according to diagnosis, locally advanced breast cancer and inflammatory breast cancer. 
Since the Eastern Health BDSG neoadjuvant guideline was disseminated in 2014, it was 
decided to stratify each cohort into groups according to a pre-guideline study year and a 
post-guideline study year in order to measure adherence.  
Cancer Registry/ARIA Computer Support 
The interview with the director of the NL Cancer Registry was instrumental in 
narrowing the choice of study years to that of 2013 and 2016 to reflect the pre- and post-
guideline dissemination time periods. A written request was submitted, and upon meeting, 
the director provided an explanation of what types of data could be expected to be 
received from the cancer registry database. As a cancer registry, not all the data of interest 
were available through this database. Therefore, any data not available from the cancer 
registry database was to be collected by hand through a retrospective individual chart 
review.  
The consultation with the director of the cancer registry was also helpful in 
explaining the changes that had taken place with the computer technology systems during 
the study’s time period. A new paperless electronic health record known as the ARIA 
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computer system had been introduced in 2014, which simplified the chart review process 
for the 2016 post-guideline dissemination time period. ARIA provides access to the 
surgical, diagnostic, and pathological reports from the hospital MediTech computer 
system, as well as the oncological first assessment and progress notes. However, the chart 
review process for the pre-guideline dissemination period of 2013 proved to be more 
complicated. It involved retrieving data from the defunct computer system known as 
OPIS which housed the oncologists’ first assessment and progress notes, the hospital 
MediTech computer system, and individual paper charts. The interview with the ARIA 
clinical support person was instrumental in obtaining the necessary computer training in 
order to retrieve the required data from that computer system. 
 General Surgery 
 The surgeon consultation was conducted as a telephone interview with a general 
surgeon. The interview questions and a list of patient- and tumor-related factors which 
had been compiled from the research literature were forwarded via email in advance of 
the interview. The surgeon indicated that tumor size (≥ 5 cm); skin or chest wall 
involvement on imaging; presentation of clinical or imaging evidence of at least N2 
(axillary lymph node level 2 disease); and/or a pathological diagnosis of inflammatory 
breast cancer were definite reasons to refer a patient for neoadjuvant consideration.  
 The surgeon suggested that extenuating factors may impact the decision to refer 
patients such as the general health of the patient and the presence of pre-existing co-
morbidities. Frailty and/or the presence of cardiac, renal, and/or vascular insufficiencies 
are often grounds for which the surgeon would proceed with primary surgery. 
Consequently, the surgeon would be aware that these health limitations were likely to 
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prohibit the use of first-line pharmaceutical therapies with potentially cardiotoxic or 
thrombus-inducing effects. Age was also considered important since breast cancer in 
younger patients tends to be of a more aggressive nature than older patients, while general 
health status was more important in the elderly. However, the presence of frailty is also 
more frequent in the elderly population ≥75 years.   
 While discussing other tumor-related characteristics which may affect the decision-
making process, the surgeon recognized tumor grade (poorly differentiated/grade 3), 
histology (such as apocrine, metaplastic) and the presence of bilateral or multi-focal 
and/or multi-centric disease as additional incentives for neoadjuvant referral. The surgeon 
also highlighted the impact of molecular subtyping and the need for testing on all needle 
core biopsy specimens. This would permit the surgeon to have prior knowledge of the 
molecular subtype information so that more cases of locally advanced HER2 positive and 
triple negative breast cancer can be referred for neoadjuvant therapy.  
 The previously mentioned patient demographics and tumor characteristics as 
described by the surgeon lent credibility to these specific factors as the optimal choices 
for investigation in this study. Some of these data were available from the Cancer 
Registry database however, the remaining required a thorough paper and computer chart 
review for both study years to complete the data collection. 
Chart Review Summary 
A copy of the chart review report has been included in Appendix D. The chart 
review process took place at the DHBMCC in St. John’s. Though the Cancer Care 
Program has a provincial focus, the Cancer Center, itself, comes under the direction of the 
Regional Eastern Health Care Board. The program director of the NL Cancer Care 
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Program granted permission to the investigator to conduct this study with access to 
patient medical information as well as permission to request patient data from the NL 
Cancer Registry. The NL Health Research Ethics Authority (HREA) website provides a 
tool to help study investigators determine whether the intent of their study is either 
research or a quality assurance initiative. The tool was completed by the investigator and 
the results indicated that this project was a program evaluation initiative, and therefore 
exempt from HREA review and approval.  
Sample 
The two groups which comprise the sample population for this study were those 
patients who had been diagnosed with locally advanced or inflammatory breast cancer, 
during the pre-guideline dissemination year of 2013 and the post-guideline dissemination 
year of 2016. The eligibility criteria for those with invasive inflammatory breast cancer 
were the clinical presentation and a skin biopsy which provided pathological confirmation 
of diagnosis. The eligibility criteria for invasive locally advanced breast cancer consisted 
of having at least one or more of the following three characteristics: 
• Tumor size > 5cm; and/or 
• Presence of clinically palpable, or radiological imaging of, ipsilateral axillary 
lymph nodes or ipsilateral internal mammary nodes which is categorized of at 
least level II lymph nodes (N2) according to the AJCC staging manual (Edge et 
al., 2010); and/or  
• Categorized as having AJCC breast cancer stages of either IIB (T3 N0 M0 only) 
or any stage III. 
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The exclusion criteria for both cohorts included metastatic disease at diagnosis, male 
breast cancers, or AJCC stages of breast cancer other than those listed in the eligibility 
criteria. In addition, the sample population was restricted to only those patients who had 
received at least two of the three primary treatment modalities of surgery, 
chemotherapy/endocrine therapy, and radiation therapy. For further clarification, the 
AJCC breast cancer staging guide can be found in Appendix A. Each patient case was 
categorized as having the outcome of being “referred” or “not referred” to the medical 
oncology discipline as indicated, in order to capture the referral rate (and calculate its 
corresponding proportion or percentage) for the cohort according to the year of study and 
diagnosis.  
Methods 
Upon receiving the written request, the director of the cancer registry performed the 
search for all newly diagnosed breast cancer patients for study years 2013 and 2016. Four 
data sources were accessed for the 2013 study year including the cancer registry dataset, 
paper charts, OPIS computer system and the hospital Meditech computer system. Only 
three data sources were necessary for the 2016 study year which included the cancer 
registry dataset, the new paperless ARIA computer system, and the Meditech computer 
system. Table 1 provides a visual demonstration of the kind of data collected and where it 
was collected from according to the study year of interest. The initial list of independent 
variables was compiled from the information provided by the literature review and the 
surgeon consultation. However, it became apparent during the chart review process that 
changes to this list were warranted in order for it to align more closely with the 
availability of the data.  
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Table 1  
Sources for Data Collection  
Variable Pre-Implementation (2013) Post-Implementation 
(2016) 
Cancer 
Registry 
Paper 
Chart  
OPIS Medi-
Tech 
 
Cancer 
Registry 
ARIA Medi
Tech 
Patient age X    X   
Year of 
diagnosis 
X    X   
Clinical tumor 
(T) size 
X    X   
Tumor histology  X X X  X X 
Tumor grade  X X X  X X 
Unilateral/ 
bilateral 
 X X X  X X 
Multifocal/ 
multicentric 
 X X X  X X 
Clinical nodal 
status (N) 
 X X X  X X 
Clinical/ 
pathological 
AJCC stage 
X    X   
Estrogen/ 
progesterone 
receptor status 
X    X   
HER2 receptor 
status 
X    X   
Chest wall/skin 
involvement 
X    X   
Facility location  X X X  X X 
  
 
 A data collection tool was adapted from the literature for use in obtaining and 
recording the required data in an organized and efficient fashion (Gregory & Radovinsky, 
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2012). A corresponding data dictionary was developed which provided definitions of the 
necessary data and ensured that the correct data were being collected. The data collection 
tool was first used during a pilot test conducted by the investigator using the first 15 
patient cases of the 2016 sample. The pilot test was beneficial in helping to define the 
term referral, recognizing the lack of consistent reporting by surgeons and the lack of 
provincial-wide synoptic pathology reporting, as well as aiding in finalizing the choice of 
independent variables for use in this evaluation project.  
 Two new Excel spreadsheets were developed to manage the eligible patient data for 
each calendar year of study provided by the cancer registry and the data collected from 
the chart review. The data was de-identified by removing all personal identification 
information such as patient name, MCP number and date of birth. Each patient case was 
then given an unrelated identification number to protect the patient’s identity and personal 
health information.    
 A multivariable analysis had been planned for this evaluation project in order to 
determine whether an association existed between being referred and the various 
independent variables chosen for study. However, the final sample size was too small to 
allow for a multivariable analysis. Microsoft Excel 365 software for Windows 10 was 
used to perform the statistical analysis for this study. The 95% confidence intervals (CI) 
were calculated for the referral rates from both years of study. 
Results 
A total of 113 patient cases were identified in the 2013 dataset however, 66 did not 
meet the eligibility criteria. This left a final sample size of 47 cases which consisted of 
four inflammatory breast cases and 43 locally advanced breast cancers. In 2016, a total of 
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133 patient cases were identified with 79 cases which did not meet the eligibility criteria. 
This resulted in a final sample size of 54 cases having two inflammatory breast cancers 
and 52 locally advanced breast cancers. A discussion of the study results has been 
provided separately according to diagnosis. 
Inflammatory Breast Cancer. 
From the results provided, it was apparent that there were four cases of 
inflammatory breast cancer in 2013 and only two in 2016. Neoadjuvant referrals were 
sent to medical oncology for all six cases. Though the sample sizes for both study years 
were exceedingly small, the results signify that 100% of inflammatory breast cancers 
were referred appropriately by their surgeons. A 100% guideline adherence rate does 
exceed the range provided in the literature review of 72% and 93% for this cohort, which 
suggests that surgeons in this province exceeded the expected adherence rate, at least for 
these six patients, during the study period. Therefore, the remaining discussion will have 
emphasis on the analyses of the locally advanced breast cancer cohort only. 
 Locally Advanced Breast Cancer. 
 
Table 2 summarizes the results of the neoadjuvant referral rates, in terms of 
numbers and proportions, for the locally advanced breast cancer cohort in this study. The 
results showed that only 23.3% (95% CI: 10.6%, 35.9%) in 2013 and 26.9% (95% CI: 
14.9%, 39.0%) in 2016 of the locally advanced breast cancer cohort were referred for 
neoadjuvant therapy discussion with a medical oncologist. These results were in sharp 
contrast compared to the inflammatory breast cancer cohort results and were much lower 
than the guideline adherence rate determined for this patient group from the literature 
review of 44% to 79%.  
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Table 2  
 
Number and Proportion of Patients Diagnosed with Locally Advanced Breast Cancer 
(LABC) in 2013 and 2016 
 
 2013 
N = 43 
 
Total 
n (%) 
2016 
N = 52 
 
Total 
n (%) Referred 
n (%) 
Not 
Referred 
n (%) 
Referred 
n (%) 
Not 
Referred 
n (%) 
Locally 
Advanced 
Breast 
Cancer 
(LABC) 
 
10 
(23.3%) 
 
33 
(76.7%) 
 
43 
(100%) 
 
14 
(26.9%) 
 
38 
(73.1%) 
 
52 
(100%) 
 
 
These results merited a closer look at the data to determine whether any subgroup 
of this cohort was apt to have clinical disease which would make them more likely to be 
referred than the others. As mentioned previously, a large tumor size (≥ 5cm) such as T3 
and T4 tumors; and/or evidence of level II nodal disease such as N2; and/or an AJCC 
stage IIB (T3N0M0 only) or any stage III breast cancer are characteristics of locally 
advanced breast cancer. The extent of lymph node involvement cannot be reliably, 
clinically determined in many cases which precludes its use, as well as the use of AJCC 
staging which also requires information on nodal involvement. Given that clinical tumor 
size can often be measured by the surgeon on examination, or by imaging, and that the 
presence of a ≥ 5cm tumor which defines a locally advanced breast cancer should 
automatically warrant a neoadjuvant referral, the investigator believed it was reasonable 
to perform a sub-analysis on the T3/T4 subgroup.  
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Locally Advanced Breast Cancer (T3/T4). 
The referral results of the sub-analysis have been summarized in Table 3 according 
to study year. There were twice as many T3 and T4 tumors diagnosed in 2016 (n = 18) 
than in 2013 (n = 9) with an actual referral rate of approximately 61% (95% CI: 38.6%, 
83.6%) in 2016. This rate falls within the parameters of the range identified in the 
literature review of 44% to 79% for the locally advanced breast cancer patient group.  
Table 3 
Number and Proportion of Patients Diagnosed with T3 and T4 Locally Advanced Breast 
Cancer (LABC) in 2013 and 2016 
T size of 
Breast 
Cancer 
2013 (T3 & T4) 
n = 43 
 
Total 
n (%) 
2016 (T3 & T4) 
n = 52 
 
Total 
n (%) Referred 
n (%) 
Not 
Referred 
n (%) 
Referred 
n (%) 
Not 
Referred 
n (%) 
T3 5(55.6%) 3(33.3%)  
9 
(20.9%) 
9(50.0%) 
 
6(33.3%)  
18 
(34.6%) T4 1(11.1%) 0(0) 2(11.1%) 
 
1(5.6%) 
Total  6(66.7%) 
 
3(33.3%) 
 
n = 43 
(100%) 
11(61.1%) 7(38.9%) n = 52 
(100%) 
 
 
However, nearly 40% of the population considered to be locally advanced did not receive 
a referral to the medical oncology discipline. In addition, the referral rate for T3/T4 
tumors in 2013 was approximately 67% (95% CI: 35.9%, 97.5%) which was higher than 
the 2016 referral rate, despite a doubling of T3/T4 tumors diagnosed in 2016.  
   Analysis of the Patient/Tumor/Facility-related Factors (All LABC). 
 An analysis of the factors which may influence the surgeons’ decision-making had 
been conducted to determine if any had affected the rate of neoadjuvant referrals for the 
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whole locally advanced breast cancer cohort. An analysis of only those factors which had 
demonstrated a sizable number of referrals or substantial differences between the years of 
interest have been summarized in Table 4. The numbers were very small for this analysis 
which prevented the investigator from drawing firm conclusions on the results. However, 
it was possible to identify some notable trends from the data. 
 The most common pathological findings in breast cancer include a ductal histology, 
unifocal tumors, and unilateral disease. This was reflected in the data of this study with 
higher numbers of patient cases having these tumor-related characteristics than any other 
in their respective categories. There was a slight increase in the referral rate in 2016 
(32.1%) compared to 2013 (25%). Unifocal and unilateral breast cancers typically 
represent less aggressive tumors than others in these categories, such as multifocal and 
multifocal/multicentric or bilateral disease. However, the numbers for these latter 
characteristics were too small to definitely indicate a reason to refer. Therefore, unifocal 
and unilateral tumors were not considered to be indicators for referral.   
Table 4 
Patient/Tumor/Facility-related Variables of LABC by Year and Referral Status 
 
Variables 2013 2016 
Referred 
n (%) 
Not Referred 
n (%) 
 
Referred 
n (%) 
Not Referred 
n (%) 
Age Range 
(years) 
 
Median Age: 58 
Range: 35 to 85 
Median Age: 61.5 
Range: 33 to 85 
41 – 50 
 
2(22.2%) 
 
7(77.8%) 5(55.6%) 4(44.4%) 
61 – 70 3(37.5%) 
 
5(62.5%) 2(11.1%) 16(88.9%) 
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Variables 2013 2016 
Facility Type 
 
 
 
Large Urban      
(University-
affiliated) 
 
8(40.0%) 12(60.0%) 8(24.2%) 25(75.8%) 
Clinical Tumor 
Size 
 
 
≤T2 
 
4(11.8%) 26(88.2%) 3(8.8%) 27(91.2%) 
T3/T4 6(66.7%) 3(33.3%) 11(61.1%) 7(38.9%) 
Lymph Node 
Status 
 
 
Negative 1(7.1%) 13(92.9%) 0(0) 4(100%) 
Positive 9(31.0%) 20(69.0%) 14(29.2%) 34(70.8%) 
AJCC Stage 
(Clin/Path) 
 
 
Stage IIIA 
 
6(23.1%) 20(76.9%) 10(31.3%) 22(68.8%) 
Tumor Histology  
Ductal 7(25.0%) 21(75.0%) 9(32.1%) 19(67.9%) 
Tumor Grade  
Grade 2 5(21.7%) 18(78.3%) 5(27.8%) 13(72.2%) 
Grade 3 3(21.4%) 11(78.6%) 7(22.6%) 24(77.4%) 
Molecular 
Subtype 
 
 
HER2 Positive 0(0) 1(100) 0(0) 3(100) 
Triple Negative 4(33.3) 8(66.7) 7(53.8) 6(46.2) 
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Nevertheless, this analysis of the locally advanced breast cancer cohort and the 
various factors of influence according to referral rate and year did find some noteworthy 
trends in the data. Among these were:  
• In 2016, a higher proportion (55.6%) of younger patient cases aged 41 to 50 
years were referred compared to 2013 (22.2%); 
• In 2016, despite a larger number of patient cases aged 61 to 70 years compared 
to 2013 (18 cases vs 8 case), a smaller proportion were referred (11.1% vs 
37.5%), respectively; 
• In 2016, despite a larger number of patient cases receiving definitive surgery at 
university-affiliated hospitals compared to 2013 (33 cases vs 20 cases), a smaller 
proportion were referred (24.2% vs 40%), respectively; 
• The number of T3/T4 tumors were approximately one third of the number of 
tumors ≤ T2 in 2013 (9 cases vs 30 cases, respectively) and approximately one 
half in 2016 (18 cases vs 30 cases, respectively). However, T3/T4 tumors were 
substantially more likely to be referred in both 2013 and 2016 (66.7% vs 11.8%) 
(61.1% vs 8.8%), respectively;  
•  Nine cases (31%) and 14 cases (29%) with positive lymph node involvement 
were referred in 2013 and 2016, respectively. However, only one case in 2013 
and no cases in 2016 were referred with negative lymph node involvement; 
• A larger number of Stage IIIA breast cancers were diagnosed in 2016 compared 
to 2013 (32 cases vs 26 cases), with a slightly higher proportion referred in 2016 
(31.3% vs 23.1%), respectively;  
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• Despite grade 3 tumors having the most aggressive nature, there was virtually no 
difference in referral rates between 2013 and 2016. However, there were slightly 
more referrals for cases with grade 2 tumors in 2016 (27.8%) compared to 2013 
(21.7%); and 
•  Despite the small numbers of patient cases, it was evident that molecular 
subtype had some impact on referral rates. A higher proportion of triple negative 
cases were referred in 2016 compared to 2013 (53.8% vs 33.3%), respectively. 
However, neither of the four cases of HER2 positive in 2013 and 2016 had been 
referred for neoadjuvant consideration.   
 Analysis of the 2016 Patient/Tumor/Facility-related Factors (T3/T4 LABC). 
 This final analysis was conducted on those patient cases with locally advanced 
breast cancers having T3/T4 tumors for the study year of 2016 only. This analysis 
provided a closer look at the referral process in terms of the impact certain factors may 
have on the surgeons’ decision-making in present day for those who should have routinely 
been offered a referral for neoadjuvant therapy. Once again, the numbers in this sample 
were too small to draw any firm conclusions overall. However, the investigator was able 
to identify certain interesting trends in the data. Table 5 provides a summary of only those 
factors which had illustrated a trend in the analysis results. These trends were: 
• Of the five patient cases in the younger age group of 41 to 50 years, four were 
referred while the other was not; 
• Of the nine patient cases who received definitive surgery in university-affiliated 
hospitals, six were referred and three were not; 
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• Of the 16 cases with positive lymph node involvement, 11 were referred and five 
were not; 
• Seven of the 11 cases with AJCC Stage IIIA breast cancer were referred while 
four of the 11 were not, and all four patient cases with Stage IIIC breast cancer 
were referred; and  
• Finally, six out of the seven patient cases with triple negative breast cancers were 
referred while one out of seven was not. 
Table 5 
Patient/Tumor/Facility-related Variables of Clinical T3/T4 Tumors of LABC by Referral 
Status for 2016  
 
Variables Referred 
n = 11 
Not Referred 
n = 7 
Age Range (in years) Median Age: 54 
Range: 34 to 79 
Median Age: 55 
Range: 33 to 85 
 
41 – 50 
 
 
4 
 
 
1 
 
 
Facility Type 
 
 
Large Urban  
(University-affiliated) 
 
6 3 
Lymph Node Status   
Positive 
 
11 
 
5 
 
AJCC Stage (Clinical or 
Pathological) 
 
 
Stage IIIA 
 
7 
 
4 
 
Stage IIIC 4 0 
Molecular Subtype 
 
 
Triple Negative 6 1 
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Discussion 
 Surgeons in this province were 100% compliant with the recommendations of the 
Eastern Health BDSG neoadjuvant guideline regarding referral of patients with 
inflammatory breast cancer, at least with the six patients studied in 2013 and 2016. 
However, the locally advanced breast cancer referral rate data can be far more 
complicated to interpret. The definition and multiple tumor features of this cohort add to 
its complexity, thereby likely impacting the surgeons’ interpretation of the guideline as 
well as the decision to refer. The initial referral rate results for all locally advanced breast 
cancers was approximately 23% (95% CI: 10.6%, 35.9%) in 2013, while the referral rate 
was approximately 27% (95% CI: 14.9%, 39.0%) in 2016. The confidence intervals for 
2016 suggest that the true referral rate may be as low as 15% or as high as 39%. The 
referral rates, including the confidence interval values, for both study years were 
substantially lower than the rate range of 44% to 79% found in the literature review. 
Although the 2016 referral rate (27%) was slightly higher than the 2013 rate (23%), the 
consistent overlap of both confidence intervals suggests that there was little difference 
between these rates.  
 The results of the T3/T4 subset analysis found a referral rate of approximately 61% 
(95% CI: 38.6%, 83.6%) in 2016 and 67% (95% CI: 35.9%, 97.5%) in 2013. These 
results did align with the referral rate range found in the literature (44% to 79%). 
However, the confidence intervals for 2016 indicate that the true referral rate could be as 
low as 38% or as high as 84%. These confidence intervals are much wider for the T3/T4 
subgroup than for the whole locally advanced breast cancer cohort and would require a 
much larger sample size to get a more accurate picture of the true referral rate for the 
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T3/T4 subgroup. Lastly, there was considerable overlap for the confidence intervals 
representing both years of study in the T3/T4 subgroup. As was true for the whole locally 
advanced breast cancer cohort, despite the finding of a higher referral rate in 2013 there 
really was little or no difference in the referral rates between 2013 and 2016. Regardless, 
the take-home message remains the same in that the referral rate for locally advanced 
breast cancer cohort requires improvement, especially for T3 and T4 tumors. 
 The sample sizes were small for each of the patient/tumor/facility-related factors 
which may affect decision-making, especially for the T3/T4 subgroup, making it difficult 
for firm conclusions to be drawn from the results. Nevertheless, some trends were 
noticeable which included younger patients, those who had surgeries performed at 
hospitals with university-affiliated programs, those diagnosed with positive lymph node 
involvement, Stage IIIA or IIIC, and/or triple negative disease which seemed to be more 
likely to be referred for consideration of neoadjuvant therapy.  
 With respect to guideline adherence for referrals of the locally advanced breast 
cancer cohort, it was readily apparent that there has been little or no change since the 
BDSG guideline was disseminated. These results appear to suggest that the guideline has 
had little or no effect on clinical practice. In Canada, as well as other developed countries, 
there has been a noted lack of compliance to clinical practice guidelines in healthcare 
(Gupta et al., 2016; Hall, Irish, Gregg, Groome, & Rohland, 2015). Physicians often 
claim time and unavailability of resources as reasons for incompliance, as well as the 
length, complexity and variety of choice that some guidelines provide (Vogel, 2011).     
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Recommendations 
As a result of the evaluation, several underlying issues had been revealed concerning the 
referral program for neoadjuvant therapy as well as the clinical practice guideline 
development program. The referral rates indicate that in 2016, only 61% of all patients 
with locally advanced breast cancers who should indisputably have received a referral to 
the medical oncology discipline for a neoadjuvant therapy discussion, did so. Despite the 
2016 referral rate being within the range identified in the literature, nearly 40% of 
patients with locally advanced breast cancer did not avail of the benefits of neoadjuvant 
therapy. Some recommendations which could be helpful in efforts to increase the rate of 
patient referrals by surgeons and improve patient outcomes are:  
I. Provide a written report of the evaluation project’s results in an executive 
summary in order to inform the administrative leads of the findings and issues 
brought to light by this study. A copy of the executive summary has been 
provided in Appendix E. Feedback and advice from the administrative body on 
how best to initiate change within the system would be welcome and of 
particular importance in initiating it. 
II. Present the results in a future meeting of the Eastern Health BDSG, using a 
PowerPoint presentation. A discussion will be encouraged to determine what 
measures can be taken within the necessary departments to improve the process 
and allow more consistent use of neoadjuvant therapy for those patients who 
would benefit the most from this treatment strategy. Some suggestions are 
standardizing receptor testing on needle core biopsies to determine molecular 
subtypes earlier; continue advocating for synoptic reporting for radiology 
28 
 
departments and pathology labs all across the province; advocate for 
standardized or synoptic reporting of the decision-making process by the 
surgeon; and encouragement of more collaborative efforts between surgeons and 
oncologists.  
III. Encourage the BDSG to implement more professional development initiatives to 
provide education regarding the interpretation of research into clinical practice, 
such as local conferences or workshops aimed at surgeons and family physicians; 
use of team-building strategies to promote a team approach which may be 
helpful in boosting the consistent use of clearly defined guidelines for 
neoadjuvant therapy referrals.  
 The process for deciding which patients to refer for neoadjuvant consideration can 
be complicated and dependent upon a host of elements which are not always easily 
defined. Clinical practice guidelines can be an important resource for surgeons to quickly 
and easily determine the best treatment option to pursue for patients in varying 
circumstances. However, many surgeons have complained about the complexity, 
lengthiness, and the time-consuming effort needed in using clinical practice guidelines. 
The following recommendations have been provided as a means by which the 
development, dissemination, and utilization of the BDSG clinical practice guidelines can 
be improved. They are: 
IV. Carry out a survey to determine whether the surgeons of NL know of the 
existence of the BDSG clinical practice guidelines, where to find them, and are 
they utilizing them. A summary of the evaluation project’s results can be 
provided in an effort to engage the surgeons’ interest. Also, a survey provides 
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surgeons with the opportunity to voice their opinions on the content of the 
guideline and any issues they may have with it. 
V. Change the future approach to clinical practice guideline development in order to 
incorporate strategies which will help meet the needs of the surgeon, such as 
creating a shorter version of the guideline and the use of treatment decision 
algorithms, such as those located in the appendices of the chart review report and 
the executive summary in Appendix D and E of this report. The future goal 
would be to make the Eastern Health BDSG guidelines more user-friendly and 
simpler to use. 
VI. Revisit the dissemination practices for new BDSG guidelines to surgeons and 
family physicians. Improving the process, requesting feedback, and following up 
on the information provided may be useful strategies in engaging physicians to 
bring about change.  
VII. Begin the process of incorporating quality indicators in future clinical practice 
guidelines to establish outcome measurement as a means of determining the 
effectiveness of the guideline and whether quality improvement actions are 
necessary.  
Next Steps 
 The next steps are to share the results and recommendations of this evaluation 
project with the Program Director of the Cancer Care Program, the chief of the medical 
oncology discipline, the chair of the Eastern Health BDSG, and then the BDSG itself. A 
written executive summary will be provided for the organizational management listed 
above. It will summarize the objectives of the evaluation project, an overview of the 
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methods, and the key results with a focus on recommendations to help address the 
identified issues. Later, a PowerPoint presentation will be provided with a similar outline 
for the BDSG membership at a regularly scheduled monthly meeting.  
 Action must be taken to follow up on and incorporate the recommendations 
provided in this project in an effort to facilitate, increase, and improve the use of 
neoadjuvant referrals for the appropriate study populations. In addition, work needs to 
begin on the use of quality indicators in the development of new clinical practice 
guidelines for quality improvement purposes. Future evaluations of other pre-existing 
guidelines, developed by the BDSG or other tumor-site groups, can be implemented by 
using this evaluation as a model and adapting its methods as necessary in order to 
measure adherence and improve patient and healthcare system outcomes.  
Advanced Nursing Practice (ANP) Competencies 
Advanced practice nurses possess extensive clinical experience, leadership 
qualities, knowledge about the inner mechanisms of their respective healthcare 
organizations, as well as the higher education which can bind these attributes into an 
astounding force for change in the healthcare realm. These nurses have been recognized 
by the Canadian Nurses Association (CNA) as being strategically poised to take on the 
role for initiating guidance and support in order to improve outcomes for patients, the 
institution, and the healthcare system as a whole. The Association of Registered Nurses of 
NL (ARNNL) has also recognized the importance of clinical nurse specialists who 
possess these attributes and use their knowledge and skills as a means to improve the 
consistency of healthcare delivery by using research evidence-based practice (2013). The 
development of clinical practice guidelines in various healthcare fields, including 
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oncology, has frequently been the domain of graduate-level nurses in this country and this 
is likely to continue. The CNA has articulated four competencies which are expected of 
an advanced nursing practice, and categorized as clinical, research, leadership, and 
consultation and collaboration (2014). Two of these categories have been demonstrated 
during the conduct of this evaluation project, namely research and leadership.  
In this evaluation project, the demonstration of the research competency for 
advanced nursing practice involved employing research methodology in the project’s  
performance and the utilization of research. Though this project was not a research study, 
the evaluation process required the use of some research methodology to carry it out. 
Some of these research methods included the utilization of descriptive objective 
measures, choosing and employing a retrospective study design, conducting semi-
structured interviews, using a data collection tool and data dictionary, as well as utilizing 
the most appropriate statistical analysis for the data. 
Research utilization was evident in the use of a comprehensive literature review, 
and the critical appraisal of the available literature, to identify and assimilate the most 
appropriate and best quality research evidence on the practice of neoadjuvant therapy and 
guideline adherence. Research utilization was also evident from the consultations process 
which helped define the populations of interest, the eligibility criteria, the periods of 
study and the data sources. The evidence from both the literature review and the 
consultations informed the chart review process which utilized research to carry out the 
evaluation project as well as to collect and analyze the results. The knowledge gained 
from the evidence collected on all three of these processes (literature review, 
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consultations, and chart review) were necessary to inform the recommendations offered 
for this project as a means to improve patient outcomes.     
As the NL representative on a national oncology Guideline Facilitators group, the 
investigator has already assumed a leadership role in the field of clinical practice 
guideline development. However, having to assume a leadership role in evaluating the 
neoadjuvant referral process within the Cancer Care Program has been a new experience 
for this investigator. The experience has provided an opportunity to identify issues within 
the healthcare system which need attention and to develop appropriate strategies that can 
be implemented in an effort to address the areas of concern. One example of an 
organizational/system gap or problem identified by the investigator was the need to 
modify or transform the neoadjuvant clinical practice guideline into a shorter and more 
user-friendly version. In response to this identified need, the investigator developed 
decision-making algorithms to assist physicians in determining appropriate treatment 
sequencing to guide the care of patients with breast cancer. Developing recommendations 
and advocating for their use are valuable approaches to take in order to improve the 
delivery of evidence-based care which fundamentally demonstrate leadership capabilities.                   
Conclusion 
The utilization of a comprehensive literature review and the consultations with 
specific individuals of expertise provided an important foundation for this evaluation 
project which informed its methodology and choice of patient/tumor/facility-related 
factors to study. The knowledge gained from this phase of the project was also crucial in 
informing the chart review process as well as the analysis and interpretation of the data. 
33 
 
The data analysis highlighted the complexity of the decision-making process meant to 
determine what patients were candidates for neoadjuvant referral. It became obvious that 
the preliminary data did not tell the full story regarding referral rates for neoadjuvant 
discussion in this province. This advanced the need for a deeper examination of the data 
which, in combination with the knowledge and extensive clinical experience, was 
sufficient to emphasize that there were other dynamics at play which were skewing the 
results.  
The results of the T3 and T4 subgroup proved to be a better representation of the 
state of neoadjuvant referral rates in NL compared to that of the entire local advanced 
breast cancer group. Nevertheless, the results still suggest that approximately 40% of the 
patients are not being referred to the medical oncology discipline for a discussion of 
regarding neoadjuvant treatment. There is obvious room for improvement which will 
require the collaboration of the various key stakeholders to implement policies and 
strategies to create change which moves the Cancer Care Program along the path of 
achieving the best patient outcomes for those diagnosed with breast cancer in the 
province of NL.  
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 In accordance with one of the main objectives of the practicum proposal, it was 
necessary to gather knowledge on how to evaluate whether adherence exists to the 
Eastern Health Breast Disease Site Group’s (BDSG) “Neoadjuvant Treatment of Primary 
Breast Cancer” evidence-based clinical practice guideline (CPG) in Newfoundland and 
Labrador (NL). One method to compile this knowledge would require a thorough search 
and review of the published literature. This would allow a close evaluation of the 
experiences of other researchers who have explored guideline adherence in a variety of 
other management- and treatment-related breast cancer (BC) topics. This literature 
summary describes the complete process of how the literature search was carried out, how 
the decisions were made regarding the choice of the studies to be used, and an in-depth 
appraisal of the findings to determine the appropriate means by which to evaluate how 
surgeons decide which patents should be referred to medical oncology for neoadjuvant 
therapy consideration.  
Literature Search Methods 
To begin this process, three important questions must be asked and answered to 
help establish the foundational basis for not only this literature review but also for this 
practicum project, itself. The questions were: 
1. Is adherence to guidelines an issue in the clinical practice of breast cancer 
management and treatment? 
2. What methods and/or measures have been used in other research studies to 
determine guideline-adherence in the management and treatment breast cancer? 
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3. What factors affect the deliverance of guideline-adherent care in the clinical 
practice of breast cancer?  
In order to answer these questions, a strategy needed to be devised which would provide a 
comprehensive review of the available literature. The aid of a librarian was enlisted at the 
Health Sciences Library, located in the Health Sciences Centre, regarding the appropriate 
choice of key terms to use in the search. The key words chosen were MeSH terms with 
broad headings intended to capture the largest number of available research possible. The 
keywords included “guideline adherence” (as a major heading), “cancer OR oncology”, 
“audit OR research methods”, and “breast”, with Boolean operators “AND” and ‘OR” as 
best suited. Using these key words, additional filters or limiters of English language only, 
full-text and human-based studies were applied. The search was carried out in both 
nursing and medical databases included PubMed, Embase, CINAHL, and the Cochrane 
Library from January 1, 2010 until January 31, 2018. This search yielded 152 research 
articles from which only three research studies were directly related to the neoadjuvant 
treatment of invasive breast cancer.  
A second search was conducted using the MeSH terms “guideline adherence 
(major)”, “cancer OR oncology”, “clinical audit OR medical audit OR quality of health 
care”, and “breast”. This second search was performed in an attempt to capture additional 
neoadjuvant research studies. Again, the filters used were English language only, full-text 
and human-based studies, with the search carried out in the same nursing and medical 
databases as the first search, with the same time line. This second search yielded 294 for a 
total of 446 literature articles, adding only one neoadjuvant research study for a result of 
four (Killelea et al., 2015; Lin et al., 2017; Mohiuddin et al., 2016; Spronk et al., 2017). 
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Clearly, four neoadjuvant research studies were too few studies in which to perform an 
appropriate literature review on guideline adherence effectively. Hence the decision was 
made to include research studies from both previous searches, which had measured 
guideline adherence with a focus on breast cancer management or treatment, other than 
the use of neoadjuvant therapy. This approach provided an opportunity to garner 
additional knowledge regarding other breast cancer-related topics on guideline adherence. 
This resulted in a retrieval of thirty-nine (39) eligible studies, which were deemed 
appropriate for the evaluation of guideline adherent clinical practice in the management 
of breast cancer. 
In addition, a third search was performed to evaluate what factors influenced the 
surgeon’s decision to refer patients with breast cancer to the medical oncology discipline 
for consideration of neoadjuvant therapy.  The Mesh terms of “surgeon clinical decision 
making”, “neoadjuvant therapy”, and “breast cancer” and the Boolean operator “AND”, 
with filters of English language only, full-text, and human studies were used to search the 
PubMed and Embase databases, over the last ten years. This search resulted in seven 
research articles. An additional hand search of the reference lists of various literature 
review articles revealed four additional articles on this topic. From the resulting 11 
articles, only five were useful in the evaluation of factors affecting neoadjuvant referral to 
medical oncology.  
Inclusion and Exclusion Criteria     
The original inclusion and exclusion criteria were meant to closely reflect the 
inclusion/exclusion criteria to be utilized in the proposed study. However, since only four 
research articles were found which related to the topic chosen, the search parameters were 
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adjusted to include all research studies of a breast cancer-related topic which attempted to 
measure guideline adherence. The inclusion criteria were for all studies with a primary 
breast cancer focus, which: 
1. Measured adherence to a specified clinical practice guideline developed by a 
credible organization, or for a national/provincial purpose;  
2. Comprised an adult female population only; 
3. Conducted at a single institution or across multiple institutions or centers; 
4. Used a retrospective cohort design; and  
5. Data extracted from cancer/tumor registries and/or patient medical records and/or 
breast cancer-specific databases only. 
 The exclusion criteria were studies with: 
1. A metastatic breast cancer cohort; 
2. Male breast cancers; 
3.  A mixture of primary cancers including breast (e.g., lung and bowel cancers); 
and/or 
4. Embedded quality indicators, use of care pathways, and post-quality improvement 
measures.  
The inclusion criteria were meant to reflect the methodology which had been agreed 
upon by the Eastern Health BDSG and which was best suited for the purposes of this 
proposed study, in terms of design, data source, and the specific guideline of use. Since 
most clinical trials include only female participants to increase the homogeneity of the 
cohort, this tactic was also utilized for this project. The inclusion of multicenter studies 
allows for more generalizable findings that may be applicable to what could be expected 
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from other centers within the westernized world. Though the findings of single institution 
studies may be more restrictive for comparison purposes, if the methodology was sound 
then the study was included.  
The exclusion criteria were defined to reduce the focus of the literature search to an 
earlier stage of breast cancer cohort having a curative potential, eliminating those with 
end-stage disease. Most breast cancer studies will exclude the rare cases of male breast 
cancer to prevent confounding, and therefore were excluded from the literature search. 
Though several research studies investigated cohorts from a mixture of different disease 
sites (e.g., lung, bowel) which included breast cancer, these were excluded in favor of 
studies which had a primary focus of breast cancer only. Studies which had employed 
quality improvement measures were also excluded, since this can affect how data is 
extracted and consolidated potentially introducing selection bias. Since the intent of this 
project is evaluation only, its utilization is meant as a pre-quality improvement initiative.  
In addition, none of the Eastern Health BDSG CPGs have embedded quality or 
performance indicators and therefore these may not be helpful in explaining the findings 
of this project. Finally, studies which evaluated post-quality improvement measures (other 
than the development and publication of a clinical practice guideline) were excluded to 
prevent confounding of the evidence. A glossary has been provided of the common 
abbreviations used in the specialty of oncology and are tabled in Table 1 of the appendix. 
Results 
 The four neoadjuvant research studies consisted of three American studies and one 
Dutch (Killelea et al., 2015; Lin et al., 2017; Mohiuddin et al., 2016; Spronk et al., 2017). 
All three of the American studies used the recommendations of the National 
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Comprehensive Cancer Network (NCCN) Breast Cancer guideline as the standard of care 
while the Dutch study referred to the recommendations of a national breast cancer 
guideline. All three of the American studies used the National Cancer Database (NCDB) 
from which to collect their data while the authors of the Dutch study selected data from a 
national multidisciplinary registry known as the NABON Breast Cancer Audit (NBCA). 
 The remaining 35 breast cancer research studies chosen demonstrated an 
international representation comprised of 13 from the United States, 11 from Germany, 
two from Australia/New Zealand while five were Dutch, two were Canadian, one British 
and one French. It should be noted that various countries have access to different 
databases from which researchers can extract the necessary breast cancer data to analyze 
their subject of interest. The American studies have the largest number of cancer- or 
breast cancer-specific database resource options from which to extract data. The most 
common sources are the NCDB, which despite its national title comprises only 70-80% of 
all cancer cases in the United States, and the Surveillance, Epidemiology, and End Results 
(SEER) data, covering approximately 26% of the cancers in the population (Hattangadi, 
Taback, Neville, Harris, & Punglia, 2012; Killelea et al., 2015; Mohiuddin et al., 2016).  
 Though the NCDB is the largest cancer database in the U.S, it has been criticized 
because it collects data only from those hospitals whose cancer programs have been 
accredited by the American College of Surgeons’ Commission on Cancer (Wu et al., 
2012). The argument raised is that study results are often only a reflection of accredited 
hospitals and not necessarily those of all hospitals across the United States, especially 
those in smaller rural areas. Other American studies used in this review extracted their 
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data from regional or state cancer registries, while two studies used the database of 
hospitals affiliated with NCCN.  
 Most of the remaining studies, from other countries other than the United States, 
obtained their data from either a national or regional cancer/tumor registry (often 
supplemented by patient data from appropriate healthcare/hospital facilities), or from 
breast cancer-specific databases created for the purposes of research. However, two 
studies, one French and one Canadian, obtained patient data alone from either regional or 
institutional healthcare systems.  
 It became apparent that certain countries, such as Germany, the Netherlands, and 
the United States, have committed to publishing their efforts to achieve national standards 
of care in the guideline-adherence of the treatment and management of breast cancer. This 
was reflected in the fact that 33 of the 39 studies had been conducted in these three 
countries alone. The NCCN and the American Society of Clinical Oncology (ASCO) are 
large national organizations in the United States, which develop evidence-based breast 
cancer treatment guidelines, while both Germany and the Netherlands have developed 
their own national guidelines. Unlike these countries, Canada does not have a national 
oncology CPG development organization, rather the onus falls upon provincial oncology 
programs to implement CPGs (either de novo or through adoption/adaptation) suitable for 
use for cancer management, within each unique provincial setting. Some of the prominent 
provincial oncology guideline developers in Canada include such organizations as Cancer 
Care Ontario and the B.C. Cancer Agency. The NL Cancer Care Program within Eastern 
Health has been developing guidelines for ten years, and the “Neoadjuvant Treatment of 
Primary Breast Cancer” CPG has been in circulation since 2014.    
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 All 39 of the studies were quantitative, analytical and of similar design, specifically 
that of an observational retrospective nature. Though each study had a breast cancer focus 
and the primary aim was whether clinical practice adhered to the recommendations of a 
specific guideline, the topics themselves varied substantially. Therefore, to simplify the 
interpretation of the results the studies were grouped according to topic and tabled 
together in the appendix. The grouped studies and corresponding table were neoadjuvant 
therapy (Table 2), adjuvant therapy (Table 3), breast conserving therapy (Table 4), 
radiation therapy (Table 5), breast cancer treatment and the elderly (Table 6), molecular 
profiling (Table 7), staging investigations (Table 8), tumor characteristics (Table 9), and 
axillary evaluation (Table 10). Three single studies concerning immediate breast 
reconstruction (Table 11), genetic counselling/testing (Table 12), and follow-up (Table 
13) are located in the appendix.     
 Each study was tabled with information on the authors’ names, country of origin, 
study design, and the main objective of the study. The sample size and methodology were 
recorded along with the study’s inclusion and exclusion criteria, the specific clinical 
practice guideline being tested for adherence, and the primary endpoints of the study. The 
key results and findings were listed, followed by the strengths and limitations of the 
study. Each study was also appraised, and the evidence graded using the Public Health of 
Canada’s (PHAC) critical appraisal tool kit (2014) resulting in a judgement being 
awarded on the strength of the study design, the quality of the study, and whether the 
evidence was direct or extrapolated were given for each study. All the studies were of a 
similar retrospective cohort design and the critical appraisal tool kit rates this design as 
moderate. A prospective randomized controlled trial, despite being considered a strong 
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study design, is not always an ethical choice for some research questions. Therefore, the 
retrospective cohort design is an appropriate choice when the intervention has occurred 
naturally without control by the investigator (Yang, Chang & Chung, 2012).  
 A potential for sampling or selection bias will always exist with retrospective 
cohort studies of this nature since random sampling cannot be used. The findings of 
studies using large national databases are generalizable only if the study population is 
similar to the population to which one wants to generalize. Having similar eligibility 
criteria will facilitate comparison across studies. The risk of misclassification bias or 
coding errors is also another concern for retrospective cohort studies and were often the 
deciding factor between being awarded a strong and a medium quality rating for the 
chosen studies of this literature summary. Information bias can also be an issue with 
retrospective studies due to lack of blinding and lack of training in appropriate data 
collection methods. The higher the risk of misclassification and information biases, the 
higher the likelihood of a real threat to the internal validity of the study. The ratings for 
quality of the 39 studies varied from low to medium, depending on the measures taken by 
the investigators of these studies to control for internal and external validity threats.  
 The methodology of the neoadjuvant studies will be instrumental in directing much 
of how this proposed study will be carried out. However, the methodology of the 
remaining study groups can also offer important insights into how to conduct or improve 
other aspects of this proposed study not addressed by the neoadjuvant studies. Each of the 
following group of studies will be reviewed for their general findings and any potential 
suggestions for use for this practicum project.      
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Neoadjuvant Therapy Studies 
Findings. The four studies concerning the use of neoadjuvant therapy were submitted in 
Table 2 of the appendix. All four of the neoadjuvant guideline-adherent studies differed in 
purpose, though all investigated the rates of neoadjuvant therapy use as an outcome of 
interest. Lin and colleagues (2017) focused on the treatment of inflammatory breast 
cancer only while Killelea et al. (2015) studied the rates of breast conserving surgery after 
neoadjuvant therapy. Both Mohiuddin et al. (2016) and Spronk et al. (2017) investigated 
the practice patterns in neoadjuvant use, though Mohiuddin and colleagues chose a 
locally advanced and borderline-lumpectomy population cohort while Spronk et al. 
concentrated solely on the locally advanced population. All three American neoadjuvant 
studies found that neoadjuvant therapy use had increased over each study’s timespan 
(Killelea et al., 2015; Lin et al., 2017; Mohiuddin et al., 2016). As per the American Joint 
Committee on Cancer staging manual (7th ed.), Mohiuddin and colleagues (2016) 
described an 44% utilization of neoadjuvant therapy for stage IIIA invasive breast cancer, 
79% in T4 tumors of stage IIIB, 53% for stage IIICs, and 93% for use in inflammatory 
breast cancer. In comparison, the Dutch neoadjuvant study reported a high rate of 79% for 
neoadjuvant therapy for all stage IIIs with no significant change over its timespan 
(Spronk et al., 2017).  
All four of these studies also found a wide variation for neoadjuvant therapy use 
across cancer facility type or location. Each of the four studies compared the type of 
facility, where the treatment had been administered, and labeled them according to 
whether they were academically affiliated with a university, a teaching or comprehensive 
community cancer center, or a general community hospital. Two studies found that 63.4% 
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to 88% of patients with stage III invasive breast cancer received neoadjuvant 
chemotherapy and/or endocrine therapy at an academic-affiliated center, while 52.6% to 
79% at a teaching/comprehensive center, and 49.1% to 75% at a general community 
hospital (Mohiuddin et al., 2016; Spronk et al., 2017). Killelea and colleagues (2015) 
found that 19% of patients with stage I to III invasive breast cancer received neoadjuvant 
therapy at an academic-affiliated center while only 13% did so at general community 
hospitals. All studies, except for Lin and colleagues (2017), were able to show a 
statistically significant association between treatment and facility type. In contrast, Lin 
and colleagues (2017) found that facility location was statistically significant for those 
who received guideline recommended tri-modality therapy (i.e., neoadjuvant 
chemotherapy, modified radical mastectomy, and post-mastectomy radiation therapy) for 
the treatment of inflammatory breast cancer. The authors suggested that this was probably 
due to the high variation in tri-modality therapy seen in the comprehensive community 
centers and the academic/research hospitals over the course of the study. The results of 
this American study found those who lived in the Midwest were more likely to receive tri-
modality therapy (77.2%) than those living in the South (66.5%).    
Quality and Insights. The quality rating for all four neoadjuvant studies was medium 
which is sufficient to justify mirroring certain components of their methodology in the 
conduct of this proposed study. It was apparent from these neoadjuvant studies that 
missing data is likely a common issue with large databases. Killelea and colleagues 
(2015) admitted that 26% of their study population were missing important clinical 
staging information as per the American Joint Committee on Cancer (AJCC) staging 
manual (7th ed.), while Mohiuddin et al. (2016) also excluded cases with incomplete 
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AJCC staging data. Patient cases were also excluded when no primary surgery was 
performed in order to reduce heterogeneity in the sample (Lin et al., 2017; Mohiuddin et 
al., 2016). Spronk and colleagues (2017) also excluded cases with unknown treatment 
sequencing. Excluding cases with incomplete clinical AJCC staging or unknown 
treatment sequencing is a necessary strategy in this proposed study since clinical staging 
and treatment sequencing are focal to the eligibility criteria for neoadjuvant therapy. In 
addition, unlike the study by Mohiuddin and colleagues, this proposed study is focused 
primarily on who gets referred for neoadjuvant therapy, not whether patients were able to 
undergo primary surgery after its completion.  Therefore, cases will not be excluded from 
this proposed study for that reason alone.  
Each of the four studies used multiple stratification measures to look at various 
independent variables to help control confounding; however, some confounders such as 
patient preference and pre-existing co-morbidities were unable to be assessed. All four 
neoadjuvant studies used large multicenter databases with large sample sizes ranging 
from 1556 to 354,204 participants. Since the likelihood is that the sample size in this 
proposed study will be much smaller than those used in the four neoadjuvant studies, it 
may be possible to reduce the risk of misclassification bias by crosschecking the data to 
ensure cases are properly identified as neoadjuvant or adjuvant therapy recipients for this 
proposed study. In addition, though no blinding will take place, the specialized training of 
the registrars at the NL cancer registry will help reduce the risk of information bias. Any 
additional data required will have to be with a chart review performed by the investigator. 
Therefore, increased diligence would be a necessity to prevent any mistakes made during 
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this data collection phase. If taken, these measures should help improve the rigor of this 
evaluation study.   
 Surgeons are the first contact that patients with breast cancer have in the oncology 
treatment realm. It is through a surgeons’ referral that patients first access the services of 
medical and radiation oncologists. Evidence from all four neoadjuvant studies suggest 
that overall surgeons adhere to evidence-based clinical practice guidelines regarding 
neoadjuvant therapy referrals at a rate in the range of 44% to 79% for patients with stage 
III locally advanced disease, and 72% to 93% for patients with inflammatory breast 
cancer (Lin et al., 2017; Mohiuddin et al, 2016; Spronk et al., 2017). Graham et al. (2015) 
conducted a similar study in Alberta, Canada and found that 59% of those with locally 
advanced breast cancer received neoadjuvant treatment. Though this study did not meet 
the eligibility criteria for inclusion for this review due to its lack of an identifiable CPG, it 
was a Canadian study with results that confirms the range found in the four chosen 
neoadjuvant studies. There are few studies of this nature to predict accurately what an 
acceptable rate for guideline adherent neoadjuvant treatment should be for patients with 
locally advanced and inflammatory breast cancers. Though these ranges, especially at the 
lower end, for neoadjuvant therapy use reveal a poor uptake of a recommended standard 
of care, it seems a reasonable option to use them as target rates for guideline adherence 
for this project.   
Adjuvant Therapy Studies  
Findings. Five of the nine studies classified under the heading of adjuvant therapy in 
Table 3 of the appendix investigated the rates of receiving guideline-adherent treatment 
for breast cancer (Anderson et al., 2015; Campbell, Janitz, Vesely, Lloyd, & Pate, 2015; 
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Holleczek & Brenner, 2014; Verschoor et al., 2016; Wu et al., 2012). The two American 
studies found an overall range of guideline-concordant adjuvant care of approximately 
90% to 92% (Anderson et al., 2015; Campbell, Janitz, Vesely, Lloyd, & Pate, 2015). In 
comparison, a third American study by Wu and colleagues (2012) indicated that 35% of 
patients did not receive guideline-adherent chemotherapy (only 65% did) and 20% of 
patients received inappropriate endocrine therapy (80% did) according to guideline 
recommendations. The authors suggested that the stark difference between their study 
results and studies performed by those such as Anderson et al. are probably due to the 
NCDB data being affiliated with accredited facilities (mentioned on page 7). In 
comparison, Wu et al. study data are from the cancer registries of several southern states, 
considered to be poorer with fewer available resources. Since all three of the studies were 
performed during the same time, there may be some merit to this argument by Wu et al. 
Meanwhile, Campbell and colleagues collected their data from one the cancer registry of 
only one state and though the data are from multiple centers within the state, it may 
restrict the data from being generalizable to other states. Lebeau et al. (2011) used odds 
ratios to determine the compliance with a CPG. These authors found that non-compliance 
to national guidelines was associated with older age (OR 2.1; 95% CI: 1.3 – 3.6) and 
region of residence (or 3.0; 95% CI: 1.2 – 7.4). These authors found that non-adherent 
clinical decision-making for specific aspects of treatment was usually associated specific 
tumor features. For example, non-compliance with radiation therapy was associated with 
disease involvement of the lymph nodes, or the presence of peritumoral vascular invasion 
(OR 1.5; 95% CI: 1.01 -2.3) while non-adherence to the overall treatment plan was 
associated with positive lymph nodes (OR 2.0; 95% CI: 1.2-3.3), grade III versus grade I 
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tumors (OR,2.9; 95% CI: 1.4-6.2) and the regional care facility of choice (OR 3.5; m95% 
CI: 1.7-7.1). 
 The authors of the remaining two studies, one German and one Dutch, stratified 
their results by specific guideline adherent treatment options (e.g., use of chemotherapy, 
endocrine therapy, targeted therapy, breast conserving surgery, sentinel node biopsy,) and 
found an increased use of these treatments over time (Holleczek & Brenner, 2014; 
Verschoor et al., 2016). Holleczek & Brenner (2014) found that the use of adjuvant 
chemotherapy increased from 60% to nearly 80% over the ten-year study period, while 
the use of endocrine therapy increased from 80% to approximately 93% and targeted 
therapy use increased from 1%-2% to approximately 48% in the same timeframe. These 
authors also found that the implementation of sentinel node biopsy (SNB) increased from 
approximately 1% at the beginning of the study to approximately 62% by the end of the 
study, with a corresponding decrease in the use of axillary lymph node dissection. 
Verschoor and colleagues (2016) also found significant changes in the use of endocrine 
therapy (23% to 56%) and chemotherapy (11% to 44%) over the study time period. 
 In addition, three German studies investigated survival outcomes for adherence and 
non-adherence to guideline recommendations of adjuvant therapy (Schwentner et al., 
2013; Wockel et al., 2010; Wolters et al., 2015). Wolters and colleagues (2015) stratified 
the time interval of the study period and found that recurrence-free survival (RFS) and 
overall survival (OS) had improved significantly from the earlier time interval (TI1) to 
the later time interval (TI2) (RFS: p <0.001, hazard ratio (HR) = 0.57, 95% CI: 0.49-0.67) 
(OS: p < 0.001, HR = 0.76, 95% CI: 0.66- 0.87). The authors also noted that patients who 
received 100% guideline adherent treatment tended to have better outcomes than those 
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who received non-guideline adherent therapy. Wockel et al. (2010) found that patients 
with a prolonged RFS and OS were significantly associated with guideline adherent 
treatment (p = 0.0001) and that patients who experienced a greater number of guideline 
treatment violations were more likely to have lower OS (p = 0.0001). Schwentner and 
colleagues (2013) investigated the participation of patients in adjuvant clinical trials and 
found that participants had an increase in RFS over non-participants (p = 0.006) but 
differences in OS were not statistically significant. The authors also found no survival 
advantage when both participants and non-participants adhered to guideline 
recommendations. However, both RFS and OS were significantly worse for non-guideline 
adherent participants (RFS: p < 0.001; OS: p < 0.001) and non-guideline adherent non-
participants (RFS: p < 0.001; OS: p < 0.001).  
Quality and Insights. All the studies had large sample sizes with the exception of the 
study by Lebeau et al. (2011) which had the smallest sample size of 926 participants. All 
the studies were also given a medium rating for quality except for the study by Lebeau 
and colleagues which was given a low rating. This was due to a series of issues with the 
study: using hospital chart reviews only for data collection (higher risk of 
misclassification bias); requiring patient consent to examine patient information which 
resulted in only accruing 67% of the eligible population (23% rejected or gave no 
response to requested consent); compliance to guidelines was only 57% (multidisciplinary 
meetings not fully established at time of study); and creating three groups for guideline 
compliance which were difficult to define and  deemed to not be an optimal model 
choice. These issues created threats to the internal validity of the study resulting in a low 
rating for quality. Therefore, only those studies awarded a medium rating for quality will 
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be considered in determining the measures or methodology for this practicum project. The 
issues noted with this study are all important pitfalls to avoid in conducting a quality 
study. 
 Advanced age was a common factor among the studies which affected whether 
patients received guideline-adherent treatment and likely will be the case for this 
proposed study. On average, those who were ≥ 75 years were at higher risk for non-
guideline adherent treatment or guideline violations. All studies stratified the age of 
patients into intervals which is particularly beneficial for de-identification purposes. 
However, it is also helpful in isolating the age where many physicians become more 
cautious about exposing elderly patients to treatments capable of great harm, especially in 
the presence of frailty and pre-existing co-morbidities.    
Breast Conserving Therapy 
Findings. These grouped studies are in Table 4 of the appendix. White and colleagues 
(2010) investigated the use of guideline-recommended breast conservation surgery (BCS) 
for the surgical treatment of ductal carcinoma in situ (DCIS) before (2002-2003) and after 
(2006-2007) the introduction of a national Australian guideline. The authors found that 
the use of BCS did not change significantly over the study timespan (78% before versus 
73% after); however, the utilization of SNB with BCS had increased from 2% pre-
guideline implementation to 21% post-guideline implementation (p < 0.001). In addition, 
post-guideline implementation found that surgeons referred 67% of patients to radiation 
therapy (RT) compared to 58% pre-guideline implementation (p = 0.04). In a single 
hospital in the U.K., Mathew et al. (2017) found that 41% of women with DCIS had 
undergone SNB though only 14% had the recommended tumor-free margin width.  
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Patrick, Hasse, Feinglass, and Khan (2017) reported the BCS rate for women 
having stage I and II invasive breast cancer was 67%, between 1998 and 2011. On 
multivariate analysis of this American study, the authors determined that women who 
were younger (≤39 years), less educated, and living in rural areas were less likely to 
receive BCS. The utilization of post-BCS RT was on average 82% with a decrease in 
frequency of use for the youngest and oldest population. Persing and colleagues (2015) 
investigated the adherence of pathology reporting according to the College of American 
Pathologists guidelines and the impact on re-excision and mastectomy rates following 
BCS. These authors found that only 44% of cases were maximally compliant. In addition, 
the rates of re-excision or mastectomy after BCS were also statistically associated with 
non-compliant reporting.  
Quality and Insights. This group of studies have mixed results in terms of usefulness in 
providing measures and methods information for this evaluation study. Mathew et al. 
(2017) was given a low rating for quality due to lack of generalizability and having an 
exceptionally long study period (1975 to 2008) where bias and/or confounding can occur 
from subtle changes over time. In addition, data being obtained from chart reviews at one 
hospital institution in the UK can introduce the concern of the potential lack of expertise 
of the data collectors in a hospital setting. Cancer registry data is collected by 
appropriately trained cancer registrars and without which the risk of misclassification bias 
is higher. The institution being studied is an academic–affiliated facility which one would 
expect to undergo progressive changes over the thirty-year period such as synoptic 
pathology reporting, change in computer systems or software which can contribute to 
improved margin measurement, and improvement in pathology slide fixatives and 
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protocols. These progressive changes can introduce a host of confounding factors which 
may affect the accuracy of margin reporting over time.  
 The remaining studies were awarded a medium quality rating. Patrick and 
colleagues (2017) had a very large sample size of 1,081,075 participants collected from 
the NCDB database while Persing et al. collected their sample of 1423 participants from 
the state of Vermont. Patrick et al. (2017) did find adherence to guidelines improved over 
time in terms of increasing rates of BCS, tumor-free margins, use of RT after BCS, and 
use of endocrine therapy and chemotherapy. Persing and colleagues (2015) also found 
advanced age (≥ 75 years) to be a significant indicator for withholding re-excision or 
mastectomy after BCS with positive margins.  
 White and colleagues (2010) had a smaller sample size of 342 participants and 
investigated the impact of a clinical practice guideline on the treatment of DCIS for a 12-
month period prior to and after. Some of the demographic and tumor characteristics 
studied included stratified age intervals, detection method of tumor/disease, tumor size 
and grade, multi-focality, presence of necrosis, microcalcifications, and surgeon case-
load. The guideline was broken down by specific recommendations and treatment and 
comparisons were made before and after the guideline was distributed, to determine 
effect. Bivariate followed by multivariate analysis captured the significant variables 
which affected the use of the new guideline. This study has a very similar methodology to 
what is envisioned for this proposed study, as well as the use of similar statistical 
measurement tools that should prove helpful in developing the evaluation plan.            
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Radiation Therapy  
Findings. The four studies of this group are in Table 5 of the appendix. Two American 
studies explored the rates of post-mastectomy radiation therapy (PMRT) in different data 
sets and different study time spans. One of these studies by Berger et al. (2017) examined 
a large sample from a national cancer database of various accredited hospitals between 
2006 and 2013. The results indicated that 62.3% of the study population received PMRT, 
with a highest proportion of these patients receiving guideline-compliant therapy in 
academic-affiliated centers. Dragun, Huang, Gupta, Crew, and Tucker (2012) conducted 
their study in Kentucky using the state tumor registry between 1995 and 2008 and found 
that only 47.3% of eligible patients received PMRT. The authors reported that women 
living in rural areas were less likely to undergo PMRT. The results of both studies also 
found that age (>70 years) and the lack of private insurance were associated with lower 
utilization of PMRT. 
Struikmans et al. (2011) investigated the rates of guideline-adherent RT after breast 
conserving surgery (BCS) and found an increase in its use over time from 32%- 45% in 
1997 to 41%-57% in 2008, though there were regional variations. On multivariate 
analysis, age ≥ 75 years and higher tumor stage were statistically significant factors 
associated with reduced use of RT after BCS. Regional variation was observed early in 
the study but adjusted to equivalency over time.  
A study by Hattangadi, Taback, Neville, Harris and Punglia (2012) compared the 
rates of whole-breast irradiation (WBI) with that of accelerated partial breast irradiation 
using brachytherapy (APBIb) post-BCS between the years of 2000 and 2007. These 
authors found that only 2.6% of patients received APBIb and an astounding almost two-
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thirds of those were deemed to be unsuitable or at the very least cautionary for this 
treatment regimen. Hattangadi et al. also found wide regional variability in APBIb use 
with the highest proportion being received in metropolitan areas.  
Quality and Insights. These studies all received a medium rating for quality, had large 
sample sizes and are suitable for consideration for measures and methodology if 
warranted. The finding brought forth by Dragun et al. (2012) that patients living in rural 
areas tend to avail less often of certain treatment options, such as radiation therapy, when 
compared to those living in urban areas has been frequently encountered in our provincial 
cancer care program. Rural versus urban treatment choices are important factors to bear in 
mind when conducting this proposed study since one of the factors of interest being 
investigated is the differences between provincial hospital facilities and surgeons’ referral 
rates for neoadjuvant treatment. Struikmans et al. (2011) also highlighted the issue of 
reduced guideline adherence for the elderly population.   
Breast Cancer Treatment and the Elderly 
Findings. Four studies were found on this topic and tabulated in Table 6 in the appendix. 
Three German studies explored the patterns of guideline-adherence and survival 
outcomes in the elderly diagnosed with breast cancer. Ebner and colleagues (2015) 
compared two groups according to age with one consisting of 50 to 69 years and the other 
consisted of those ≥ 70 years. Hancke et al. (2010) compared two similar age groups of 
women however these authors stratified the ≥ 70 years group into three additional groups 
(70 to 74, 75 to 79, and ≥80). In addition, van Ewijk and colleagues (2015) performed a 
comparison between a <65 age group with a 65-80 age group. All three studies found that 
the elder patients in each study were more likely to receive treatment with guideline 
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violations than their younger study counterparts [Ebner et al., 2015: 32.8% in 50-69 years 
versus 53.5% ≥ 70 years; Hancke et al., 2010: RT 9% for 50-69 years versus 33.7% for ≥ 
70 years, chemotherapy (CT) 34.5% for 50-69 years versus 76.3% for ≥ 70 years; van 
Ewijk et al., 2015: 27% for < 65 years versus 42.7% for > 65 years for non-study 
participants]. The studies by Ebner et al. and van Ewijk et al. found that non-guideline 
adherent treatment was significantly associated with decreased disease-free survival 
(DFS), RFS and OS, though van Ewijk and colleagues found this to be true only when RT 
was omitted.    
In 2004, an American study by McCormick and colleagues (2014) explored the 
guideline-concordant adjuvant treatment of women with hormone-receptor positive, stage 
I breast cancer who were ≥70 years of age. The recommendation at the time was to omit 
RT from the treatment regimen of these women after BCS. The results found that the pre-
guideline implementation period only yielded a 17% omission of RT in this age group, 
while the post-guideline implementation period was not dramatically better with a 26% 
RT omission. Again, a wide variation was noted among NCCN institutions. 
Quality and Insights. The studies in this group all received a medium rating for quality 
and all had relatively large sample sizes. The three German studies highlighted the 
strategy of stratifying the years of age to isolate the group where the most guideline 
violations occur. These studies have been helpful in determining the strategy for this 
study which will involve stratifying the patients ages in 10-year intervals, beginning with 
< 40 years, 41 to 50 years, 51 to 60 years, 61 to 70 years, and concluding with >70 years.  
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Molecular Profiling 
Findings. Four studies looked at various aspects of molecular profiling of breast cancer 
and they are located in Table 7 of the appendix. A Dutch study by Schreuder et al. (2017) 
explored gene expression profiles (GEP) by utilizing the MammaPrint® 70-gene test for 
all women with hormone receptor positive BC who were stratified either has either low-
risk or high-risk. This was not the indicated use for this test since it had initially gained 
approval for use for those women whose risk was moderate (neither clearly high- nor 
low-risk), and where the benefit of further treatment such as chemotherapy was unsure. 
The results found that 68.5% of patients were treated according to GEP result and not 
clinical presentation. GEP result alone was responsible for altering clinical low-risk 
patients to a high-risk category and vice versa, outside the recommendations of a national 
guideline.  
Two German studies investigated the survival outcomes for triple negative breast 
cancer [estrogen receptor-/progesterone receptor-negative (ER/PR), human epidermal 
growth factor receptor 2-negative (HER2)] in women with invasive breast cancer. 
Schwentner et al. (2013) and Schwentner et al. (2012) found that 9.2% and 10.0% of the 
non-metastatic breast cancer population had triple-negative breast cancer, respectively. 
Both studies found that DFS/RFS and OS were significantly worse for those with triple-
negative breast cancer compared to those with non-triple-negative breast cancers. In 
addition, both studies found that guideline violations were significantly more likely in the 
treatment of triple-negative breast cancers than non-triple-negative breast cancers (p < 
0.001). An American study by Chen and Li (2015) explored breast cancer subtypes and 
investigated whether an association existed with race or ethnicity. The authors found that 
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American Indians and Alaskan native were four times as likely to be diagnosed with stage 
IV triple-negative breast cancer. In addition, African American women had a 40% to 70% 
higher risk of developing stage IV breast cancer and guideline violations were more likely 
to occur in the treatment of African American and Hispanic women. 
Quality and Insights. All these studies received a medium rating for quality and varied 
from large to very large sample sizes. Though hormone receptor and HER2 receptor 
testing is usually performed on the definitive surgical specimen, surgeons or oncologists 
can request testing be performed on the biopsy specimen (providing enough tissue is 
available). The likelihood is that this information would not be available to the surgeon in 
the majority of cases when the time of decision-making is at hand. The initial plan for this 
proposed study had been to only collect information that would have been available to the 
surgeon at the time of decision regarding treatment sequencing. However, the two 
German studies influenced the decision to request the pre- or post-operative hormone 
receptor and HER2 receptor status on all patient cases from the cancer registry. This 
would aid in the attempt to identify the cases that would have benefited the most from 
neoadjuvant therapy such as the triple negative and HER2 positive cases. The study by 
Chen and Li (2015) is a very interesting one however, the provincial cancer registry does 
not collect race or ethnicity data on patients and therefore would not be a suitable 
independent variable to pursue.            
Staging Investigations 
Findings. Three studies, in Table 8 of the appendix, examined the rates of unnecessary 
staging investigations for women with early-stage breast cancer. The American study by 
Hahn et al. (2015) found that about 15% of patients had obtained at least one imaging test 
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and approximately half of those tests had been ordered for symptom investigation. The 
two remaining studies were Canadian, one by Han et al. (2012) which collecting their 
sample population from the patient records at a single hospital in Toronto, Ontario while 
the other, conducted by Simos et al. (2015), extracted their data from Ontario’s tumor 
registry. Though the sample size was small (in relation to most of the 39 studies used), 
Han and colleagues found that at least 55% of their sample population had undergone 
unnecessary imaging tests for stages I, II, and III breast cancer. However, distant 
metastasis was found in only 1.3% of those investigated and all had stage III disease. 
Simos and colleagues had a much larger sample size (26,547) and found 85.9% of those 
patients had undergone at least one investigational imaging test, though the mean for each 
patient was 3.7 tests. Despite guidelines which recommended against routine imaging for 
stage I and II BC patients, 79.6% and 92.7%, respectively underwent inappropriate 
testing.  
Quality and Insights. All three studies were given a medium rating for quality. The first 
two studies had large sample sizes while Han et al. was much lower at 231 participants. 
Though the results of the Han et al. (2012) study were from a single institution, the results 
are still generalizable if the sample population is similar to the target population of 
interest. The use of the cancer registry database for the proposed study will allow access 
to multiple centers around the province and have a similar sample population which 
should increase its generalizability as well. Both Canadian studies were conducted in 
Ontario and are likely more reflective of the pattern for inappropriate imaging for staging 
within other provinces. Non-adherence to breast cancer guidelines has been a problem in 
Canada for many years (Latosinsky, Fradette, Lix, Hildebrand, & Turner, 2007) and the 
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findings of the two Canadian studies in this group are a reminder that this may also be the 
case in this proposed study.  
Tumor Characteristics 
Findings. The two German studies in this group are in Table 9 of the appendix. They 
explored certain breast cancer characteristics such as the locality of tumors and bilateral 
versus unilateral tumors in order to determine whether the presence of either were 
associated with survival outcomes. In another study by Schwentner, Wolters, 
Wischnewsky, Kreienberg, and Wockel (2012), 4.3% of breast cancer cases were found to 
be bilateral while the remainder were unilateral only. The authors found that despite 
bilateral breast cancer having a poorer RFS and OS, fully guideline-concordant therapy 
was only obtained by 15.7% of all bilateral patients. In addition, as the number of 
guideline violations increased, the survival outcomes decreased. Wolters and colleagues 
(2015) found that unifocal tumors comprised 79.2% of the breast cancer cases included in 
the study while 15.6% had multifocal disease and 5.2% were diagnosed with multicentric 
disease. According to Zhou et al. (2013), whether tumors are multifocal or multicentric 
depends upon which anatomical quadrant of the breast the tumor resides. Multiple foci of 
tumor (multifocal) are located within the same quadrant while multicentric disease are in 
different quadrants of the breast. Wolters et al. (2015) found that the results of their study 
indicated that RFS was significantly worse for multifocal (p = 0.007) and multicentric (p 
= 0.019) disease compared to unifocal tumors, while OS was significantly inferior for 
multicentric (p = 0.001) disease but not for multifocal tumors (p = 0.321). In addition, 
guideline-concordant therapy was lower in the multifocal and multicentric disease in 
comparison to unifocal tumors (p < 0.001).  
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Quality and Insights. Both studies by Schwentner et al. (2012) and Wolters and 
colleagues (2015) received a medium rating for quality and had large sample sizes. The 
results of both studies have influenced the request for data related to the pre-surgical 
imaging detection of bilateral versus unilateral disease and the presence of multicentric, 
unifocal or multifocal disease.        
Axillary Evaluation 
Findings. Two studies, in Table 10 of the appendix, explored the surgical evaluation of 
the lymph nodes of the axilla in the treatment of invasive breast cancer and DCIS. Chong 
et al. (2013) investigated the use of axillary lymph node dissection (ALND) after SNB in 
women with early stage invasive breast cancer. These authors found that despite 24.1% of 
the sample population with ≤ 3 cm tumors having at least one positive sentinel node, only 
78.7% of these went on to undergo an ALND. In addition, in the remaining 75.9% of the 
sample population with ≤ 3 cm tumors who had a negative sentinel node, 9.6% went on to 
undergo ALND. In tumors > 3 cm, half of the sample population had at least one positive 
sentinel node though 15.3% of these patients did not go on to have an ALND. In this 
same cohort, an ALND was performed on 21% of patients who had a negative sentinel 
node. 
 The second study was conducted by Mitchell et al. (2017) who investigated the 
patterns of surgical evaluation of the axilla in patients with DCIS. The authors reported 
that BCS was performed in 63% of the cases with the use of SNB increasing from 7.2% 
to 39.4% over the span of the study (p < 0.01). For patients who received a total 
mastectomy (37%), the use of SNB also increased over the study period from 24.3% to 
77.1% (p < 0.01). Mitchell and colleagues also found that academic/research hospitals 
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were more likely to evaluate the axilla for both total mastectomy and BCS patients 
compared to that of community hospitals. 
Quality and Insights. Both studies were rated medium for quality and had large sample 
sizes but neither offered any insights for the purposed study since the independent 
variable of interest would primarily be the clinical presentation of nodal involvement not 
the surgery that followed.  
Single Studies 
Findings. Van Bommel et al. (2017), a Dutch study in Table 11, found that younger 
patients (<50 years) with invasive breast cancer were more likely to undergo immediate 
breast reconstruction than older patients (50-65 years) while younger patients with 
multifocal disease underwent immediate breast reconstruction more frequently. 
 In an American study in Table 12, Stuckey et al. (2016) found that, in a sample of 
314 patients eligible for genetic counselling and testing, only 34.1% were referred. 
Women who were more likely to be referred were those with a suspicious family history 
and those who chose a contralateral mastectomy. 
 In Table 13, a study by Grandjean et al (2012), with a small sample size of 196 
patients, conducted an evaluation of the adherence to a 5-year follow-up guideline. The 
first year included fewer follow-up visits than recommended while the second to the fifth 
years indicated more visits than recommended took place. However, 28% of the sample 
were lost to follow-up before completing the full five years. 
 Quality and Insights. Van Bommel et al. (2017) had a large sample size while Stuckey 
et al. (2016) was smaller with 314 participants. Both studies received a medium rating for 
quality. However, Grandjean et al. (2012) received a low rating due to the loss of nearly a 
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third of their sample population which likely compromised the study findings. These 
studies provided little or no insight into the purposed study. 
Guideline Adherent Studies Summary 
 Not all 39 studies were useful in providing insight into the modeling of this 
evaluation study in terms of its methodology and measurement features, though many of 
them were. The configuration of my study will closely resemble that of White et al. 
(2010) which will involve collecting data on all patients diagnosed with breast cancer 
who are eligible for neoadjuvant therapy for a 12-month period before and a 12-month 
period after the implementation of the Eastern Health BDSG neoadjuvant guideline. The 
proportion of patients who were referred for neoadjuvant treatment will be calculated for 
each of the two calendar years and compared to determine whether any significant change 
has occurred in the rate. Since most of the 39 studies used chi-square testing to determine 
differences in rates over time, this measurement will be used for this study as well. 
Important strategies have been underscored by reviewing these studies such as reducing 
the threats to the internal and external validity of the proposed study by: 
• Having the services of a trained registrar to collect the data from the cancer 
registry to protect against selection, misclassification and information biases;  
• Extensive oncology experience of the investigator will be beneficial in ensuring 
the accuracy of the neoadjuvant and non-neoadjuvant data from the chart review 
to control for misclassification bias; 
• Investigating multiple independent variables in order to reduce, as much as 
possible, the effect of known confounders; 
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• Using appropriate statistical testing with a criterion for statistical significance 
(alpha = 0.05). 
These strategies will be effective in producing a study plan that exhibits quality and rigor.  
Other insights and suggestions offered by these studies are: 
• Identify cases with missing data (e.g., missing clinical AJCC staging) and exclude 
when a chart review does not recover the missing data. Document the number and 
reasons for exclusion in the final report; 
• Stratify the patient age in intervals such as < 40, 41 to 50, 51 to 60, 61 to 70, > 70 
years; 
• Use the calculated ranges of neoadjuvant treatment for locally advanced and 
inflammatory breast cancers as a target rate of guideline adherence; 
• Expect there will be some rural versus urban differences in neoadjuvant referral 
rates; 
• Will not access patient-related information such as patient preference or pre-
existing co-morbidities; 
• The likelihood is that few older patients (>70 years) will be referred for neoadjuvant 
consideration.    
Factors Which Influence Surgeons Decision 
Study Findings 
 The 39 grouped studies did provide some insight into which patient characteristics, 
tumor-related, and facility-related data should be collected for this evaluation study. In 
addition, the research literature retrieved from the third literature search has also been 
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helpful in narrowing the list of potential independent variables that require data 
collection.  A recent Canadian research study by Urquhart et al. (2016) used semi-
structured interviews to explore the decision-making of surgeons related to utilizing a 
referral to oncology services for consideration of (neo)adjuvant treatment. The authors 
described seven factors which appear to influence a surgeons’ decision-making through 
the clinical encounter, mediating factors, and the outer context. These are “…indications 
and contraindications for therapy; patients’ beliefs and preferences; a belief that 
oncologists are the experts; knowledge of local standards of care; consultation with 
oncology colleagues; navigating patient logistics; and system resources and capacity” 
(Urquhart et al., 2016, E11). During the semi-structured interviews for this study, all of 
the surgeons felt that there was a lack of formal processes in place to enable them to 
consult with their oncology colleagues. In the absence of which, these surgeons believed 
informal discussions with their fellow surgeons aided in treatment decision-making and 
doing so would be sufficient to improve the quality of care.   
 Mamounas et al. (2016) used the answers of an online survey to evaluate how 
disease- and patient-related factors influenced the surgeon’s decision to refer patients with 
breast cancer to medical oncology services, for a discussion regarding neoadjuvant 
therapy. These authors identified 11 of these disease- and patient-related factors which 
included: 
• Skin/chest wall involvement; 
• Tumor size; 
• Histologic grade and type; 
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• HER2 status; 
• Estrogen and progesterone status; 
• Inflammatory breast cancer; 
• Clinical assessment of axillary lymph node involvement; 
• Patient’s age; 
• Patient’s health and comorbidities; 
• Patient’s preference for timing of surgery; and  
• Patient’s level of interest in BCS (p.3511). 
In addition, all four of the neoadjuvant studies investigated independent variables 
such as patient demographics, tumor features, facility type and location to determine 
whether any of these factors were associated with the utilization of neoadjuvant therapy 
(Killelea et al., 2015; Lin et al., 2017; Mohiuddin et al., 2016; Spronk et al., 2017). The 
findings of these studies for locally advanced disease suggest that younger age (<50 
years) and larger clinical tumor size (T3, T4) are both positive indicators for receipt of 
neoadjuvant therapy, with a trend for increased use over time. Evidence in three of the 
studies also suggested a wide variation in neoadjuvant treatment utilization (i.e., referral 
to medical oncology) in relation to hospital type, with higher rates in academic healthcare 
facilities (those affiliated with a university) than those without this affiliation, such as 
community and cottage hospitals (Lin et al., 2017; Mohiuddin et al., 2016; Spronk et al., 
2017). Data on independent variables, such as patient and physician preference, which 
play a role in the decision-making are not typically available in retrospective designs of 
this nature and will also be the case in the proposed study as well. 
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Quality and Insights 
Mamounas et al. (2016) provided a comprehensive list of patient characteristics and 
tumor-related factors which may influence the decision-making process of the surgeon. 
Though the study design of descriptive exploratory is described as weak in PHAC’s 
critical appraisal tool, the quality of this study was found to be strong. Therefore, its use 
is approved for developing the list of factors to be investigated in the proposed study. 
Many of the factors highlighted in the Mamounas and colleagues’ study were also used in 
the four neoadjuvant studies described in the previous section (pages 10 – 14). The only 
other useful tumor-related factors were identified from the tumor characteristics group 
which were bilateral versus unilateral tumors and the presence of multicentric and/or 
unifocal/multifocal disease (page 26 – 27). These factors may play a role in the decision-
making process, however a consultation with a general surgeon is necessary to determine 
if this is so.  
Though the initial plan was to only collect data available to the surgeon at the time 
of decision-making, it seems prudent to also collect data on tumor molecular subtyping in 
terms of hormone receptor status (i.e., ER/PR) and HER2 status. This information may be 
helpful at a later stage in promoting the use of neoadjuvant therapy especially for triple 
negative and HER2 positive tumors. The list of independent variables will be finalized 
after a consultation with a general surgeon. Many of the studies used multivariable 
analysis with the aid of a logistic regression model in order to determine what patient-, 
tumor-, and facility-related factors have a significant association with surgeons’ treatment 
decision-making. This will also be the measurement strategy of choice for this evaluation 
study.  
75 
 
Conclusion  
  This literature review and summarization have been fundamentally important in 
developing a plan with which to evaluate whether clinical practice adheres to the 
recommended guidelines developed by the participants of the Eastern Health BDSG. It 
has provided an opportunity to examine the means necessary to protect and strengthen the 
internal validity of the proposed study, by reducing biases and confounding where 
possible. The knowledge gained will be instrumental in developing a study that reflects 
quality and rigor in its methodology. Performing a review of the work that has been 
completed by others can also help expedite and narrow the focus for this project. 
Combining this work with the knowledge gained from consulting with various 
institutional experts, identified in the practicum proposal will enable the conception of a 
comprehensive plan to gather the necessary data, perform the appropriate analysis, and 
determine whether the healthcare systems’ referral process operates as intended for the 
benefit of our breast cancer population. If indicated, recommendations and system 
changes may be warranted to improve the quality of care delivered.         
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Appendix 
Table 1: Glossary of Abbreviations for Research Literature Summary                                                  
Abbreviation/ 
symbol 
Definition Abbreviation/ 
symbol 
Definition 
 AHS                                                                                                                                                                                      Alberta Health 
Services  
DFS Disease-free
survival 
ALND Axillary lymph node 
dissection  
ER- or ER neg. Estrogen 
receptor-
negative 
ASCO American Society of 
Clinical Oncology  
ER+ or ER pos. Estrogen 
receptor-
positive 
assoc. Associated ET Endocrine 
therapy 
ASTRO American Society of 
Radiation Oncology 
f/u Follow-up 
BCS Breast conservation 
surgery  
HER2 – or HER2 
neg. 
Human 
epidermal 
growth factor 
receptor-
negative 
BCT Breast conservation 
therapy  
HER2 + or HER2 
pos. 
Human 
epidermal 
growth factor 
receptor-
positive 
BL Borderline 
lumpectomy 
candidates 
HR Hazard ratio 
b/w Between Hx History 
CI                                                                                                                                                                                                                                                                                                                                                                                                                                                             Confidence interval LA Locally
advanced 
CCO Cancer Care Ontario  LCIS Lobular 
carcinoma in 
situ 
CPG                                                                                                                                                                                                                                                                                                                               Clinical practice
guideline  
LN Lymph nodes 
CT Chemotherapy LR Local 
recurrence 
DCIS Ductal carcinoma in 
situ 
MRI 
 
 
 
Magnetic 
resonance 
imaging 
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Abbreviation/ 
symbol 
Definition Abbreviation/ 
symbol 
Definition 
LVI Lymphatic vascular 
invasion 
RFS Recurrence-free 
survival  
NAC Neoadjuvant 
chemotherapy 
RR Relative risk 
NCCN National 
Comprehensive 
Cancer Network  
pt. Patient 
NICE National Institute for 
Clinical Excellence  
RT Radiation 
therapy 
NST Neoadjuvant systemic 
therapy   
SN Sentinel node 
OR                                Odds ratio  SNB Sentinel node 
biopsy 
OS Overall survival  SOC Standard of care 
PMRT Post-mastectomy 
radiation therapy 
TNBC Triple negative 
breast cancer 
(means ER-, 
PR-, & HER2-) 
PR- or PR neg. Progesterone 
receptor-negative  
TT Tri-modality 
therapy (means 
surgery, 
chemotherapy 
& radiation 
therapy) 
PR+ or PR 
pos. 
Progesterone 
receptor-positive  
vs. Versus 
PS Performance status  yrs. Years 
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Research Literature Summary Tables 
Table 2: Neoadjuvant Therapy for Locally Advanced/Inflammatory Breast Cancer 
Author(s), 
Country, 
Study Design 
& Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
1. Killelea et 
al., (2015). 
 
USA 
 
Retrospective 
cohort design 
 
Objective: To 
analyze national 
trends in breast 
conservation 
therapy (BCT) 
after 
neoadjuvant 
chemotherapy 
(NAC). 
 
 
 
 
 
 
 
 
 
 
  
• N = 354,204;  
• Convenience sample 
from a national 
cancer database b/w 
2006 and 2011; 
• Inclusion criteria - 
women with stage I 
to III invasive BC; 
• Exclusion criteria – 
clinical stage T4; 
• NCCN guideline: 
Recommends pts 
with stage IIA, IIB, 
and certain stage 
IIIA, if BCS is 
desired, should be 
offered NAC. 
 
• Primary endpoint: 
Rates and patterns of 
BCT and NAC 
treatment in BC. 
 
• Overall, 169,376 
(47.8%) 
underwent 
lumpectomy, with 
decreasing rates of 
51.3% in 2006 to 
46.5% in 2011; 
• Overall, 59,063 
(16.7%) received 
NAC, with rates 
increasing 
significantly from 
13.9% in 2006 to 
20.5% in 2011 (p 
< 0.001); 
• For tumors > 3 
cm, NAC 
consistently led to 
an increased rate 
of BCT (70% 
increase in odds 
of BCT with NAC 
compared to 
adjuvant therapy) 
(OR 1.7; 95% CI: 
1.6, 1.8); 
• Pathological 
complete response 
rate was 29.7% in 
this cohort (7880 
pts) with 
lumpectomy rate 
of 41% for this 
group. 
 
 
 
 
 
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Direct Evidence 
 
Strengths 
• Very large sample 
size; 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification bias 
or coding errors; 
• Missing data on use of 
NAC for pts in pursuit 
of BCT but ultimately 
had a mastectomy due 
to presence of positive 
margins which may 
introduce selection 
bias; 
• Does not account for 
patient-related 
confounding factors 
such as treatment 
preference. 
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Author(s), 
Country, 
Study Design 
& Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
2. Lin et al., 
(2017). 
 
USA 
 
Retrospective 
cohort design 
 
Objective: To 
compare 
facility-level 
and patient-level 
factors in the 
use of 
trimodality 
therapy (TT) of 
CT, RT and 
surgery for the 
treatment of 
nonmetastatic 
inflammatory 
BC. 
 
 
• N = 5537; 
• Convenience 
sample from a 
national cancer 
data base b/w the 
years of 2003 to 
2011; 
• Inclusion criteria – 
women with non-
metastatic 
inflammatory BC 
who underwent 
locoregional 
treatment; 
• Exclusion criteria – 
those who didn’t 
eventually undergo 
surgery, had a prior 
cancer dx., and 
those treated at a 
healthcare facility 
which had treated 
<5 pts with 
inflammatory BC 
over study period; 
• NCCN guideline: 
The treatment of 
non-metastatic 
inflammatory BC 
should include TT. 
 
• Primary endpoints: 
Rates of TT in 
non-metastatic 
inflammatory BC. 
 
 
 
 
 
• Use of TT 
fluctuated 
annually over 
study period 
(range, 67.3% - 
75.7%); 
• On multivariate 
model, use of TT 
more likely 
among the young, 
higher income, 
pathologic N1 
tumors (all p 
<.05); 
• Use of TT was not 
found to be 
statistically 
significantly 
associated with 
type of facility (p 
= .33); 
• The variance 
attributable to 
facility-level 
factors was 
substantial at 11% 
while the variance 
attributed to pt.-
level factors was 
3.4% for the 
underuse of TT. 
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Direct Evidence 
 
Strengths 
• Large sample size; 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification bias or 
coding errors; 
• May have missed cases 
assigned to non-regular 
physician providers 
creating selection bias; 
• Difficulties encountered 
in drawing conclusions 
about improvement in 
pt care because of 
limited outcome 
variables available from 
the database used; 
• This database only 
collected two facility-
level factors, without 
physician-level data 
which may create 
confounding. 
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Author(s), 
Country, 
Study Design 
& Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
3. Mohiuddin 
et al., 
(2016). 
 
USA 
 
Retrospective 
cohort design 
 
Objective: To 
examine the 
patterns of 
neoadjuvant 
chemotherapy 
(NAC) and 
neoadjuvant ET 
use among 
younger women 
in various 
cancer centers. 
 
 
 
 
 
• N = 118,086; 
• Convenience 
sample from a 
national cancer data 
base, b/w 2006 and 
2012; 
• Inclusion criteria -  
women < 65 yrs 
with clinical stage 
IIA (T2N0 only) to 
IIIC BC (stratified 
into two groups: 
locally advanced 
(LA) and 
borderline eligible 
for lumpectomy 
(BL); 
• Exclusion criteria – 
those with earlier 
breast cancers, 
metastatic disease, 
incomplete data on 
stage/receipt of 
systemic 
therapy/primary 
surgery; 
• NCCN guideline: 
Recommend 
neoadjuvant 
systemic therapy 
for pts with LA and 
BL candidates who 
desire BCS. 
 
• Primary endpoint:   
Neoadjuvant 
systemic therapy 
rates in those < 65 
with BC. 
 
 
 
• The LA group 
included 20,720 
pts (including an 
inflammatory BC 
group of 3591); 
• Use of NAC (± 
ET) in LA group 
was especially 
high for T4 
disease (79% for 
stage IIIB non-
inflammatory BC 
and 93% for 
inflammatory 
BC); 
• Across almost all 
stages and 
receptor subtypes, 
the use of NAC 
was lower in 
community vs 
academic centers;  
• Multivariate 
analysis revealed 
use of NAC in 
community was 
lower than 
academic centers 
(BL candidates: 
adjusted risk ratio 
(RR) 0.73; 95% 
CI: 0.69, 0.77) 
(LA candidates: 
adjusted RR 0.78; 
95% CI: 0.74, 
0.83); 
• Overall use of 
neoadjuvant ET 
alone was rare (≤
2%) for all stages. 
 
 
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Direct Evidence 
 
Strengths 
• Very large sample size; 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification bias 
or coding errors; 
• Missing data on use of 
NAC may introduce 
selection bias; 
• Does not account for 
patient-related 
confounding factors 
such as treatment 
preference. 
 
 
 
90 
 
Author(s), 
Country, 
Study Design 
& Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
4. Spronk et 
al., (2017). 
 
Netherlands 
 
Retrospective 
cohort design 
 
Objective: To 
examine the 
clinical practice 
of neoadjuvant 
chemotherapy 
(NAC) for stage 
III BC pts in all 
Dutch hospitals. 
 
 
• N = 1556; 
• Convenience 
sample from a 
national BC audit 
database, from 
2011 to 2015; 
• Inclusion criteria – 
women aged 18-70 
yrs with stage III 
BC, treated 
surgically; 
• Exclusion criteria - 
≥70 yrs., a prior 
cancer diagnosis, 
unknown sequence 
of chemo and 
surgery; 
• National Dutch BC 
guideline 
recommends NAC 
for pts with stage 
III BC aged <70 
yrs.  
 
• Primary endpoint: 
Rates of NAC in 
stage III BC. 
• A total of 1230 of 
the 1556 pts 
(79%) received 
NAC; 
• No change noted 
in use of NAC 
over time, but a 
large variation in 
use of NAC was 
noted b/w 
hospitals (0 -
100%); 
• Significant 
independent 
predictors of NAC 
were age <50 yrs, 
breast MRI, large 
tumor size, 
advanced nodal 
disease, hormone 
receptor negative 
status and hospital 
participation in 
neoadjuvant 
clinical trials (all 
p < 0.001); 
• NAC use in stage 
III BC was not 
influenced by 
hospital type and 
hospital surgical 
volume. 
 
 
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Direct Evidence 
 
Strengths 
• Large sample size; 
• Multicenter study of all 
Dutch hospitals 
included (100% 
enrollment).  
 
Limitations 
• Potential for 
misclassification bias 
or coding errors; 
• Does not account for 
pt-related factors such 
as preference or lack of 
knowledge concerning 
NAC option, which 
may create 
confounding. 
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Table 3: Adjuvant Therapy  
Author(s), 
Country, 
Study Design 
& Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
5. Anderson, 
Morris, 
Kimmick, 
Trentham-
Dietz, 
Camacho, 
Cheng, …& 
Lipscomb. 
(2015). 
 
USA 
 
Retrospective 
cohort design 
 
Objective: To 
examine local 
definitive 
treatment for 
non-metastatic 
BC.  
 
 
 
 
 
 
 
 
 
 
• N = 6505; 
• Convenience 
sample from a 
pooled data of 7 
state or regional 
cancer registries in 
2004; 
• Inclusion criteria -  
women with stage 0 
to IIIA primary BC; 
• Exclusion criteria – 
those with locally 
advanced or 
metastatic disease; 
• NCCN guideline: 
Recommends local 
definitive therapy as 
indicated with 
primary surgery, 
node dissection, and 
use of RT based on 
stage of disease.  
 
• Primary endpoints: 
Rates of guideline 
concordant loco-
regional treatment 
for BC. 
 
• Approximately 
90% received 
guideline 
concordant loco-
regional treatment 
(GCLRT); 
• The odds of BCS 
vs mastectomy 
were higher for 
increased yrs of 
age (OR= 1.01, p = 
0.031), higher 
tumor stage (OR= 
0.49 and 0.21, p = 
0.002 for stage II 
and IIIA 
respectively) 
public insurance, 
and presence of 
mild comorbidity; 
• RT following BCS 
was the most 
omitted treatment 
component causing 
non-concordance 
in the study 
population (only 
80% received RT); 
• In multivariate 
regression, effects 
of treatment 
facility, DCIS, 
race, and 
comorbidity on 
non-concordant 
care differed by 
age. 
 
 
 
 
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Large sample size;  
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification bias 
or coding errors; 
• Potential for selection 
bias due to missing 
data and use of data 
from accredited 
cancer programs; 
• Data does not account 
for influence of pt 
choice which can 
introduce 
confounding; 
• Data did not reflect 
sentinel lymph nodal 
assessments during 
that year which may 
introduce 
confounding.  
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Author(s), 
Country, 
Study Design 
& Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
6. Campbell, 
Janitz, 
Vesely, 
Lloyd, & 
Pate. (2015). 
 
USA 
 
Retrospective 
cohort design 
 
Objective: To 
describe the 
extent to which 
pts receive 
guideline-based, 
stage-specific 
treatments for 
localized 
invasive BC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• N = 4177;   
• Convenience 
sample from a 
single state-wide 
cancer registry b/w 
2003 to 2006; 
• Inclusion criteria – 
women with 
localized or early-
stage BC; 
• Exclusion criteria – 
those with 
metastatic disease, 
identified through 
death certificate or 
at autopsy, Hx of 
cancer, diagnosis by 
mammogram 
without 
pathological 
confirmation, out-
of-state cases, 
mesotheliomas, 
Kaposi sarcomas, 
and lymphomas; 
• NCCN guideline: 
Recommends 
primary treatment 
total or modified 
radical mastectomy 
or BCS followed by 
RT ± CT and/or 
ET for localized or 
early-stage BC as 
SOC (standard of 
care).   
 
• Primary endpoints: 
Rates of guideline-
directed SOC in 
BCS pts. 
 
• Overall, 92% of 
cohort were treated 
with recognized 
SOC; 
• However, in ≥65 
yrs group, the only 
variables related to 
SOC were age, 
primary payer, and 
comorbid 
conditions; 
• Women ≥75 yrs 
had a lower odds 
of meeting SOC 
than those 65-74 
yrs (OR 0.30; 95% 
CI: 0.20, 0.43); 
• Those ≥65 yrs 
without insurance, 
with comorbidities, 
or with unknown 
comorbidity status 
had significantly 
lower odds of 
meeting SOC; 
• Among those < 65 
yrs of age, 
insurance type, 
diagnosis year, 
larger tumor size, 
and comorbidities 
were associated 
with meeting SOC. 
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Large sample size; 
• Multicenter study.  
 
Limitations 
• Potential for 
misclassification bias or 
coding errors; 
• Missing data on 
comorbidities can 
introduce selection bias; 
• Lack of information on 
ER, PR, and HER2 
status could introduce 
potential confounding 
related to the effect it 
would have on 
treatment options; 
• Lack of individual data 
on poverty or education 
which could introduce 
confounding and limit 
study strength; 
• Data from only one 
state and therefore may 
not be generalizable to 
other state(s). 
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Author(s), 
Country, 
Study Design 
& Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
7. Holleczek & 
Brenner. 
(2014). 
 
Germany 
 
Retrospective 
cohort design 
 
Objective: To 
examine the 
usage of BC 
treatment, the 
extent of 
adherence to 
CPG, and 
survival of BC 
pts according to 
recommended 
treatment 
options.   
 
 
• N = 8571;  
• Convenience 
sample from a state-
wide cancer registry 
b/w 2000 and 2009; 
• Inclusion criteria – 
women ≥15 yrs 
with invasive BC;  
• Exclusion criteria – 
previous history of 
BC, in situ disease; 
• German national 
guideline (S3): 
Recommends 
specific treatment 
decisions based on 
tumor-related 
factors. 
 
• Primary endpoints: 
Rate of guideline-
adherent treatment 
usage, relative 
survival, relative 
excess risk (RER) 
in BC. 
 
• Increasing 
guideline 
adherence seen 
over time; 
• Use of BCS 
increased from 
59% to 67% over 
time span of study; 
• Rise in use of SNB 
(62%) over time; 
• CT use for lymph 
node pos. or 
hormone receptor 
neg. tumors 
increased from 
60% to 79%. Use 
of ET for hormone 
receptor pos. or 
mixed tumors rose 
from 79% to 93%, 
while trastuzumab 
treatment use for 
HER2 positive 
tumors rose to 
47%; 
• Non-guideline 
compliant 
treatment was 
associated with 
increased cancer-
related mortality 
[e.g., LN+ /HR-ve 
BC not treated with 
CT had a 5-yr 
relative survival of 
29% (Relative 
Excess Risk of 
death (RER): 2.89, 
95% CI: 1.46, 
5.71) compared to 
54% for pts who 
received CT].  
 
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Large sample size; 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification bias 
or coding errors; 
• Missing comorbidity 
data may create 
selection bias; 
• Data from one state 
may not be 
generalizable to rest 
of the country; 
• Confounding factors 
may affect outcomes. 
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Author(s), 
Country, 
Study Design 
& Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
8. Lebeau, 
Mathoulin-
Pelissier, 
Bellera, 
Tunon-de-
Lara, Daban, 
Lipinski, 
…& Migeot. 
(2011). 
 
France 
 
Retrospective 
cohort design 
 
Objective: To 
measure the 
compliance with 
CPGs for the 
management of 
non-metastatic 
BC care and to 
identify factors 
assoc. with non-
compliance at a 
clinical and 
organizational 
level. 
 
 
• N = 926;  
• Convenience 
sample from pt. 
medical records 
from multiple 
centers b/w 2003 
and 2004; 
• Inclusion criteria – 
women with 
invasive unilateral 
BC; 
• Exclusion criteria – 
metastatic disease, 
previous cancer 
diagnosis; 
• French national 
guideline: 
Recommends 
treatment for non-
metastatic 
according to pt. and 
tumor 
characteristics. 
 
• Primary endpoint: 
OR 
 
• Non-compliance 
with clinical 
decisions for 
treatment was 
assoc. with older 
pt. age (OR 2.1; 
95% CI: 1.3, 3.6) 
and healthcare 
region (OR 3.0; 
95% CI: 1.2, 7.4); 
• Non-compliance 
with clinical 
decisions for RT 
was assoc. with 
LN involvement 
or the presence of 
peritumoral 
vascular invasion 
(OR 1.5; 95% CI: 
1.01, 2.3) and 
non-compliance 
with overall 
treatment was 
assoc. with 
presence of 
positive LNs (OR 
2.0; 95% CI: 1.2, 
3.3), grade III vs 
grade I (OR 2.9; 
95% CI: 1.4, 6.2), 
and one healthcare 
region vs another 
(OR 3.5; 95% CI: 
1.7, 7.1). 
 
 
 
 
 
 
 
  
Strength of Study Design: 
Moderate 
 
Quality of the Study: Low 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Moderate sample size; 
• Multicenter study. 
 
Limitations 
• Much higher potential 
for misclassification 
bias or coding errors 
due to data collected 
from medical records; 
• Having to obtain 
patient consent 
allowed for a loss of 
23% of the eligible 
population which 
probably introduced 
selection bias; 
• Missing data created 
selection bias in an 
inability to explain 
non-compliance; 
• Potential for 
confounding. 
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Author(s), 
Country, 
Study Design 
& Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
9. Schwentner, 
van Ewijk, 
Kurzeder, 
Hoffman, 
Konig, 
Kreienberg, 
…& 
Wockel. 
(2013). 
 
Germany 
 
Retrospective 
cohort design 
 
Objective: To 
determine 
whether BC 
participation in 
adjuvant clinical 
trials improves 
survival, and 
whether 
guideline 
adherent 
adjuvant therapy 
is an equal 
alternative. 
 
• N = 9433; 
• Convenience 
sample from a 
specialized multi-
center BC database 
b/w 1992 and 2008; 
• Inclusion criteria – 
women with BC 
(either in a clinical 
trial or not) who 
received adjuvant 
therapy; 
• Exclusion criteria – 
in situ disease, 
metastatic disease, 
bilateral BC, occult 
disease, phylloides, 
and those with 
incomplete f/u, and 
unknown study 
participation status; 
• German national 
consensus guideline 
(S3): Recommends 
specific loco-
regional and 
systemic treatment 
decisions based on 
tumor-related 
factors.  
 
• Primary endpoints: 
RFS, OS in BC. 
 
 
 
 
 
 
 
 
• 13.3% (1255) 
participated in 
adjuvant clinical 
trials (PA) while 
86.7% (8178) did 
not (NPA); 
• RFS higher 
among PA than 
NPA (p = 0.006) 
but no significant 
difference in OS; 
• No significant 
difference b/w 
guideline adherent 
NPA compared to 
PA; 
• However, survival 
was significantly 
poorer in both 
non-guideline 
adherent PA 
(RFS: p < 0.001) 
(OS: p < 0.001) 
and non-guideline 
adherent NPA 
(RFS: p < 0.001) 
(OS: p < 0.001) as 
compared to 
guideline adherent 
PA.  
 
 
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Large sample size; 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification bias 
or coding errors; 
• Selection bias in 
clinical trial eligibility 
criteria; 
• Confounders can 
affect 
treatment/outcomes, 
especially co-
morbidities. 
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Author(s), 
Country, 
Study Design 
& Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
10. Verschoor, 
Kuijer, 
Verloop, van 
Gils, Sonke, 
Jager, …& 
Elias. 
(2016). 
 
Netherlands 
 
Retrospective 
cohort design 
 
Objective: To 
assess the 
impact of 
treatment 
guideline 
changes on the 
administration 
of adjuvant 
systemic therapy 
(AST) in early-
stage BC pts and 
the adherence of 
such on a 
nation-wide 
level.  
 
 
 
 
 
 
 
 
 
• N = 124,472;  
• Convenience 
sample from a 
national cancer 
registry, b/w 1990 
and 2012; 
• Inclusion criteria – 
women with early-
stage grade I – II 
BC who received 
AST; 
• Exclusion criteria – 
LA, or metastatic 
disease; 
• National Dutch 
guidelines: 
Recommends 
treatment for early-
stage BC as per 
guideline at each 
given time period.  
 
• Primary endpoints: 
Rates of AST and 
guideline adherence 
in stage I and II BC. 
• Adjuvant ET use 
increased from 
23% to 56% over 
timeframe, while 
CT from 11% to 
44%; 
• 8% received ET 
and 3% received 
CT without 
guideline 
indication, while 
10% - 29% did not 
receive either ET 
or CT despite a 
guideline 
indication; 
• Unfavorable 
clinicopathological 
factors generally 
decreased the risk 
of under-treatment 
and increased the 
risk of 
overtreatment; 
• There was an 
increased risk of 
ET under-treatment 
in younger women 
(RR < 35 yrs vs 
60-69 yrs 1.79; 
95% CI: 1.30, 
2.47) and in 
women with 
HER2+ disease 
(RR 1.64; 95% CI: 
1.46, 1.85). 
 
 
 
 
 
 
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Very large sample size; 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification bias 
or coding errors; 
• Does not account for 
confounding from lack 
of pt-related 
information such as 
adherence to therapy or 
specific reasons for 
nonadherence; 
• Selection bias may be 
present. 
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Key Results and 
Findings 
Strengths/ Limitations 
11. Wockel, 
Kurzeder, 
Geyer, 
Novasphenn
y, Wolters, 
Wischnewsk
y, …& 
Varga. 
(2010). 
 
Germany 
 
Retrospective 
cohort design 
 
Objective: To 
analyze the 
impact of a 
German breast 
cancer guideline 
adherence on 
clinical 
outcomes. 
 
 
• N = 3976;  
• Convenience 
sample from a 
specialized multi-
center BC database 
b/w 2001 and 2005; 
• Inclusion criteria - 
pts with invasive 
BC; 
• Exclusion criteria – 
metastatic disease, 
in situ disease, 
bilateral tumors, 
occult carcinomas, 
phylloides or 
sarcomas, or if 
incomplete tumor 
excision occurred 
after surgery;  
• German national 
consensus guideline 
(S3): Recommends 
specific loco-
regional and 
systemic treatment 
decisions based on 
tumor-related 
factors.   
 
• Primary endpoint: 
RFS, OS. 
 
 
 
 
 
 
 
 
 
 
• A significant 
assoc. exists b/w 
treatment 
adherence and 
prolonged RFS 
and OS (p = 
0.0001); 
• The greater the 
number of 
violations in 
guideline 
adherence, the 
lower the OS (p = 
0.0001); 
• Advanced age at 
diagnosis was 
assoc. with 
reduction in 
guideline 
adherence; 
• Guideline 
adherence for 
therapeutic 
modalities BCT, 
mastectomy, 
ALND, and ET 
was > 80%, CT 
guideline 
adherence was 
71.4%. 
 
 
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Large sample size 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification bias 
or coding errors; 
• Selection bias may 
have occurred due to 
risk assessment 
dataset excluding 
those > 70 yrs.; 
• Confounding factors 
such as physician-
related barriers and 
pt.-related factors may 
have affected results. 
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Author(s), 
Country, 
Study Design 
& Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
12. Wolters, 
Wischhusen, 
Stuber, 
Weiss, 
Krockberger
, Bartmann, 
…& 
Diessner. 
(2015). 
 
Germany 
 
Retrospective 
cohort design; 
 
Objective: To 
determine 
whether clinical 
outcomes of 
women with BC 
have improved 
during the last 
20 yrs 
irrespective of 
whether they 
were treated in 
accordance with 
clinical 
guidelines or not 
 
 
• N = 9061;  
• Convenience 
sample from a BC 
specialized 
multicenter 
database b/w 1991 
and 2009 [1991-
2000 (TI1) & 2001-
2009 (TI2)]; 
• Inclusion criteria - 
women with 
invasive BC and 
RFS ≥ 3 months; 
• Exclusion criteria – 
non-invasive BC, 
males, RFS < 3 
months; 
• German national 
consensus guideline 
(S3): Recommends 
specific loco-
regional and 
systemic treatment 
decisions based on 
tumor-related 
factors.  
 
• Primary endpoints: 
RFS, OS. 
 
 
 
 
 
 
 
 
 
 
 
 
• Clinical outcome 
of all pts 
significantly 
improved in TI2 
compared to TI1 
[RFS: p < 0.001, 
HR = 0.57, 95% 
CI (0.49, 0.67); 
OS: p < 0.001, HR 
= 0.76, 95% CI 
(0.66, 0.87)]; 
• OS and RFS of 
guideline-adherent 
pts also improved 
in TI2 compared 
to TI1; 
• The percentage of 
guideline-
conforming 
systemic therapy 
(ET & CT) 
significantly 
increased (p < 
0.001) in the time 
cohort TI1 - TI2 
for the non-
adherent group. 
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Large sample size; 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification bias 
or coding errors; 
• Missing comorbidity 
data may create 
selection bias; 
• Confounding factors 
may affect outcomes. 
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Author(s), 
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& Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
13. Wu, Lund, 
Kimmick, 
Richardson, 
Sabatino, 
Chen, …& 
Lipscomb. 
(2012). 
 
USA 
 
Retrospective 
cohort design 
 
Objective: To 
explore how 
factors such as 
race/ethnicity, 
insurance, 
poverty and 
education, and 
facility were 
assoc. with the 
receipt of 
guideline-
concordant 
adjuvant 
systemic 
therapy. 
 
 
• N = 6734;  
• Convenience 
sample from a 
national program of 
seven state cancer 
registries from 
2004; 
• Inclusion criteria – 
women ≥20 yrs 
with invasive BC;   
• Exclusion criteria – 
previous history of 
cancer, Paget’s 
disease, 
mesothelioma, 
Kaposi’s sarcoma, 
lymphoma, in situ 
disease, diagnosis 
by autopsy or death 
certificate; 
• NCCN guideline: 
Recommends CT 
dependent upon 
specific tumor 
factors such as size, 
grade, histology, 
and LN status. 
 
• Primary endpoints: 
Rates of guideline-
concordant receipt 
of adjuvant CT, 
regimens among 
adjuvant CT 
recipients, and ET. 
 
• Overall, 35% of 
women did not 
receive guideline-
concordant CT, 
12% received 
non-guideline-
concordant 
regimens, and 
20% received 
non-guideline-
concordant ET; 
• Significant 
predictors for 
receipt of non-
guideline- 
concordant CT 
included age ≥ 65 
yrs of age, race, 
insurance type, 
residing in high-
poverty low-
education areas, 
and treatment at 
non-specialized 
facilities; 
• Predictors of non-
guideline regimen 
use included lack 
of insurance, 
poverty, and low 
education after 
adjustment; 
• Poverty and 
treatment at non-
specialized 
facilities predicted 
non-guideline ET 
after adjustment.  
 
  
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence:    
Extrapolation 
 
Strengths 
• Large sample size; 
• Multicenter study 
which allows 
generalizability. 
 
Limitations 
• Potential for 
misclassification bias 
or coding errors; 
• Lost almost 20% of 
eligible cases due to 
missing 
data/information 
which may introduce 
selection bias; 
• One diagnosis year 
analysis does not 
allow for trend of 
change over time. 
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Findings 
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14. Mathew, 
Karia, 
Morgan, Lee, 
Ellis, 
Robertson, & 
Bello. (2017). 
 
Great Britain 
 
Retrospective 
cohort design 
 
Objective: To 
assess predictors 
for local 
recurrence (LR) 
in pts undergoing 
breast conserving 
surgery (BCS) for 
ductal carcinoma 
in situ (DCIS). 
 
 
 
 
 
• N = 582; 
• Convenience 
sample from a 
single institutions’ 
databases and pt 
medical records 
b/w 1975 and 
2008; 
• Inclusion criteria – 
women with DCIS 
who underwent 
surgical treatment 
(mastectomy and 
BCS) ±RT;  
• Exclusion criteria: 
previous history of 
treated invasive 
BC and developed 
subsequent DCIS; 
• Local guideline 
(prior to change in 
2008): Margin 
width of ≥10mm 
is preferred for pts 
undergoing BCS 
for DCIS. 
 
• Primary endpoint: 
Rates of DCIS LR 
in BCS. 
 
• Overall, 239 women 
had BCS for DCIS, 
with overall LR rate 
of 17% (40/239); 
• LR more common 
in pts ≤ 50 yrs 
(32%) vs > 50 yrs 
(14%) (p = 0.02); 
• LR for margins of 
<5mm was 43% vs 
5-9mm with 12% vs 
≥10mm with 14% 
p = 0.01); 
• Multivariate 
analysis found age 
≤50 yrs, and 
<5mm pathological 
margins were 
independent 
prognostic factors 
for LR. 
 
 
Strength of Study 
Design: Moderate 
 
Quality of the Study: 
Low 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Moderate sample 
size. 
 
Limitations 
• Potential for 
misclassification 
bias or coding 
errors. Though risk 
may be higher for 
misclassification 
error when data 
collected from 
individual hospital 
records; 
• Risk may also be 
higher for selection 
bias;  
• Data from single 
institution may not 
be as generalizable 
as multicenter 
studies; 
• Retrospective 
oncology data that 
covers a thirty-year 
period is open any 
number of 
confounding factors 
in terms of changes 
in treatment.  
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Author(s), 
Country, Study 
Design & 
Objective 
Sample & 
Methods 
 
Key Results and 
Findings 
Strengths/ 
Limitations 
15. Patrick, 
Hasse, 
Feinglass, & 
Khan. (2017). 
 
USA  
 
Retrospective 
cohort design 
 
Objective: To 
assess the 
progress in recent 
years of breast 
conserving 
therapy use in 
contemporary BC 
care. 
 
 
• N = 1,081,075; 
• Convenience 
sample from a 
national cancer 
data base, b/w 
1998-2011; 
• Inclusion criteria - 
women with 
invasive BC 
whose tumors 
were ≤2 cm; 
• Exclusion criteria 
– those with 
missing stage at 
diagnosis, males, 
missing zip codes, 
missing margin 
info, missing RT 
status; 
• NCCN guideline: 
For stage I – II 
BCs with T1 
tumors, BCS is 
recommended.  
 
• Primary 
endpoints: Rates 
of BCS and 
mastectomy in 
stage I and II BC. 
 
• Overall, 67% 
received BCS and 
33% underwent 
mastectomy; 
• Younger women 
(≤39 yrs) had the 
lowest odds of BCS 
(OR 0.49; 95% CI: 
0.48, 0.50); 
• Rates of BCS were 
significantly lower 
by race, income, 
insurance type and 
education; 
• 95% of BCS pts had 
tumor-free margins, 
with younger 
women (≤39 yrs) 
being 28% (OR 
0.72; 95% CI: 0.68, 
0.76) less likely to 
have tumor free 
margins compared 
to women aged 50-
69; 
• Overall,82% had 
post-lumpectomy 
RT and improved 
over time (less 
frequent in 
youngest and 
oldest); 
• Post-surgery ET use 
increased over time, 
while adjuvant CT 
use remained stable. 
ET use was 
significantly lower 
for race and 
education, while CT 
rates were lower as 
age increased. 
 
 
Strength of Study 
Design: Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Very large sample 
size; 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification 
bias or coding 
errors; 
• Potential for 
selection bias due to 
data collected from 
accredited cancer 
facilities only; 
• Does not account for 
patient-related 
treatment preference 
and co-morbidities 
which could 
introduce 
confounding.  
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Methods 
 
Key Results and 
Findings 
Strengths/ 
Limitations 
16. Persing, 
Jerome, 
James, Callas, 
Mace, 
Sowden, …& 
Sprague. 
(2015).  
 
USA 
 
Retrospective 
cohort design 
 
Objective: To 
determine 
whether 
compliance with 
the College of 
American 
Pathologists 
(CAP) guidelines 
affects re-excision 
and mastectomy 
rates after BCS 
with negative 
margins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• N = 1423;  
• Convenience 
sample from a 
state-wide BC 
imaging service 
b/w 1998 and 
2006; 
• Inclusion criteria – 
women whose 
initial BC surgery 
was BCS; 
• Exclusion criteria 
– all reports with 1 
or more positive 
margins, path. 
reported from slide 
reviews, 
synchronous 
primaries, reports 
of no residual 
tumor found on 
excision following 
a positive biopsy; 
• CAP guideline: 
Recommends 
pathologists 
document distance 
to closest negative 
margin with 
further 
recommendation 
to include margin 
distance at all six 
specimen 
orientations.  
 
• Primary endpoints: 
Re-excision and 
mastectomy rates 
and the CAP 
compliance in BC. 
 
 
• Pts with non-
compliant margin 
reporting were 1.7 
times (95% CI: 
1.15, 2.48) more 
likely to undergo re-
excision and/or 
mastectomy than 
those with 
maximally 
compliant reporting; 
• Level of 
compliance most 
strongly assoc. with 
frequency of 
mastectomy, with 
non-compliant 
margin reporting 
assoc. with a 2.5-
fold increase (95% 
CI: 1.6, 3.8) in 
mastectomy rates 
compared to 
maximally 
compliant reporting; 
• Trend less clear for 
frequency of re-
excision alone, 
although pts with 
minimal compliant 
reporting were 
more likely to 
undergo re-
excision compared 
to pts with 
maximally 
compliant reports 
(OR=1.6; 95% CI: 
1.1, 2.4). 
 
 
Strength of Study 
Design: Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Large sample size; 
• Multicenter study.   
 
Limitations 
• Potential for 
misclassification 
bias or coding 
errors; 
• Lack of data 
concerning 
additional decision-
making factors that 
influence treatment 
options may have 
introduced selection 
bias; 
• Certain pathological 
features not 
reported may have 
influenced decision 
to re-excise 
therefore 
introducing 
confounding; 
• Other system-level 
factors may also 
affect re-excision 
and mastectomy 
rates which create 
confounding.  
 
 
 
103 
 
Author(s), 
Country, Study 
Design & 
Objective 
Sample & 
Methods 
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Limitations 
17. White, 
Pruden, 
Kitchen, 
Villanueva, & 
Erbas. (2010). 
 
Australia 
 
Retrospective 
cohort design 
 
Objective: To 
examine the 
impact of the 
Australian 
treatment 
recommendations 
for DCIS on 
clinical practice 
and surgeons’ 
attitudes to the 
recommendations.  
 
 
• N1 = 342;   
• Convenience 
sample from a 
state-wide cancer 
registry b/w 
2002/2003 and 
2006/2007; 
• Inclusion criteria – 
women with DCIS 
before and after 
implementation of 
the guideline 
recommendations; 
• Exclusion criteria 
– LCIS, 
microinvasion; 
• Australian 
treatment 
guideline: 
Recommends 
image-guided core 
biopsy, obtaining 
clear margins, no 
ALND, RT after 
BCS. 
 
• Primary endpoint: 
Rates of cases 
adhering to 
guideline. 
 
 
 
 
 
 
 
 
 
 
 
• Compared to pre-
guideline 
implementation 
period, more BCS 
cases were referred 
to a RT oncologist 
(67% vs 58%) and 
more received RT 
(53% vs 44%) post-
guideline 
implementation; 
• Tumors > 20mm, 
intermediate grade 
and moderate 
necrosis were more 
likely to receive RT 
post-guideline 
implementation; 
• Among BCS, an 
increase SNB use 
was noted over the 
study period, with 
SNB more likely for 
larger tumors and 
tumors detected 
outside the 
screening program 
(both p < 0.01); 
• Among mastectomy 
cases post-guideline 
implementation, the 
only factor assoc. 
with SNB was 
annual caseload (p 
< 0.01), with Drs. 
Treating 10-15 
cases of DCIS more 
likely to perform 
SNB than those 
treating < 5 cases 
(OR 8.91; 95% CI: 
2.25, 35.34).  
Strength of Study 
Design: Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Moderate sample 
size; 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification 
bias or coding 
errors; 
• Potential for 
selection bias; 
• Does not account 
for confounding 
factors in RT use 
such as patient 
treatment 
preference. 
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Table 5: Radiation Therapy 
Author(s), 
Country, Study 
Design & 
Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ 
Limitations 
18. Berger, Wang, 
Kaufman, 
Williamson, 
Ibarra, Pollitt, 
…& Yao. 
(2017).  
 
USA 
 
Retrospective 
cohort design 
 
Objective: To 
examine the 
compliance rates of 
a post mastectomy 
radiation therapy 
(PMRT) before and 
after an 
implemented 2008 
quality measure 
(NAPBC) for BC 
patients with 
positive axillary 
lymph nodes (LN). 
 
 
• N = 34,752; 
• Convenience 
sample from a 
national cancer data 
base b/w the years 
of 2006 to 2013; 
• Inclusion criteria – 
post-mastectomy 
women > 18 yrs 
with invasive BC 
with ≥4 positive 
LN; 
• Exclusion criteria – 
multiple primary 
cancers, in situ or 
stage IV disease, or 
those who had 
neoadjuvant 
therapy; 
• NCCN/ASCO 
guidelines: Post-
mastectomy pts 
with ≥4 positive 
LNs should receive 
PMRT. 
 
• Primary endpoints: 
Rates of post-
mastectomy RT.  
 
 
 
 
 
 
 
 
• 62.3% or 21,638 of 
the sample received 
PMRT;  
• Significantly higher 
proportion of pts were 
treated with PMRT at 
accredited academic 
centers compared to 
non-accredited 
hospitals respectively 
(28% vs 16.4%); 
• Accredited academic 
centers also 
demonstrated 
considerably higher 
post-guideline 
compliance rates with 
PMRT than hospitals 
(2009: OR 1.41; 95% 
CI: 1.04, 1.93; 2011: 
OR 1.20; 95% CI: 
1.00, 1.56); 
• Pts less likely to 
receive PMRT were 
older, had lower 
income, and had 
either 
Medicare/Medicaid or 
were uninsured. 
 
 
 
 
      
Strength of Study 
Design: Moderate 
 
Quality of the 
Study: Medium 
 
Directness of 
Evidence: 
Extrapolation 
 
Strengths 
• Very large sample 
size; 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification 
bias or coding 
errors; 
• May have missed 
cases assigned to 
non-regular 
physician 
providers creating 
selection bias; 
• Difficulties 
encountered in 
drawing 
conclusions about 
improvement in 
pt care because of 
limited outcome 
variables 
available from the 
database used. 
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Author(s), 
Country, Study 
Design & 
Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ 
Limitations 
19. Dragun, Huang, 
Gupta, Crew, & 
Tucker. (2012). 
 
USA 
 
Retrospective 
cohort design 
 
Objective: To 
analyze trends of 
PMRT for LA BC 
prior to and since 
the ASCO 
guidelines, as well 
as the disparities 
and barriers to 
recommended care.  
 
 
• N = 8889; 
• Convenience 
sample from a state 
cancer registry b/w 
1995 and 2008; 
• Inclusion criteria – 
women ≥20 yrs 
with stage II (Group 
1- T2, N0) (Group 2 
– T1-2, N1) or III 
(Group 3 – T3-4, 
N2-3) BC; 
• Exclusion criteria – 
in situ disease, stage 
I or IV disease, 
previous history of 
cancer, first course 
treatment other than 
mastectomy; 
• ASCO guideline: 
Recommends 
PMRT is SOC for 
most stage II and III 
BC. 
 
• Primary endpoints: 
Rates of PMRT 
over time. 
 
 
 
 
 
 
 
 
 
 
 
• 24% received PMRT 
over study period 
(rates for Groups 1, 
2, and 3 were 7.5%, 
19.5%, and 47.3%, 
respectively); 
• Since 2001, use of 
PMRT increased 
from 21.1% to 
26.5%, p <0.0001, 
occurring mainly in 
Group 3 (from 40.8% 
to 51.2%, p <0.0001); 
• The average rate of 
PMRT remained 
constant in Group 1 
and decreased in 
Group 2; 
• Rate of PMRT was 
significantly lower in 
those >70 yrs, 
diagnosis prior to 
2001, rural 
populations, and 
Medicare pts (all p < 
0.0001); 
• In terms of disease 
specifics, pts was less 
likely to receive 
PMRT if they had 
stage II cancer, 
smaller tumor size, 
limited axillary 
surgery, or well-
differentiated and/or 
ductal histology (all p 
< 0.0001). 
 
 
 
 
 
 
Strength of Study 
Design: Moderate 
 
Quality of the 
Study: Medium 
 
Directness of 
Evidence: 
Extrapolation 
 
Strengths 
• Large sample 
size; 
• Multicenter 
study. 
 
Limitations 
• Potential for 
misclassification 
bias or coding 
errors; 
• Potential for 
missed data 
makes selection 
bias a 
fundamental risk 
with non-
randomized data; 
• Potential for 
confounding 
factors. 
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Author(s), 
Country, Study 
Design & 
Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ 
Limitations 
20. Hattangadi, 
Taback, 
Neville, Harris, 
& Punglia. 
(2012). 
 
USA 
 
Retrospective 
cohort design 
 
Objective: To 
evaluate patterns of 
accelerated partial 
breast irradiation 
using 
brachytherapy 
(APBIb) use after 
BCS compared 
with external beam 
whole breast 
irradiation (WBI) 
and whether APBIb 
treatment was 
concordant with 
guidelines.  
 
 
 
 
 
• N = 138,815; 
• Convenience sample 
from a national 
multi-center 
database of tumor 
registries b/w 2000 
and 2007; 
• Inclusion criteria – 
women with DCIS 
or invasive BC; 
• Exclusion criteria – 
previous cancer 
diagnosis, diagnosis 
obtained through 
death certificate or 
autopsy; metastatic 
disease, LCIS, 
mastectomy, 
incomplete RT 
information; 
• ASTRO guideline: 
Recommends 
appropriate pt. 
selection for APBI 
application based on 
pt. characteristics 
and clinical factors 
(3 groups – suitable, 
cautionary, & 
unsuitable. 
 
• Primary endpoints: 
Rates of WBI and 
APBI, and rates of 
guideline 
adherence. 
 
 
 
 
 
• Overall, 2.6% (3576) 
of pts received 
APBIb, and 65.8% of 
them were classified 
as cautionary or 
unsuitable; 
• 5% of pts who 
received APBIb were 
deemed suitable, 
3.4% were deemed 
cautionary, and 1.6% 
were deemed 
unsuitable by 
guideline standards 
(p < 0.001); 
• APBIb use increased 
from 0.4% in 2000 to 
6.6% in 2007 and 
vary widely b/w 
regions and 
institutions; 
• For pts with invasive 
BC, black women 
(OR 0.80; 95% CI: 
0.70, 0.92; p=0.002), 
Hispanic women (OR 
0.78; 95% CI: 0.67, 
0.90; p<0.001), and 
“other” races (OR 
0.5; 95% CI: 0.41, 
0.62, p <0.001) were 
less likely to receive 
APBIb than white 
and non-Hispanics 
women. 
 
 
 
Strength of Study 
Design: Moderate 
 
Quality of the 
Study: Medium 
 
Directness of 
Evidence: 
Extrapolation 
 
Strengths 
• Very large 
sample size; 
• Multicenter 
study. 
 
Limitations 
• Potential for 
misclassification 
bias or coding 
errors; 
• Potential for 
missing data and 
a resulting 
selection bias; 
• No discussion on 
study limitations; 
• Potential for 
confounding 
factors. 
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Author(s), 
Country, Study 
Design & 
Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ 
Limitations 
21. Struikmans, 
Aarts, Jobsen, 
Koning, 
Merkus, 
Lybeert, …& 
Coebergh. 
(2011). 
 
Netherlands 
 
Retrospective 
cohort design 
 
Objective: To 
evaluate the use of 
primary RT for pts 
with stages I-III BC 
in four of nine 
Dutch Cancer 
Centers. 
 
 
• N = 65,966;  
• Convenience sample 
from a nation-wide 
cancer registry of 4 
out of 9 cancer 
centers, b/w 1997 
and 2008; 
• Inclusion criteria – 
women with stages 
I-III BC; 
• Exclusion criteria – 
metastatic disease or 
unknown metastatic 
status; 
• A national BC 
treatment guideline: 
Recommends the 
use of RT according 
to tumor, stage, and 
surgery type. 
 
• Primary endpoints: 
Rates of primary 
RT and BCS. 
 
• Overall, there was a 
significant increase in 
the use of primary 
RT ranging from 
55%-61% (1997) to 
58%-68% (2008) and 
confirmed by 
multivariate analyses 
(OR 0.5; 95% ci: 0.4, 
0.5); 
• This was partly 
explained by a higher 
rate of BCS followed 
by RT in 87%-99% 
of cases, and a 
reduced rate of total 
mastectomy followed 
by RT in 26%-47% 
of cases; 
• Increasing age 
(especially >75 yrs) 
was assoc. with a 
reduced use of RT 
confirmed by 
multivariate analyses 
(OR ≥75 yrs vs <55 
yrs: 0.1; 95% CI: 0.1, 
0.2); 
• Regional variances 
were observed in the 
use of RT after BCS 
and mastectomy early 
in the study (1997), 
however this variance 
decreased over time 
(2008). 
 
 
 
 
 
 
 
 
Strength of Study 
Design: Moderate 
 
Quality of the 
Study: Medium 
 
Directness of 
Evidence: 
Extrapolation 
 
Strengths 
• Very large 
sample size; 
• Multicenter 
study. 
 
Limitations 
• Potential for 
misclassificatio
n bias or coding 
errors; 
• Cannot exclude 
selection bias; 
• Potential for 
confounding 
from pt.-
specific 
preferences. 
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Table 6: Breast Cancer Treatment in the Elderly 
Author(s), 
Country, Study 
Design & 
Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ 
Limitations 
22. Ebner, 
Hancke, 
Blettner, 
Schwentner, 
Wockel, 
Kreienberg, 
…& van 
Ewijk. (2015). 
 
Germany 
 
Retrospective 
cohort design 
 
Objective: To 
investigate the 
associations 
among tumor 
characteristics, 
guideline 
adherence, and 
outcome, and 
compare these 
associations b/w 
younger (yBCP) 
and older (oBCP) 
BC pts. 
 
 
• N = 7732;  
• Convenience sample 
from a multicenter BC 
database, b/w 1992 
and 2008; 
• Inclusion criteria – 
women who are yBCP 
(50 – 69 yrs) vs. 
oBCP (≥70 yrs); 
• Exclusion criteria - 
<50 yrs, those with 
missing data; 
• A national consensus 
guideline: 
Recommends 
treatment based on 
intrinsic subtype of 
BC. 
 
• Primary endpoint: 
DFS, OS, and 
guideline adherence 
in BC. 
 
• oBCP had 
significantly higher 
tumor stages (p < 
0.001), higher 
numbers of 
positive LNs (p = 
0.001), and more 
hormone receptor-
positive tumors (p 
= 0.001). oBCP 
also had lower 
tumor grading (p = 
0.001) and less 
frequent HER2neu 
overexpression (p 
= 0.003); 
• Analysis found that 
any nonguideline-
adherent treatment 
(or guideline 
violation) was 
significantly more 
common in oBCP 
than in yBCP (p < 
0.001; 
• Nonguideline-
adherent treatment 
is assoc. with 
decreased DFS 
[(yBCP HR 1.752; 
95% CI: 1.484, 
2.069) (oBCP HR 
1.702; 95% CI: 
1.402, 2.066)] (p = 
0.815) and OS 
[(yBCP HR 1.852; 
95% CI: 1.518, 
2.259) (oBCP HR 
1.693; 95% CI: 
1.392, 2.060)] (p = 
0.515) in pts with 
BC independent of 
age.  
Strength of Study 
Design: Moderate 
 
Quality of the Study: 
Medium 
 
Directness of 
Evidence: 
Extrapolation 
 
Strengths 
• Large sample size; 
• Multicenter study.   
 
Limitations 
• Potential for 
misclassification 
bias or coding 
errors; 
• Potential for 
selection bias; 
• Confounding may 
occur due to lack of 
data regarding 
comorbidities which 
may have affected 
the subjective 
judgement of the 
physician leading to 
nonguideline-
adherent treatment 
in oBCP; 
• Non-compliance to 
treatment may also 
be another 
confounding factor 
to affect results. 
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Author(s), 
Country, Study 
Design & 
Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ 
Limitations 
23. Hancke, 
Denkinger, 
Konig, 
Kurzeder, 
Wockel, Herr, 
…& 
Krelenberg. 
(2010). 
 
Germany 
 
Retrospective 
cohort design 
 
Objective: To 
determine if non-
adherence to 
treatment 
guidelines occurs 
for women aged 
≥70 yrs. and 
changes OS and 
DFS.  
 
 
• N = 1922;  
• Convenience sample 
from a specialized 
multi-center BC 
database b/w 1992 
and 2005, comparing 
pts aged 50 - 69 yrs to 
pts aged ≥ 70 yrs 
(stratified into three 
groups: 70 – 74 yrs, 
75-79 yrs, and ≥ 80 
yrs); 
• Inclusion criteria - 
women ≥50 yrs. with 
invasive BC; 
• Exclusion criteria – 
contralateral BC, in 
situ disease, 
metastatic disease, 
neoadjuvant CT, and 
age < 50 yrs.; 
• St. Gallen 
consensus/German 
national consensus 
guideline (S3): 
Recommends specific 
loco-regional and 
systemic treatment 
decisions based on 
tumor-related factors.   
 
• Primary endpoints: 
DFS, OS 
 
• Women > 70 yrs. 
less often 
received 
recommended 
BCS (70-79 yrs.: 
74%-83%; > 79 
yrs.: 54%) than 
women aged ≤
69 yrs. (93%); 
• Non-adherence to 
guidelines on RT 
(< 70 yrs.: 9%; 
70-79 yrs.: 14%-
27%; >79 yrs.: 
60%) and CT 
(<70 yrs.:33%; 
70-79 yrs.: 54%-
77%; >79 yrs.: 
98%) increased 
with age; 
• Omission of RT 
significantly 
decreased OS (≤
69 yrs.: HR = 
3.29; P<0.0001; 
≥70 yrs.: HR 
1.89; p = 0.0005) 
and DFS (≤69 
yrs.: HR 3.45; p < 
0.0001; ≥70 
yrs.: HR 2.14; p < 
0.0001). 
• OS and DFS did 
not differ 
significantly for 
adherence to 
surgery, CT, or 
ET. 
 
 
 
 
  
Strength of Study 
Design: Moderate 
 
Quality of the Study: 
Medium 
 
Directness of 
Evidence: 
Extrapolation 
 
Strengths 
• Large sample size; 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification 
bias or coding 
errors; 
• Potential for 
selection bias; 
• Potential 
confounding 
factors included 
lack of knowledge 
regarding 
comorbidities, and 
frailty.  
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Author(s), 
Country, Study 
Design & 
Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ 
Limitations 
24. McCormick, 
Ottesen, 
Hughes, Javid, 
Khan, 
Mortimer, 
…& Edge. 
(2014). 
 
USA 
 
Retrospective 
cohort design 
 
Objective: To 
analyze changes 
in patterns of 
treatment among 
older women 
within NCCN 
institutions before 
and after a 
guideline change.  
 
 
• N = 1292;   
• Convenience sample 
from a multicenter BC 
database, b/w 2000 - 
2004 and 2005 - 2009; 
• Inclusion criteria - 
women ≥70 yrs with 
stage I (T1 N0) 
hormone receptor-
positive BC treated 
with BCS;  
• Exclusion criteria – 
had tumor > 2 cm, 
mastectomy, no 
surgery, hormone 
receptor-negative, 
positive LNs, received 
systemic CT, ET, or 
both (including RT 
before surgery), and 
f/u of <365 days after 
diagnosis; 
• NCCN guideline 
(2004): 
Recommends 
omitting RT after 
BCS for women ≥
70 yrs with stage I 
ER+/PR+ BC, who 
receive ET. 
 
• Primary endpoint: 
Rate of RT use in 
BC after BCS. 
 
 
 
 
 
 
 
• Overall, 1005 
(78%) received 
RT and 287 (22%) 
did not; 
• RT was omitted in 
17% before 
guideline change 
and 26% omitted 
after; 
• When stratified by 
age groups, 
omission of RT 
was significantly 
assoc. with older 
age, specifically 
age ≥80 yrs [(OR 
80-84 yrs: 3.35; 
95% CI: 2.12, 
5.30) (OR 85+ 
yrs: 9.04; 95% CI: 
5.04, 16.21)] (p < 
0.0001); 
• RT also more 
likely to be 
omitted for those 
without axillary 
surgery, smaller 
tumor size, and 
those with higher 
comorbidity 
scores. Also, more 
likely to omit RT 
in those who 
received ET alone, 
compared to those 
who received CT; 
• Wide variation 
among NCCN 
institutions in 
omission of RT 
(7% - 51%). 
 
 
Strength of Study 
Design: Moderate 
 
Quality of the Study: 
Medium 
 
Directness of 
Evidence: 
Extrapolation 
 
Strengths 
• Large sample size; 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification 
bias or coding 
errors; 
• Potential for 
selection bias; 
• Individual provider 
biases and 
interpretation of 
clinical trial 
findings may 
create a 
confounding 
factor. 
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Author(s), 
Country, Study 
Design & 
Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ 
Limitations 
25. Van Ewijk, 
Wockel, 
Gundelach, 
Hancke, Janni, 
Singer, …& 
Schwentner. 
(2015). 
 
Germany 
 
Retrospective 
cohort design 
 
Objective:  
Clinical trials are 
largely 
unavailable to pts 
> 65 yrs, therefore 
an evaluation of 
whether 
guideline-
adherent adjuvant 
treatment is an 
equal alternative 
for this cohort is 
undertaken.  
 
 
• N = 4142;   
• Convenience sample 
from a BC specialized 
multicenter database 
b/w 1992 and 2008; 
• Inclusion criteria – 
women (< 65yrs vs. 
65-80 yrs) with 
primary invasive BC; 
• Exclusion criteria – 
bilateral BC, in situ 
disease, metastatic 
disease, phylloides, 
occult disease, those 
with incomplete f/u, 
unknown study 
participation status, 
unknown guideline 
conformity, receiving 
NAC, missing data on 
covariates; 
• German national 
consensus guideline 
(S3): Recommends 
specific loco-regional 
and systemic 
treatment decisions 
based on tumor-
related factors.  
 
• Primary endpoints: 
RFS, OS, and rate of 
guideline-adherent 
adjuvant treatment in 
BC. 
 
 
• 23.2% were < 65 
yrs and 76.8% 
were 65-80 yrs; 
• Pts ≥65 yrs were 
significantly more 
likely to have 
positive LNs, 
higher tumor 
grades, lower 
endocrine 
responsiveness, 
and higher rates of 
HER2 
overexpression, 
while elderly (65-
80 yrs) had 
significantly more 
co-morbidities and 
more favorable 
tumor biologies; 
• Pts ≥65 yrs not 
enrolled in clinical 
trials 
demonstrated a 
significantly 
inferior RFS (HR 
= 1.67; p < 0.001) 
and OS (HR = 
1.98; p < 0.001) 
compared to 
clinical trials 
participants < 65. 
 
 
 
 
Strength of Study 
Design: Moderate 
 
Quality of the Study: 
Medium 
 
Directness of 
Evidence: 
Extrapolation 
 
Strengths 
• Large sample size; 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification 
bias or coding 
errors; 
• Missing 
comorbidity data 
may create 
selection bias; 
• Confounding 
factors may affect 
outcomes.  
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Table 7: Molecular Profiling 
Author(s), 
Country, 
Study Design 
& Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
26. Chen & Li. 
(2015). 
 
USA 
 
Retrospective 
cohort design 
 
Objective: To 
utilize newly 
available data to 
characterize 
racial/ethnic 
differences in 
cancer stages 
and treatment 
patterns across 
BC subtypes 
using a 
nationally 
representative 
sample. 
 
 
• N = 102,064;  
• Convenience sample 
from multiple cancer 
registries, b/w 2010 
and 2011;  
• Inclusion criteria - 
women ≥ 20 yrs 
with primary invasive 
BC and known stage, 
hormone receptor and 
HER2 status; 
• Exclusion criteria – 
unknown HER2 or 
hormone receptor 
status, unknown 
cancer stage, 
unknown 
race/ethnicity; 
• NCCN guideline: 
Recommends the 
same primary 
treatment (total 
mastectomy, or BCS 
with RT) for women 
(< 70 yrs with stage 
I/II disease and 
tumors <2.0 cm) 
meeting those criteria 
regardless of their ER, 
PR, and HER2 status. 
 
• Primary endpoints: 
BC risk and guideline 
concordant treatment 
according to hormone 
receptor/HER2 status.  
 
• Overall, women 
of all other 
racial/ethnic 
groups had a 20% 
to 60% higher 
risk of stage II-IV 
BC compared to 
non-Hispanic 
whites; 
• African 
American women 
had 40% - 70% 
higher risks of 
stage IV BC 
across all four 
subtypes (OR 
1.6; 95% CI: 1.4, 
1.7); 
• American 
Indian/Alaska 
Native women 
had a 3.9-fold 
higher risk (OR 
3.9; 95% CI: 1.7, 
9.2) of stage IV 
TNBC; 
• African 
American and 
Hispanic whites 
were 30% - 40% 
[(OR 1.4; 95% 
CI: 1.3, 1.6) (OR 
1.3; 95% CI: 1.2, 
1.4), 
respectively] 
more likely to 
receive non-
guideline 
concordant 
treatment for BC 
overall and across 
subtypes. 
 
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Very large sample size; 
• Multicenter study. 
 
Limitations 
• Potential risk for 
misclassification bias 
(e.g., race/ethnicity) or 
coding errors; 
• Missing data may 
create selection bias 
with excluded pts; 
• Variation in reporting, 
testing, and 
interpretation of tumor 
biomarkers b/w 
hospitals may have 
introduced 
misclassification 
errors; 
• These registries lack 
data on other aspects of 
BC care such as CT, 
ET, and trastuzumab 
use, as well as pt-
related factors which 
may have contributed 
to observed disparities. 
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Author(s), 
Country, 
Study Design 
& Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
27. Schreuder, 
Kuijer, 
Rutgers, 
Smorenburg, 
van Dalen, 
& Siesling. 
(2017). 
 
Netherlands 
 
Retrospective 
cohort design 
 
Objective: 
Assess the use 
and impact of 
gene expression 
profiles (GEP), 
using 
MammaPrintᵀᴹ 
70-gene 
signature, on 
adjuvant CT 
national 
guidelines 
according to 
clinical high or 
low risk. 
 
 
 
• N = 26,425; 
• Convenience sample 
from a national cancer 
registry b/w the years 
of 2011 to 2014; 
• Inclusion criteria – 
women with ER+ 
early BC (stratified as 
low-risk or high-risk); 
• Exclusion criteria – 
prior hx of malignancy 
or adjuvant CT; >70 
yrs; pts who guideline 
already advises use of 
GEP as an adjunct to 
guide adjuvant 
treatment decisions; 
• National Dutch 
guideline: 
Recommends use of 
GEP in early BC pts, 
in whom benefit of CT 
is uncertain. 
 
• Primary endpoints: 
Rates of GEP testing 
in accordance with 
guideline 
recommendation in 
adjuvant CT treatment 
decision-making. 
 
•  Overall, 68.5% 
of pts with 
discordant 
clinical and 
genomic risk 
estimation were 
treated in line 
with the GEP test 
result; 
• GEPs assigned 
20.3% of clinical 
low-risk pts to a 
high genomic risk 
category; 
• GEP use was 
independently 
associated with 
an increased risk 
of receiving CT 
in clinical low-
risk pts (OR 2.12, 
95% CI: 1.44, 
3.11); 
• GEPs assigned 
35% of clinical 
high-risk patients 
to a low genomic 
risk category; 
• In clinical high-
risk pts who 
received a GEP, a 
low-risk GEP 
result was 
strongly 
associated with a 
decreased risk of 
CT 
administration 
(OR 0.05, 95% 
CI: 0.03, 0.07). 
 
 
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Very large sample size 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification bias 
or coding errors. 
• Potential for selection 
bias; 
• Despite a 
multivariable logistic 
regression analysis, 
confounding by 
indication cannot be 
ruled out. 
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Author(s), 
Country, 
Study Design 
& Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
28. Schwentner, 
Wockel, 
Konig, 
Jasnni, 
Boner, 
Blettner, 
…& Van 
Ewijk for the 
Brenda 
study group. 
(2013). 
 
Germany 
 
Retrospective 
cohort design 
 
Objective: To 
compare 
survival in pts 
with triple 
negative BC 
(TNBC) to those 
with other BC 
subtypes (non-
TNBC).  
 
 
 
   
 
 
• N = 9156; 
• Convenience sample 
from a specialized 
multi-center BC 
database b/w 1992 
and 2008; 
• Inclusion criteria – 
women with invasive 
BC; 
• Exclusion criteria – in 
situ disease, 
metastases, bilateral 
BC, primary occult 
disease, phylloides 
tumor, incomplete f/u, 
unknown HER2 status 
or ER/PR status, or 
missing data on 
chosen variables; 
• German national 
consensus guideline 
(S3): Recommends 
specific loco-regional 
and systemic 
treatment decisions 
based on tumor-
related factors.  
 
• Primary endpoint: 
DFS, OS. 
  
 
• 844 pts (9.2%) 
had TNBC; 
• TNBC 
demonstrated 
significantly 
decreased OS 
(HR 1.92; p < 
0.001) and DFS 
(HR 1.53; p < 
0.001) than non-
TNBC; 
• TNBC pts aged 
≥ 65 yrs had a 
significantly 
worse OS (HR 
0.31; p < 0.001) 
and DFS (HR 
0.42; p < 0.001) 
compared to 
TNBC pts aged 
50-64; 
• Guideline 
adherence was 
significantly 
lower in all age 
groups of TNBC 
pts compared to 
non-TNBC pts (p 
< 0.001); 
• TNBC pts in all 
three age groups 
who were treated 
by guidelines had 
a better OS and a 
better DFS. 
 
 
 
 
 
 
 
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Large sample size; 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification bias 
or coding errors due 
to missing data; 
• Selection bias is 
always a fundamental 
risk with non-
randomized data; 
• Potential for 
confounding factors. 
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Author(s), 
Country, 
Study Design 
& Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
29. Schwentner, 
Wolters, 
Koretz, 
Wischnewsk
y, 
Kreienberg, 
Rottscholl, 
& Wockel. 
(2012). 
 
Germany 
 
Retrospective 
cohort design 
 
Objective: To 
analyze the 
assoc. b/w 
guideline-
adherent 
adjuvant 
treatment and 
survival 
outcomes in 
TNBC by 
investigating the 
impact of 
different 
guideline-
adherent 
therapies for 
TNBC on 
survival. 
 
 
• N = 3658; 
• Convenience sample 
from a specialized 
multi-center BC 
database b/w 2000 
and 2005; 
• Inclusion criteria – 
women with invasive 
BC; 
• Exclusion criteria – in 
situ disease, 
metastatic disease, 
bilateral BC, occult 
disease, and those 
with incomplete f/u; 
• German national 
consensus guideline 
(S3): Recommends 
specific loco-regional 
and systemic 
treatment decisions 
based on tumor-
related factors.  
 
• Primary endpoints: 
RFS, OS. 
 
• 10.1% (371) pts 
had TNBC; 
• Compared to 
hormone 
receptor-
positive/HER2- 
BC (p = 0.001) 
(HR 1.75; 95% 
CI: 1.27, 2.40), 
the recurrence 
rate of TNBC 
was significantly 
higher (p < 
0.001) (HR 2.86; 
95% CI: 2.17, 
3.76); 
• 5-yr RFS and OS 
was significantly 
lower in TNBC 
[RFS: 74.8% 
(95% CI: 68.8-
80.8%) vs 86.5% 
(95% CI: 84.6-
88.4%) (log-rank 
p = 0.0001)] [OS: 
75.8% (95% CI: 
69.9-81.8%) vs 
86.0% (95% CI: 
84.1-87.9%) (log-
rank p = 
0.0001)]; 
• Overall, 66.8% 
TNBC were 
found with one or 
more (18%) 
guideline 
violations, which 
subsequently 
impaired OS and 
RFS (with RT 
and CT having 
the most 
important impact 
on survival). 
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Large sample size; 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification bias 
or coding errors due 
to missing data; 
• Selection bias is 
always a fundamental 
risk with non-
randomized data; 
• Potential for other 
unknown confounding 
factors; 
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Table 8: Staging Investigations 
Author(s), 
Country, 
Study Design 
& Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
30. Hahn, Tang, 
Lee, Munoz-
Plaza, 
Adesina, 
Shen, …& 
Gould. 
(2015).  
 
USA 
 
Retrospective 
cohort design 
 
Objective: To 
evaluate and 
compare use of 
imaging for 
staging of breast 
cancer in two 
integrated health 
care systems 
(i.e., KP and 
IH). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• N = 10,010;  
• Convenience sample 
from tumor 
registries and EMRs 
of two regional 
health care systems, 
b/w 2010 and 2012; 
• Inclusion criteria - 
women with stages 0 
to IIb BC; 
• Exclusion criteria – 
history of previous 
cancer diagnosis 
(except non-
melanoma skin 
cancers); 
• NCCN/CCO/AHS/A
SCO and Choose 
Wisely campaign 
guidelines: 
Recommends 
against use of 
advanced imaging 
for staging of early 
BC.   
 
• Primary endpoint: 
Rate of unnecessary 
staging imaging in 
early-stage BC. 
 
• Overall, at least 
15% of pts (1480) 
received at least one 
imaging test, with 
no statistically 
significant 
differences b/w the 
two regions; 
• Cat scan was most 
commonly used 
imaging modality 
(73%); 
• Close to half (48%) 
of all imaging tests 
were performed for 
diagnostic 
purposes; 
• 55% of imaging at 
KP were considered 
diagnostic while 
only 33% at IH.  
 
 
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Very large sample size 
over geographically 
distinct regions; 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification bias 
or coding errors; 
• Included data from 
only three of the seven 
KP regions, so 
potential for selection 
bias and 
misclassification 
error; 
• Only had a small 
number of chart 
abstractions (16%) in 
pre-surgical imaging 
and did not investigate 
other imaging services 
which may create 
confounding; 
• Generalizability of 
results may be limited 
due to large integrated 
health care systems. 
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Author(s), 
Country, 
Study Design 
& Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
31. Han, 
Hogeveen, 
Goldstein, 
George, 
Brezden-
Masley 
Hoch, …& 
Simmons. 
(2012). 
 
Canada 
 
Retrospective 
cohort design 
 
Objective: To 
assess 
consistency of 
radiological 
staging in an 
academic 
community 
oncology setting 
with standard 
guidelines and 
to determine the 
overall impact 
of non-
adherence. 
 
 
• N = 231; 
• Convenience sample 
from pt. records of a 
single institution 
b/w 2009 and 2010; 
• Inclusion criteria – 
women with stage I 
- III BC who had 
received diagnosis 
and surgery at the 
study institution; 
• Eligibility criteria – 
recurrent BC, in situ, 
or stage IV, primary 
surgery or oncology 
referral to other 
institutions; 
• CCO guideline: 
Recommends stage 
I – no staging 
investigations, stage 
II – bone scan only, 
stage III – 
chest/abdominal 
imaging and bone 
scan. 
 
• Primary endpoints: 
Rates of over-
staging and 
guideline 
adherence. 
 
 
 
 
 
 
 
 
 
 
• 55% (129) of pts 
underwent 
unnecessary 
investigations 
according to 
guideline; 
• 59% of stage I and 
58% of stage II pts 
were over-
investigated; 
• Distant metastases 
at time of dx was 
found in 1.3%, all 
of whom all had 
stage III disease; 
• Estimated cost of 
non-adherence is 
approx. $78 
Canadian per early-
stage BC pt.  
 
  
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Moderate sample size; 
• Canadian provincial 
study. 
 
Limitations 
• Potential for 
misclassification bias or 
coding errors due to 
missing data; 
• Single institution 
studies may not be 
generalizable; 
• Potential for selection 
bias by eliminating 
those who may have 
received diagnosis and 
surgery at different 
settings; 
• No discussion of 
statistical calculations 
or study limitations; 
• Potential for 
confounding factors 
such as determining 
whether imaging for 
staging or diagnostic 
purposes. 
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Author(s), 
Country, 
Study Design 
& Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
32. Simos, 
Catley, van 
Walraven, 
Arnaout, 
Booth, 
McInnes, 
…& 
Clemons. 
(2015). 
 
Canada 
 
Retrospective 
cohort design 
 
Objective: To 
determine 
whether practice 
patterns in 
Ontario conform 
with the 
guideline 
recommendation 
to not perform 
imaging to 
detect metastatic 
disease in the 
majority of pts 
with early-stage 
BC, who are 
asymptomatic.  
 
 
 
 
 
 
 
 
 
 
 
 
 
• N = 26,547;  
• Convenience 
sample from a 
provincial cancer 
registry linked to a 
hospital database 
b/w 2007 and 2012; 
• Inclusion criteria – 
women with early-
stage (stage I – II) 
invasive BC; 
• Exclusion criteria – 
prior BC diagnosis, 
stages 0/III/IV 
disease, 
null/unknown stage 
disease, DCIS, LA 
or inoperable 
disease; 
• CCO guideline: 
Recommends no 
imaging for stage I 
and a bone scan for 
stage II disease for 
staging of early BC 
pts. 
 
• Primary endpoints: 
Rate of 
inappropriate 
staging imaging in 
early-stage BC. 
 
• 85.9% (22,811) had 
at least one imaging 
test for distant 
metastatic disease, 
with a total of 
83,249 imaging 
tests performed 
(mean of 3.7 
imaging tests per 
pt); 
• Despite guidelines 
(CCO and ASCO) 
recommending no 
imaging for 
asymptomatic, 
stage I and II pts, 
imaging was 
performed in 79.6% 
and 92.7% of cases, 
respectively; 
• Of all imaging tests, 
23.8% were 
classified as 
confirmatory 
investigations 
(additional imaging 
test performed on a 
body site that had 
already been 
imaged); 
• Imaging more 
likely for younger 
pts, those with more 
comorbidities, 
higher grade/stage 
tumors, undergone 
pre-op breast 
ultrasound, 
mastectomy or 
surgery in the 
community setting. 
 
 
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Very large 
representative sample 
size; 
• Multicenter study; 
• Canadian provincial 
study (results may be 
more likely to be 
comparable and 
relatable to other 
Canadian provincial 
studies). 
 
Limitations 
• Potential for 
misclassification bias 
or coding errors due to  
missing data to 
determine specific 
indication for 
imaging; 
• Potential confounding 
since data did not 
allow determination of 
symptomatology 
timeline. 
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Table 9: Breast Cancer Characteristics 
Author(s), 
Country, Study 
Design & 
Objective 
Sample & 
Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
33. Schwentner, 
Wolters, 
Wischnewsky, 
Kreienberg, & 
Wockel. 
(2012). 
 
Germany 
 
Retrospective 
cohort design 
 
Objective: To 
examine survival 
parameters in pts 
with bilateral 
(BBC) vs 
unilateral (UBC) 
unifocal BC, and 
treatment patterns 
and their 
influence on 
guideline 
adherence on pt. 
survival. 
 
 
• N = 5292; 
• Convenience 
sample from a 
specialized 
multi-center BC 
database b/w 
2000 and 2005; 
• Inclusion criteria 
– women with 
either BBC or 
UBC; 
• Exclusion 
criteria – in situ 
disease, 
metastatic 
disease, bilateral 
BC, occult 
disease, and 
those with 
incomplete f/u; 
• German national 
consensus 
guideline (S3): 
Recommends 
specific loco-
regional and 
systemic 
treatment 
decisions based 
on tumor-related 
factors. 
 
• Primary 
endpoints: RFS, 
OS. 
 
 
 
 
 
 
• 4.3% (229) pts had 
BBC and 95.7% 
(5063) had UBC; 
• No significant 
difference b/w 
different hospitals in 
terms of guideline 
adherence; 
• Pts with BBC were 
found to have a 
significant inferior 
RFS (p < 0.001) 
(HR 1.89; 95% CI: 
1.46, 2.45) 
compared to UBC 
even after adjusting 
for tumor size, nodal 
status and grading (p 
= 0.022) (HR 1.39; 
95% CI: 1.05, 1.85); 
• OS was also 
significantly 
impaired for BBC 
pts (p = 0.004) (HR 
1.55; 95% CI: 1.15, 
2.07) though this 
was not significant 
after adjusting; 
• Only 15.7% of pts 
with BBC were 
treated with 100% 
guideline-adherence; 
• Outcome decreases 
significantly with 
the # of guideline 
violations. 
 
 
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Moderate sample size; 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification bias 
or coding errors due 
to missing data; 
• Selection bias is 
always a fundamental 
risk with non-
randomized data; 
• Potential for other 
unknown confounding 
factors. 
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Author(s), 
Country, Study 
Design & 
Objective 
Sample & 
Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
34. Wolters, 
Wockel, 
Janni, 
Novopashenn
y, Ebner, 
Kreienberg, 
…& 
Schwentner. 
(2013). 
 
Germany 
 
Retrospective 
cohort design 
 
Objective: To 
investigate the 
impact of 
multicentric 
(MC)/multifocal 
(MF) BC, and 
whether current 
validated 
guidelines present 
effective 
treatment 
recommendations 
to improve 
outcomes for 
these subtypes of 
BC.  
• N = 8935; 
• Convenience 
sample from a 
specialized 
multi-center BC 
database b/w 
1992 and 2008; 
• Inclusion criteria 
– women with 
invasive BC 
having unifocal 
(UF), MC, or MF 
tumors;   
• Exclusion 
criteria – in situ 
disease, 
metastatic 
disease, bilateral 
BC, occult 
disease, 
phylloides, and 
those with 
incomplete f/u; 
• German national 
consensus 
guideline (S3): 
Recommends 
specific loco-
regional and 
systemic 
treatment 
decisions based 
on tumor-related 
factors.  
 
• Primary 
endpoints: RFS, 
OS. 
 
 
• 79.2% (7073) had 
UF tumors, 15.6% 
(1398) had MF, and 
5.2% (464) had MC; 
• Compared to UF 
BC, RFS was 
significantly worse 
for pts with MC 
[RFS p = 0.019; HR 
1.38 (95% CI: 1.06, 
1.80)] and pts with 
MF [RFS p = 0.007; 
HR 1.25 (95% CI: 
1.06, 1.48)]; 
• OS was also 
significantly worse 
for MC pts [OS p 
=0.001; HR 1.46 
(95% CI: 1.16, 
1.83)] but no 
significant 
difference found in 
OS b/w MF and UF 
BCs [OS p = 0.321; 
HR 0.92 (95% CI: 
0.79, 1.08)]; 
• Guideline adherence 
was significantly 
lower in pts with MF 
(n=580; 41.5%) and 
MC (n=204; 44.0%) 
compared to pts with 
UF (n=3871; 54.7%) 
(p < 0.001) tumors; 
• Guideline violations 
were assoc. with a 
highly significant 
deterioration in RFS 
and OS throughout 
all subgroups except 
MC. 
 
  
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence:    
Extrapolation 
 
Strengths 
• Large sample size; 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification bias 
or coding errors due 
to missing 
information; 
• Selection bias is 
always a fundamental 
risk with non-
randomized data; 
• Potential for 
confounding factors. 
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Table 10: Axillary Lymph Node Evaluation 
Author(s), 
Country, 
Study 
Design & 
Objective  
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
35. Chong, 
Walters, de 
Silva, 
Taylor, 
Spillane, 
Kollias, … 
& 
Maddern. 
(2013). 
 
Australia/New 
Zealand 
 
Retrospective 
cohort design 
 
Objective: To 
examine the 
patterns of 
ALND after 
SNB in 
women treated 
for early-stage 
BC.   
 
 
• N = 14,879; 
• Convenience sample 
from a national 
multi-center BC 
surgery database b/w 
2006 and 2010; 
• Inclusion criteria – 
women with invasive 
BC, either ≤3 cm or 
>3 cm; 
• Exclusion criteria – 
those with missing 
data, or had received 
NAC; 
• Cancer 
Australia/New 
Zealand treatment 
guidelines: 
Recommends SNB 
as valid alternative to 
ALND when BC 
tumor ≤3 cm; 
ALND when SN is 
positive; observe 
axilla only if SNB is 
negative. 
 
• Primary endpoints: 
rates of ALND after 
positive and negative 
SNB. 
 
 
 
 
• For those with 
tumors ≤3 cm, 
24.1% had at least 
one pos. SN (only 
78.7% of these 
underwent 
ALND). The 
remaining 75.9% 
had a neg. SN, 
though 9.6% went 
on to have ALND;  
• For those with 
tumors >3 cm, 
half had a pos. SN 
with 15.3% not 
undergoing 
ALND. While 
21% of pts with a 
neg. SN went on 
to have ALND; 
• Only pts age >70 
yrs was 
statistically 
significant 
favoring SN pos. 
pts not proceeding 
to second surgery 
(p < 0.001) (OR 
2.3; 95% CI: 1.6, 
3.3); 
• Among pts with 
an neg. SN result, 
those with >3cm 
tumors (p < 
0.001), higher 
tumor grade (p = 
0.006), dx of LVI 
(p = 0.008) and 
age <40 yrs (p = 
0.01) were more 
likely to proceed 
to ALND. 
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Very large sample size; 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification bias 
or coding errors; 
• Selection bias is 
always a fundamental 
risk with non-
randomized data; 
• Potential for 
confounding due to 
individual health 
provider biases and 
interpretation of 
clinical trial findings. 
 
 
122 
 
Author(s), 
Country, 
Study 
Design & 
Objective  
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
36. Mitchell, 
Lin, Shen, 
Colfry, 
Kuerer, 
Shaitelman 
…& 
Bedrosian. 
(2017). 
 
USA 
 
Retrospective 
cohort design 
 
Objective: To 
analyze all 
surgical 
approaches to 
axillary 
evaluation in 
pts with DCIS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• N = 88,083; 
• Convenience sample 
from a national 
cancer data base b/w 
1998 and 2011; 
• Inclusion criteria – 
women with DCIS 
who either 
underwent 
mastectomy or BCS; 
• Exclusion criteria – 
history of prior 
cancer, received 
chemotherapy, 
insurance status 
unknown, treated at 
other specified types 
of cancer programs; 
• NCCN/ASCO 
guidelines: 
Recommends the use 
of SNB, not ALND 
for the surgical 
management of 
DCIS, in the absence 
of invasive cancer or 
proven axillary 
disease. 
 
• Primary endpoint: 
Rates of SNB or 
ALND in DCIS. 
 
• 37% (31,912) of 
pts underwent 
total mastectomy 
while 63% 
(55,349) had 
BCS; 
• The use of SNB 
for mastectomy 
increased from 
24.3% to 77.1%, 
while ALND 
decreased from 
50.0% to 16.3% 
(p<0.01); 
• The use of SNB 
for BCS increased 
from 7.2% to 
39.4%, and 
ALND decreased 
from 12.9% to 
4.5% (p<0.01); 
• On multivariate 
analysis, those 
who underwent 
total mastectomy 
at community 
cancer program 
were less likely to 
have an axillary 
examination 
compared to an 
academic/research 
program [OR 0.63 
(95% CI: 0.54, 
0.75)] and [OR 
0.84 (95% CI: 
0.76, 0.93)], 
respectively; 
• Facility type and 
location were also 
significant for 
those who 
underwent BCT. 
Strength of Study Design: 
Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Very large sample size; 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification bias 
or coding errors due to 
missing data on use of 
NAC; 
• Selection bias is 
always a fundamental 
risk with non-
randomized data; 
• Does not account for 
patient-related factors 
such as treatment 
preference. 
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Table 11: Immediate Breast Reconstruction 
Author(s), 
Country, Study 
Design & 
Objective 
Sample & Methods Key Results and 
Findings 
Strengths/ 
Limitations 
37. Van Bommel, 
Mureau, 
Schreuder, 
van Dalen, 
Vrancken-
Peeters, 
Schrieks, ,,, & 
Siesling. 
(2017). 
 
Netherlands 
 
Retrospective 
cohort design 
 
Objective: To 
evaluate the use 
of immediate 
breast 
reconstruction 
(IBR) after 
mastectomy for 
invasive BC and 
DCIS and 
determine 
whether any 
variation is 
associated with pt 
and tumor factors. 
 
 
 
 
 
 
 
• N = 16,953; 
• Convenience sample 
from a national 
multicenter BC 
database, from 2011 
to 2013; 
• Inclusion criteria – 
women with either 
DCIS or invasive 
BC; 
• Exclusion criteria – 
presence of 
metastatic disease, 
non-mastectomy 
surgical 
interventions; 
• National 
Dutch/NICE 
guidelines: 
Recommends 
considering IBR in 
all pts who undergo 
mastectomy. 
 
• Primary endpoint: 
IBR rates for 
invasive BC and 
DCIS. 
 
• On average 16.8% 
(2536) of pts with 
invasive BC 
underwent IBR, while 
42% (786) of those 
with DCIS had IBR;  
• For invasive BC, 
younger pts (<50 yrs) 
utilized IBR more 
frequently (OR 1.73; 
95% CI: 1.58, 1.91) 
compared to 50-65 yrs 
age group. Used less 
often in those with 
large tumors and/or 
involved lymph nodes; 
• For DCIS, younger 
age and multifocality 
significantly increased 
IBR rates. Older age 
(≥65 yrs) had a OR of 
0.16 compared to pts 
50-65 yrs, while pts 
with multifocal disease 
had a 1.56-fold higher 
chance of undergoing 
IBR compared to those 
with unifocal tumors 
(95% CI: 1.22, 1.99); 
• After adjustments, 
variation in use of IBR 
b/w hospitals remained 
large. 
 
 
 
 
  
 
Strength of Study 
Design: Moderate 
 
Quality of the 
Study: Medium 
 
Directness of 
Evidence: 
Extrapolation 
 
Strengths 
• Very large 
sample size; 
• Multicenter 
study. 
 
Limitations 
• Potential for 
misclassification 
bias or coding 
errors. 
• Registration 
(selection) bias 
may be present 
which may also 
create 
misclassification 
error; 
• Does not account 
for confounding 
pt-related factors, 
such as 
preference, lack 
of knowledge, 
beliefs of 
physicians/surge
ons, or hospital-
related factors 
(urban vs rural, 
availability of a 
plastic surgeons). 
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Table 12: Genetic Referrals 
Author(s), 
Country, 
Study 
Design & 
Objective 
Sample & Methods 
 
Key Results and 
Findings 
Strengths/ 
Limitations 
38. Stuckey, 
Febbraro, 
Laprise, 
Wilbur, 
Lopes, & 
Robison. 
(2016). 
 
USA 
 
Retrospective 
cohort design 
 
Objective: To 
evaluate the 
referral 
patterns for 
genetic 
counseling and 
testing of 
women with 
an history of 
BC diagnosis 
who are < 50 
yrs.  
 
 
 
 
 
 
 
 
 
 
 
 
• N = 314;  
• Convenience sample 
from an institutional 
tumor registry and a 
chart review from an 
academic oncology 
program b/w 2004 and 
2010; 
• Inclusion criteria – 
women ≤ 50 yrs 
without a documented 
BRCA mutation, who 
meet the eligibility 
criteria for high risk; 
• Exclusion criteria – 
those who did not 
meet the eligibility 
criteria for high risk; 
• NCCN guideline: 
Recommends that pts 
who meet the 
eligibility criteria 
should trigger referral 
for genetic counseling 
(BC diagnosis at ≤50 
yrs, TNBC, ≥2 BC 
primaries in one 
individual, male BC, 
Aahkenazi Jewish 
descent, and BC at any 
age with family 
history of breast 
and/or ovarian 
cancer).  
 
• Primary endpoint: 
Rates of genetic 
counseling referral for 
high risk pts (≤ 
50yrs).  
• An overall referral 
rate of 34.1% (107 
of the 314 women) 
indicated a 
suboptimal referral 
to genetic 
counseling (but did 
increase over 
time); 
• 77.6% of those 
referred received 
counseling and 
95.2% underwent 
genetic testing 
(16.5% had a 
BRCA mutation); 
• Women with a 
suspicious family 
history were more 
likely to be 
referred (67.3% vs 
36.2%; p < 
0.0001); 
• Women who chose 
prophylactic 
contralateral 
mastectomy also 
were more likely to 
be referred (63.6% 
vs 36.4%; p < 
0.0001). 
 
 
  
Strength of Study 
Design: Moderate 
 
Quality of the Study: 
Medium 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Moderate sample size. 
 
Limitations 
• Potential for coding 
errors; 
• Misclassification error 
and/or selection bias 
may have been 
introduced if pts 
received genetic 
counseling/testing 
elsewhere, or from 
missing data when 
referrals may not have 
been charted; 
• Differences in pre-
existing guidelines 
(other than NCCN) 
and changes at a 
program level may 
have resulted in larger 
number of referrals 
which could create 
confounding. 
• Single institution 
studies are not as 
generalizable has 
those from multicenter 
studies. 
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Table 13: Follow-up Guidelines 
Author(s), 
Country, 
Study Design 
& Objective 
Sample & 
Methods 
 
Key Results and 
Findings 
Strengths/ Limitations 
39. Grandjean, 
Kwast, de 
Vries, 
Klaase, 
Schoevers, & 
Siesling. 
(2012). 
 
Netherlands 
 
Retrospective 
cohort design 
 
Objective: To 
evaluate 
adherence with 
f/u criteria as 
suggested by a 
national 
guideline and to 
determine the 
factors that 
influence the 
adherence to the 
guideline.  
 
 
• N = 196; 
• Convenience 
sample from a 
national cancer 
registry database 
in 2003; 
• Inclusion criteria - 
women with 
invasive BC 
treated in 2 
hospitals; 
• Exclusion criteria 
– metastatic 
disease, or a 
contralateral BC; 
• A national 
guideline: 
Recommends f/u 
care for 5 years 
(physical exam 
four times in 1st yr, 
twice in 2nd yr, and 
annually 
thereafter), and 
annual 
mammogram. 
 
• Primary endpoints: 
Rates of 
completion of 5 yr 
f/u, a disease 
relapse, death, or 
lost to f/u. 
 
• A total of 54 pts 
did not complete 
the full 5 yrs of 
f/u; 
• In the first yr, pts 
visits were fewer 
than 
recommended; 
• In 2nd to 5th yrs, 
visits were more 
often than 
recommended 
(nearly double) 
(p<0.05), and 
was assoc. with 
receipt of RT 
(p<0.01); 
• Physical exams 
performed during 
97% of visits but 
mammograms 
were performed 
slightly less than 
recommended.  
 
  
Strength of Study Design: 
Moderate 
 
Quality of the Study: Low 
 
Directness of Evidence: 
Extrapolation 
 
Strengths 
• Moderate sample size; 
• Multicenter study. 
 
Limitations 
• Potential for 
misclassification bias or 
coding errors; 
• Losing 28% of the study 
population will likely 
introduce confounding of 
results; 
• Sample size may affect 
external validity; 
• Potential for confounding 
factors.  
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This practicum project will provide an opportunity to conduct a program evaluation 
on how often surgeons in Newfoundland and Labrador (NL) utilize the services of 
medical oncology to discuss the option of neoadjuvant therapy for patients diagnosed 
with locally advanced or inflammatory breast cancer. This program evaluation will also 
help determine whether these surgeon referrals are being made in concordance with the 
Eastern Health Breast Disease Site Groups’ (BDSG) clinical practice guideline 
“Neoadjuvant Treatment of Primary Breast Cancer” (2014).  A comprehensive literature 
search and summarization of the research findings has been completed. The highlights of 
the most common methodologies and strategies utilized in the field of breast cancer for 
evaluating evidence-based oncology guideline adherence. The next step outlined in the 
practicum proposal was to carry out a series of consultations with key individuals within 
the organization, at the Dr. H. Bliss Murphy Cancer Center (DHBMCC), who have the 
expertise necessary to aid in the development of an evaluation plan to obtain the desired 
data.  
Methods 
The consultation process will permit the investigator to avail of the expertise of 
others to achieve the following objectives necessary to successfully develop an evaluation 
plan. These objectives were:  
1. To develop appropriate eligibility criteria using inclusion and exclusion criteria for 
patients newly diagnosed with either locally advanced or inflammatory breast 
cancer; 
2. To identify factors which may affect the surgeons’ decision-making for choice of 
primary treatment modality in locally advanced or inflammatory breast cancer; and 
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3.  To assess the feasibility of obtaining the required data from the cancer registry 
database and patients’ medical records.   
Setting and Sample 
The setting chosen was the DHBMCC where all but one of the key individuals 
worked. These individuals were all colleagues and co-workers of the investigator and 
with whom a rapport has already been established. The meeting with each individual took 
place in their own offices, face-to-face with the exception of one which was carried out 
via telephone. This allowed each of the individuals to feel at ease in their own space and 
each office provided comfortable seating for all. Finally, each office was also equipped 
with a door to provide both a quiet and private environment in which to meet. 
Four of the five individuals were healthcare professionals while the remaining one 
was a certified cancer registrar. These individuals were chosen for consultation due to 
their years of expertise in their field and were deemed to be experts. Two of the 
individuals were medical oncologists, who specialize in the field of breast cancer 
treatment and management. One was a general surgeon who routinely performed breast 
surgery for patients with breast cancer and was also a member of the Eastern Health 
BDSG. The divisional manager of the cancer registry was consulted to help determine 
whether it was feasible to obtain the data needed to perform this evaluative process. 
Finally, the ARIA computer system clinical support person was interviewed to discuss the 
various computer systems that would need to be accessed to obtain data from individual 
patient medical records.  
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Data Collection, Management and Analysis 
Data Collection. Though this project is a quantitative evaluation study, it is not 
unusual for such a study to have a qualitative component. In this case, valuable 
information was required from the key individuals necessary to move forward with this 
project and the decision was made to use interviews to obtain it. To accomplish this, a list 
of open-ended questions was generated for each interviewee. These questions were 
formulated not just to obtain specific answers but to also allow the respondent the 
opportunity to provide context and detail to his/her replies. A list of the questions used 
have been added to Appendix A of this report. Notes were taken during the interviews 
without the use of tape recording to allow respondents to speak freely. Each respondent(s) 
was asked a different set of questions necessary for providing the specific information 
being pursued.  
The general surgeon was interviewed via telephone while the remaining 
respondents were interviewed face-to-face. A semi-structured question and answer 
interview was conducted for each separately, with the exception of the two medical 
oncologists who were interviewed together. Prior to beginning each interview, the 
individual was informed of the purpose of the evaluation and how the information 
provided would be used. Once the interviewer had exhausted the list of questions, the key 
aspects of the discussion were summarized by the interviewer to ensure the interpretation 
was correct. The individuals were thanked for their participation and advised that the 
findings of the evaluation will be available in a PowerPoint presentation for staff and/or 
in an oral report delivered to the BDSG at the end of the practicum. The interviews took 
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place during working hours (i.e., 8:30 am to 5:00 pm) at a time convenient for the 
interviewees. The interviews were between 20 to 40 minutes in length.  
The medical oncologists were asked to develop appropriate eligibility criteria (i.e., 
inclusion and exclusion criteria) for patients diagnosed with locally advanced or 
inflammatory breast cancer, how to define the control and experimental groups, and what 
years should be studied to determine guideline adherence outcomes. In addition, they 
were also asked to identify factors that may influence decision-making about treatment 
sequencing. Interviewing the two oncologists together permitted an opportunity for the 
physicians to reach a consensus on the eligibility criteria best suited for the purposes of 
the program evaluation. 
 Once an explanation of the project was provided, the cancer registrar was asked 
whether it was feasible to collect the data required through the cancer registry database. 
In addition, the registrar was asked whether patients who had received neoadjuvant 
therapy were identified in the database, as well as how to access the 
patient/tumor/facility-related variables of interest. Next, the computer clinical support 
person was asked about how to assess data not available in the cancer registry database. A 
new computer system (i.e., ARIA) had been introduced during the time covered by the 
evaluation; it was important to determine how to access the data, depending on the year of 
study under investigation. Being unfamiliar with the operation of the ARIA system, the 
assistance of the clinical support person will be extremely helpful in navigating an 
unfamiliar computer database.  
The telephone interview with the general surgeon was performed at the beginning 
of N6661 due to timing conflicts in meeting during the latter weeks of N6660. 
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Approximately two weeks prior to the interview, the surgeon had been emailed a 
description of the project’s purpose, how the information gained would be of benefit, as 
well as a list of patient- and tumor-related factors which may affect the surgeon’s decision 
as to whether a patient may be a candidate for neoadjuvant therapy. This list which is 
located in Appendix A, had been generated from the previously conducted literature 
review and the survey results of surgeons in a research study carried out by Mamounas et 
al. (2016). This interview was highly valuable in defining which patient/tumor factors are 
deemed most important to consider in determining whether a medical oncology referral 
was warranted for the consideration of neoadjuvant therapy.  
Data Management and Analysis. After each interview was completed, the notes 
taken were typed and saved in a Word document format. Inside this document, each 
respondent was given a unique identifier. The content of the interview notes was 
analyzed, summarized and are included in this report. Since each interviewee, except for 
the two medical oncologists, were asked very different questions it was impossible to 
synthesize the answers. This is usually a technique reserved for identifying themes or 
patterns in the responses of several participants in a qualitative research study who had 
been asked similar questions. The interview with the medical oncologists was conducted 
with them together and prevented synthesis since its focus was more consensus-based. 
Therefore, it was more appropriate to summarize the responses and arrange it in a clear, 
concise manner in order to allow for the achievement of those objectives outlined earlier 
in the report.  
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Ethical Considerations 
 A meeting with the program director of the provincial cancer care program was 
arranged to discuss the practicum proposal and its topic. The project will require access to 
the cancer registry database as well as the electronic patient health records, and we 
discussed whether an ethics review board approval would be necessary. The program 
director agreed that this was clearly an evaluation of a pre-existing health service by a 
staff member and should be exempt from ethics review board approval. The 
Newfoundland and Labrador’s Health Research Ethics Authority screening tool was 
completed and can be found in Appendix B. The results indicate that the most probable 
purpose of the project is for a quality improvement or evaluation function. The program 
director granted permission to proceed with the evaluation project, including permission 
to access both the cancer registry database and electronic patient health records.  
The privacy and confidentiality of the individuals who agreed to be interviewed for 
these consultations was protected by using a unique identifier in the notes taken at the 
interviews. There is no direct personal identification of these individuals in any of the 
reports needed for this practicum project. The only direct identification of these 
individuals would be in a practicum proposal document, shared between only my 
supervisor and myself, and will be kept securely in a password protected computer 
system, within a locked office at the DHBMCC. All individuals volunteered to be 
interviewed or did so as a part of their job descriptions. Consent was not specifically 
requested though all individuals agreed to participate. 
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Results 
  The results are presented according to who were consulted. These are individual(s) 
from:  
Medical Oncology. The consultation began with a series of questions for the medical 
oncologists to help isolate the exact group of patients necessary for the project. The 
following summary is meant to reflect the content of the ensuing discussion. The first 
objective of this consultation was to decide what patients should be included in this 
evaluation. Though historically neoadjuvant therapy had been used primarily in the 
presence of locally advanced disease and inflammatory breast cancer, its use in the 
management of early-stage operable breast cancer for those who desire breast conserving 
surgery is gaining in popularity. However, both physicians believed that insufficient data 
would be available in this province for a cohort of patients with early stage breast cancer 
where neoadjuvant therapy would be used to facilitate breast conservation. Over the 
years, both physicians have triaged newly referred breast cancer cases, and neither could 
recall even one case of a neoadjuvant referral for the intent of breast conserving 
measures. They felt that this was probably related to the lack of available surgeons with 
specialty-training in breast cancer management in this province, since the overwhelming 
majority tend to be general surgeons. Therefore, the decision was made to focus primarily 
on the locally advanced and the inflammatory breast cancer population only. 
  The discussion next centered on how to best to stratify the study population in order 
to evaluate how often surgeons utilize the referral process for the medical oncology 
discipline, intended for neoadjuvant treatment purposes. The physicians agreed that the 
best approach was to divide the eligible study population into two groups, which 
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consisted of those referred to medical oncology for neoadjuvant consideration (i.e., had 
received chemotherapy and/or endocrine therapy first) and those not referred (i.e., had 
received surgery first). Each of two groups will be further stratified according to 
diagnosis, either has having a locally advanced breast cancer or an inflammatory breast 
cancer.     
 The next topic concerned the eligibility criteria of the patients who should be 
chosen to represent the study population of interest for this evaluation. The physicians 
concluded that the specific eligibility criteria for locally advanced breast cancer and 
inflammatory breast cancer should be in accordance with the American Joint Committee 
on Cancer (AJCC) Staging manual, 7th ed., (2010). Therefore, all women with 
pathologically-confirmed, clinically measured tumors ≥ 5 cm in size and/or significant 
lymph node involvement [including stage IIB (T3N0 only) and all stage IIIs], which are 
inoperable or where it’s questionable whether clear margins can be achieved, are deemed 
to have locally advanced breast cancer. The eligibility criteria for inflammatory breast 
cancer will be all women with a pathologically-confirmed diagnosis and a defined clinical 
appearance of erythema and edema (peau d’orange). The physicians also suggested that 
the exclusion criteria should be those with in situ disease only; those with metastatic 
disease at diagnosis; male breast cancers; or those diagnosed with breast cancer, having 
any stages other than those listed in the inclusion criteria.  
This evaluation is also concerned with whether the Eastern Health’s BDSG 
guideline had an impact on surgeons’ utilization of medical oncology referrals for 
neoadjuvant therapy discussion. The medical oncologists were advised that the plan is to 
evaluate the neoadjuvant referral rate for a year prior to the implementation of the 
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guideline in 2014, and the year following.  To reflect this intention, the two original 
groups (referred and non-referred) would be further stratified by year of study to assess 
the guideline’s impact. The physicians agreed that 2013 was an appropriate choice for the 
pre-implementation year. However, they suggested that 2016 would be a better choice for 
the post-implementation year, due to the opinion that 2015 was deemed too early to 
accurately gauge guideline impact. Since the tumor registry data was unavailable for 
2017, this eliminated this choice as a potential year of study. 
The physicians noted that the reasons for referring patients with locally advanced or 
inflammatory breast cancer are often multi-factorial. They suggested that factors, such as 
patient demographics (e.g., age), tumor-related characteristics (e.g., histologic subtypes, 
clinical tumor stage, clinical nodal status, tumor grade, hormone receptor status), as well 
as physician-related (e.g., surgery type: lumpectomy, mastectomy) and hospital-related 
information (e.g., facility type, location) can all play a role in determining which patients 
will receive a consultation with a medical oncologist.  
Provincial Cancer Registry. An explanation of the data desired was provided to the 
director of the cancer registry, and a discussion regarding the feasibility of obtaining it 
followed. The director explained that there may be some variation in what information 
could be provided according to year of study interest. This was due to the replacement of 
the OPIS computer system at the DHBMCC with the new ARIA electronic patient health 
record computer system in 2014. The ARIA system can be accessed by the cancer registry 
database while the OPIS computer could not. The director for the cancer registry will 
collect the data as requested from the registry database, insert it into an Excel spreadsheet 
format, and transfer its contents to the guardianship of the investigator. 
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It was decided that the pre-guideline implementation data will include all female 
patients diagnosed with breast cancer, meeting the outlined eligibility criteria, from 
January 1, 2013 to December 31, 2013, inclusive. The director clarified that since the 
ARIA system was not available in 2013, the tumor registry database at that time may not 
have access to all data related to the factors/variables of interest for this evaluation. 
Therefore, some of the data will likely have to be collected individually from the patient 
health records in the OPIS system, by the investigator. To assess the post-guideline 
implementation data, the eligible patients who were diagnosed from January 1, 2016 to 
December 31, 2016 will be identified, with most of the additional factors/variables data 
being available through the cancer registry database. However, any data not available will 
again be the responsibility of the investigator for its collection from the ARIA electronic 
health record.  
The discussion continued regarding the specific patient/tumor/facility-related data 
that would be captured from the cancer registry database. The director advised that patient 
demographics, such as name, age at diagnosis, and MCP number would be collected, 
requiring de-identification which would be the responsibility of the investigator to 
perform. In addition, tumor characteristics (e.g., tumor size, histology, and lymph node 
status), names of referring surgeon/physician, type of surgery, and name and type of 
hospital/facility will also be collected from the database for each patient, upon request.  
Information Technology. ARIA is the first paperless electronic patient health record at 
the DHBMCC and has been in service since 2014. It can integrate information from the 
hospital health information system, known as Meditech as well as allow in-hospital 
access to the medical records of oncology patients at the DHBMCC. The clinical support 
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staff confirmed that to access patient health records from 2013 will require using the 
OPIS system which is still computer accessible. However, this system still necessitates 
the user to access Meditech for radiology, pathology, and laboratory test results if this 
information is required. Any data needed from patient health records in 2016 will be 
available in ARIA. Though this system is both complex and has a steep learning curve, 
the clinical support person has agreed to provide instruction and mentoring in its use.  
General Surgeon.  The telephone interview began with a reiteration of the purpose of the 
evaluation project and the questions of interest to be asked. The first question asked was 
regarding which patient-related factors were most important in influencing a surgeon’s 
decision-making in determining the sequencing of treatment. The surgeon agreed that a 
patient’s health and co-morbidities, as well as the patient’s preference for timing of 
surgery and level of interest in breast conserving surgery were all of equal value in the 
decision-making process. Although patient age was important, it played a lesser role in 
treatment decisions if the patient was of good health and had few co-morbidities.  
 The surgeon suggested that the initial tumor-related characteristics which would 
initiate a strong response to pursue a medical oncology referral for neoadjuvant therapy 
consideration would include evidence of locally advanced disease such as large tumor 
size of ≥ 5 cm in length of any dimension, involvement of the skin or chest wall 
involvement on clinical examination, and/or a pathological diagnosis of inflammatory 
breast cancer. The clinical presentation of axillary lymph node involvement is important 
but not always helpful in determining the level of lymph nodes involvement. Other 
features which may affect the surgeon’s propensity to refer include histology and grade.   
Lobular carcinomas are known to be less aggressive than ductal carcinomas and 
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frequently are treated with surgery first. Well differentiated tumors are associated with a 
favorable prognosis (e.g., tubular, cribiform) and often are less likely to be referred to 
medical oncology than poorly differentiated which are associated with an aggressive 
nature and a poor prognosis (e.g., apocrine, metaplastic). Bilateral breast cancer as well as 
multifocal and/or multicentric disease may also play a role in influencing the surgeons’ 
decision to refer.  
A discussion then ensued regarding the research evidence which suggests that there 
is a survival advantage for molecular subtypes, such as triple negative and human 
epidermal growth factor receptor (HER2) positive breast cancers when these patients 
receive specific targeted neoadjuvant therapy. The surgeon acknowledged that this 
research has begun to change practice across the country and admitted that molecular 
subtyping, especially triple negative subtypes, has influenced his decision to refer patients 
to medical oncology as well. The question than arose whether surgeons should be 
requesting immunohistochemistry testing for estrogen/progesterone and HER2 receptors 
on all core biopsies of suspected locally advanced breast cancers. This surgeon suggested 
that some provinces provide hormone receptor and HER2 testing on all breast core 
biopsies regardless of size which would standardize the approach.  
Finally, the surgeon was asked if there were any other characteristics or factors 
which weren’t listed that he may feel was of equal importance in influencing the 
treatment sequence. The surgeon suggested that in extenuating circumstances the 
definition of locally advanced can be tumors < than 5 cm. For instance, when the patient 
has small breasts and though the tumor size may not meet the standard definition of 
locally advanced, the tumor itself may be locally advanced for that patient.          
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Conclusion 
The consultation process provided the opportunity to accumulate the information 
needed to move forward with the development of an evaluation action plan. This process 
has created a clarity of how this practicum project can be achieved and has helped guide 
the investigator towards the identification of the next series of steps required to extract the 
data, safeguard its security and perform the analysis. The practicum project has begun to 
solidify and give shape to an idea which began merely as a notion discussed at a meeting. 
It is very exciting to see how the accomplishment of each activity, outlined in Nursing 
6660, has combined to bring the investigator closer to the reality of finally developing 
and carrying out the evaluation plan. The end goal of which will be to help determine the 
status of the neoadjuvant referral and use for patients with breast cancer in this province 
and potentially inspire the necessary program adjustments to ultimately aid in improving 
outcomes for these patients.     
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Appendix A 
Questions for the medical oncologists: 
1. What breast cancer patient cohorts should be included in this neoadjuvant referral 
evaluation project? 
2. How should the eligible breast cancer population be stratified in terms of groups?  
3. What are the specific inclusion and exclusion criteria which would describe the 
eligible sample population?  
4. What year(s) should be reviewed and data extracted from the cancer registry to 
determine the rates of adherence before and after the implementation of the Eastern 
Health BDSG guideline? 
5. What other data should be extracted from either the cancer registry and/or patients’ 
medical records, which may aid in determining what variables influence surgeons to 
refer patients with locally advanced or inflammatory breast cancer, for neoadjuvant 
therapy consideration?   
 
Questions for the director of the cancer registry: 
1. Given the purpose for this evaluation project, is it possible to collect the data of all 
female patients who meet the eligibility criteria? 
2. Is it possible to identify those patients who received a referral for neoadjuvant 
discussion or actually received neoadjuvant therapy?  
3. Can patient/tumor/facility-related data be collected on each patient from the cancer 
registry database? 
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Questions for the ARIA clinical support: 
1. What is the process to follow to obtain data from the patient health records for the 
years of 2013 and 2016?   
 
Questions for the general surgeon: 
1. What tumor-related characteristics would influence your decision to refer your patient 
with breast cancer to medical oncology for consideration of neoadjuvant therapy? 
2. What patient-related characteristics would influence your decision to refer your patient 
with breast cancer to medical oncology for consideration of neoadjuvant therapy? 
3. Are there other characteristics or factors not on the list that you personally deem to be 
important in considering the use of neoadjuvant therapy for your patients? 
 
Patient-related and tumor-related characteristics/factors 
• Skin/chest wall involvement; 
• Tumor size; 
• Histologic grade and type; 
• Human epidermal growth factor receptor status; 
• Estrogen and progesterone status; 
• Inflammatory breast cancer; 
• Clinical assessment of axillary lymph node involvement; 
• Patient’s age; 
• Patient’s health and comorbidities; 
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• Patient’s preference for timing of surgery; and  
• Patient’s level of interest in breast conservation surgery. 
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Appendix B: Health Research Ethics Authority Screening Tool 
 Question Yes   No 
1. Is the project funded by, or being submitted to, a research funding 
agency for a research grant or award that requires research ethics 
review? 
    
2. Are there any local policies which require this project to undergo 
review by a Research Ethics Board? 
    
 IF YES to either of the above, the project should be submitted to a 
Research Ethics Board. 
IF NO to both questions, continue to complete the checklist. 
 
    
3. Is the primary purpose of the project to contribute to the growing 
body of knowledge regarding health and/or health systems that are 
generally accessible through academic literature? 
 
    
4. Is the project designed to answer a specific research qu 
estion or to test an explicit hypothesis? 
    
5. Does the project involve a comparison of multiple sites, control sites, 
and/or control groups? 
    
6. Is the project design and methodology adequate to support 
generalizations that go beyond the particular population the sample is 
being drawn from? 
    
7. Does the project impose any additional burdens on participants 
beyond what would be expected through a typically expected course 
of care or role expectations? 
 
    
LINE A: SUBTOTAL Questions 3 through 7 = (Count the # of Yes 
responses) 
0 7 
8. Are many of the participants in the project also likely to be among 
those who might potentially benefit from the result of the project as it 
proceeds? 
  
 
 
 9. Is the project intended to define a best practice within your 
organization or practice? 
   
  10. Would the project still be done at your site, even if there were no 
opportunity to publish the results or if the results might not be 
applicable anywhere else? 
   
  11. Does the statement of purpose of the project refer explicitly to the 
features of a particular program, organization, or region, rather than 
using more general terminology such as rural vs. urban populations? 
   
12. Is the current project part of a continuous process of gathering or 
monitoring data within an organization? 
  
LINE B: SUBTOTAL Questions 8 through 12 = (Count the # of Yes responses) 4 1 
 SUMMARY:  Line B = 4   >  Line A = 0  Quality/Evaluation 
See Interpretation Below  
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Interpretation: 
• If the sum of Line A is greater than Line B, the most probable purpose is research. The 
project should be submitted to an REB. 
• If the sum of Line B is greater than Line A, the most probable purpose is 
quality/evaluation. Proceed with locally relevant process for ethics review (may not 
necessarily involve an REB). 
• If the sums are equal, seek a second opinion to further explore whether the project should be 
classified as Research or as Quality and Evaluation. 
These guidelines are used at Memorial University of Newfoundland and were 
adapted from ALBERTA RESEARCH ETHICS COMMUNITY CONSENSUS 
INITIATIVE (ARECCI).  Further information can be found 
at: http://www.hrea.ca/Ethics-Review-Required.aspx. 
NOTE: Since the YES answers are greater in Line B (4) than those in Line A (0), 
this indicates that this practicum project is likely to be a Quality Initiative or 
Evaluation Project.  
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Appendix D: Chart Review Report 
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The overall objective of this program evaluation was to determine whether 
surgeons in the province of Newfoundland and Labrador (NL) were adhering to a 
multidisciplinary-developed oncology clinical practice guideline, developed by the 
Eastern Health Breast Disease Site Group (BDSG). The 2014 guideline “Neoadjuvant 
Treatment of Primary Breast Cancer” outlines which patients may be appropriate for 
neoadjuvant therapy (Eastern Health, 2014). This evaluation project will determine 
whether eligible patients, diagnosed with locally advanced or inflammatory breast cancer, 
are being referred to the services of medical oncology at the Dr. H. Bliss Murphy Cancer 
Center (DHBMCC) or any of its satellite clinics around the province of NL, for 
consideration of neoadjuvant treatment. A chart review has been chosen as the best option 
by which data can be collected to allow the comparison of neoadjuvant referral rates prior 
to and after the dissemination of the guideline in an attempt to establish whether guideline 
adherence has occurred. This report will provide an overview of the methods used in 
conducting the chart review process; outline the benefits and limitations of the 
retrospective chart review; discuss the measures taken to improve the rigor of the data 
collection process; and summarize the results and recommendations of this evaluation 
project.  
Objectives 
The primary aim of this evaluation was to determine how effective the Eastern 
Health Breast Disease Site Groups’ (BDSG) guideline “Neoadjuvant Treatment of 
Primary Breast Cancer” (2014) had been in influencing surgeons and the corresponding 
rates of neoadjuvant referral to the medical oncology discipline for eligible patients with 
breast cancer. The objectives of this evaluation were to:  
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1. Compare the rates of patient referrals to the service of medical oncology for 
neoadjuvant therapy discussion pre- and post-guideline implementation; and 
2. Identify the factors that are associated with the surgeon’s decision to refer eligible 
patients to the medical oncology service for a discussion regarding neoadjuvant 
therapy. 
Overview 
The retrospective chart review was conducted on women, newly diagnosed with 
breast cancer, to compare the rates of neoadjuvant referral during the calendar year of 2013 
(pre-guideline dissemination) and in 2016 (post-guideline dissemination).  The data were 
extracted from the provincial cancer registry, three computer systems consisting of the 
hospital-based system (MediTech), the former DHBMCC system (OPIS), and the new 
DHBMCC electronic record system (ARIA), as well as the former DHBMCC paper patient 
charts. Data were extracted from these same sources on patient demographics, as well as 
tumor- and facility-related characteristics to help identify the factors most likely to 
influence the surgeons’ decision to refer.  
Health care professionals, including clinical nurse investigators, have been using the 
medical records of patients to conduct retrospective research for the purpose of quality 
assurance and improvement in clinical practice for many years. In fact, researchers have 
found that retrospective chart reviews comprise about 25% of published scientific research 
(Vassar & Holzmann, 2013; Worster & Haines, 2004). Retrospective chart reviews allow 
for a direct chronology of events between exposure and outcomes from which the 
investigator can determine association (but not causation). Retrospective chart reviews are 
also beneficial for conducting quality assurance studies, pilot studies, or other research 
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where it is impractical or unethical to carry out as prospective studies (Worster & Haines, 
2004). Since the overall aim of this project was to evaluate the neoadjuvant referral process 
of an oncology program, this approach appeared to be the most practical methodology of 
choice. 
Methods 
Setting and Sample 
 The setting for this evaluation project was located at the DHBMCC in St. John’s, 
within the Eastern Health Regional healthcare district and the Cancer Care provincial 
program of NL. The sample population of interest consisted of two distinct groups of 
women who were newly diagnosed with invasive mammary carcinoma, also known as 
invasive breast cancer, between January 1, 2013 to December 31, 2013 and January 1, 2016 
to December 31, 2016. These two groups of women were those with a pathological 
diagnosis of locally advanced breast cancer and those with a pathological diagnosis of 
inflammatory breast cancer.  
Study Population Criteria 
The Eastern Health BDSG “Neoadjuvant Treatment of Primary Breast Cancer” 
guideline describes locally advanced breast cancer as having a clinically large tumor (> 
5cm) and/or significant clinical lymph node disease (at least N2) and defined as having 
either stage IIB (T3N0 only) or any stage III breast cancers as outlined in the American 
Joint Committee on Cancer (AJCC) breast cancer staging (Edge et al., 2010). A copy of 
the AJCC breast cancer staging has been added in Appendix A of this report. The BDSG 
guideline also describes inflammatory breast cancer has an aggressive disease which is 
characterized by the rapid development of erythema and edema in the breast. This disease 
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presents clinically with the classic peau d’orange appearance in the skin of the breast and 
is usually diagnosed pathologically with a skin biopsy. The exclusion criteria were patient 
cases that consisted of male patients; in situ disease only; metastatic breast cancer on 
presentation or on initial staging; any AJCC stage of invasive cancer other than those 
included in the eligibility criteria; and cases which were ineligible for surgery and/or all 
other cancer-related treatment (chemotherapy, endocrine therapy, radiation therapy).  
 Outcomes and Variables of Interest 
The main outcome of interest was the number of patients who were referred to 
medical oncology for neoadjuvant treatment consideration for 2013 and for 2016 in order 
to determine the referral rate for each respective year. This outcome was categorized as 
being ‘referred’ or ‘not referred’. Several cases were identified where surgeons consulted 
with a medical oncologist prior to providing surgical treatment and in all cases the 
surgeons followed the oncologists’ recommendations. These cases were categorized as 
‘referred’ with the acknowledgement of the surgeons’ consultation with a medical 
oncologist. The actual treatment sequence received by each patient was categorized as 
either ‘neoadjuvant’ or ‘adjuvant’ treatment.  
The variables of interest in this project were those pertaining to a variety of pre-
determined patient, tumor and facility-related factors which may play a role in the 
surgeons’ decision-making. The patient demographics of interest were age at diagnosis, 
year of diagnosis, and pathologic diagnosis. Pre-existing co-morbidities had also been 
considered initially to be used as a patient demographic but were excluded because pre-
existing conditions such as diabetes, hypertension, or obesity have no effect on whether 
treatment can be offered or not. The decision to deem patients to be ineligible for 
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treatment tends to be standard for both surgical and pharmaceutical intervention when 
these patients have a previous medical history of heart failure, stroke, deep vein 
thrombosis, renal failure, and general frailty. Osteoporosis can also exclude these patients 
from the option of aromatase inhibitors. Therefore, cases in which the patient was 
ineligible for definitive surgery and/or one other treatment offered by the DHBMCC (e.g., 
chemotherapy or radiation therapy) were excluded from the sample. 
The tumor characteristics of interest consisted of: 
• clinical tumor size 
• tumor histology   
• tumor grade  
• unilateral versus bilateral disease 
• unifocal versus multifocal disease  
• presence of multicentric disease  
• chest wall/skin involvement  
• clinical lymph node status   
• clinical or pathological AJCC stage  
• molecular subtype, and 
• the tissue specimen used to perform hormone receptor testing on. 
Initially, tumor palpability had been considered a tumor-related factor of interest. 
However, this factor was not always reported consistently and accurately in the medical 
record, and therefore was excluded. Two additional tumor-related factors were added 
which were found to potentially have an impact on decision-making: 
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1. Molecular subtyping involves special testing based upon the presence/absence of 
hormone receptors, estrogen receptor (ER) and progesterone receptor (PR), and 
the potential over-amplification of the human epidermal growth factor receptor 
(HER2). The presence of certain molecular subtypes such as HER2 positive (i.e., 
ER/PR negative, HER2 positive) and triple negative breast cancers 
(ER/PR/HER2 negative) indicates an important component which may affect the 
surgeons’ decision to refer, if available at the time decision-making takes place; 
and   
2. Whether the testing to garner this information was performed on the needle core 
biopsy or the post-operative surgical specimen.  
The facility-related factor consisted of the name of the facility which, in turn, 
provided information regarding whether the healthcare facility was a university-affiliated 
institution or a community hospital.  
Diagnostic and Decision-Making Process 
Two algorithms were designed by the investigator accompanied by a corresponding 
description. The ‘Diagnosis and Treatment’ algorithm and description are provided in 
Appendix B. Its purpose was to clarify the diagnostic process for patients with breast 
cancer by featuring the sequence of events after a suspicious lesion has been found. The 
‘Surgeons’ Decision to Refer’ algorithm and accompanying description are located in 
Appendix C. This algorithm outlines the three options that surgeons’ can choose from 
when deciding whether to proceed with surgery, refer the patient for neoadjuvant 
discussion, or collaborate with a medical oncologist to discuss treatment sequencing.  
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Data Collection 
The data collection process was distinctly different between the study years of 2013 
and 2016 due to the variation and number of data sources involved. The 2013 patient 
cases were available in paper chart format with the addition of DHBMCC physician 
progress notes in the electronic OPIS computer system. The 2016 dataset was available 
only on electronic records via the ARIA computer system. The ARIA system required 
only a user name and password, and minimal training to access the necessary records for 
abstracting the data. ARIA housed all patient reports from diagnostic imaging, operating 
room, and pathology as well as the progress notes from oncologists and surgeons, 
including letters of correspondence between surgeons and family doctors. The 2016 data 
were extracted from three sources: the cancer registry dataset, the ARIA electronic patient 
records, and occasionally the hospital MediTech computer system. The 2013 data were 
extracted from four sources: the cancer registry dataset, the DHBMCC paper charts, the 
former OPIS and the MediTech computer systems. Each of the data sources will be 
described below and followed by a table outlining the best source from which the 
variables of interest could be found.     
Cancer Registry Database. 
The NL Cancer Registry is a national cancer database which is governed and 
operated by the Eastern Health Provincial Cancer Care Program. The registry collects 
cancer-related health information and uses it to monitor and promote the improvement of 
cancer care within the province. A letter of request was drafted and emailed to the 
divisional manager of the provincial cancer registry, and a copy of which has been 
included in Appendix D. It outlined the eligibility criteria and years of interest for this 
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study. One of the responsibilities of the divisional manager, a registered cancer registrar, 
is to extract cancer registry data for approved research, evaluation and quality 
improvement projects. The divisional manager completed the search of the cancer registry 
database and the resulting list of patients’ names, ages, corresponding medical care plan 
(MCP) numbers, and coded tumor-related data were entered into an Excel spreadsheet. 
These were emailed to the investigator along with a copy of the decoding information.   
OPIS Computer System. 
The OPIS computer system was the former system used only at the DHBMCC prior 
to the 2014 introduction of the ARIA electronic record. The OPIS system was used as a 
method for tracking patient charts and clinic appointments, in addition to recording the 
patients’ personal identification information and the dictated oncologists’ first assessment 
and progress notes. However, no hospital, laboratory data, or outside communication 
between physicians was available on this system.  
It was extremely difficult to obtain access to the defunct OPIS computer system 
from the Heath Technology and Data Management (HTDM) department, despite a formal 
request from the Program Director and multiple email correspondence between the 
HTDM and the investigator. Finally, it was determined that access was only available 
through the office computers of a small number of oncologists who practiced at the 
DHBMCC before 2014. This method of access was not a practical approach for the 
number of cases that needed to be researched, the amount of time required, and the 
interference with the oncologists’ regular office work schedule. The decision was made to 
perform a hand search of the available paper charts to obtain the majority of the data 
required, leaving the OPIS system for access to the health information of patients 
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(consisting of only two) whose paper charts had been stored in an external storage 
facility. These reviews, and any additional data not available from paper charts, were 
conducted on an OPIS-equipped computer of an oncologist colleague, who allowed the 
investigator the opportunity to access the system while the oncologist attended clinic 
patients.  
The OPIS system was also useful in eliminating 16 patients on the cancer registry 
dataset who had never been seen within the Cancer Care Program. There are a variety of 
reasons why patients who were referred to the program would have never been seen by an 
oncologist including the patient’s choice to refuse the consult, the patient being 
considered too unwell, or the death of the patient prior to appointment from the effects of 
cancer or other health issues.  
 Paper Patient Charts. 
The majority of the paper charts of patient cases diagnosed in 2013 were located in 
the Medical Records department of the DHBMCC and the manager of the Medical 
Records division gave the investigator permission to access the paper charts included in 
the study. The data collection required a special identification number derived from a 
portion of the patient’s MCP number. The investigator was instructed by the medical 
records staff on the three areas within the Medical Records department where the paper 
charts were filed, as well as description of how to determine the ‘look-up number’ for 
locating specific charts. The manager informed the investigator, at that time, that due to 
the limitation of space within the department, some old paper charts had been removed 
and stored in an outside facility. However, the manager of Medical Records felt confident 
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that since the year of interest was just one year prior to the ARIA electronic record system 
coming online, most of the charts should be still at the DHMBCC, later found to be true.  
Since the cancer registry dataset provided the patients’ MCP numbers, the 
investigator determined the look-up number and located all but two of the paper charts 
successfully. The investigator selected two to three charts at a time from the list provided 
by the tumor registry dataset and collected the data using a data collection tool for each 
case. All imaging, operating room and pathology reports outside the Eastern Health 
region were located on the paper charts. This was a common practice employed by the 
clerical staff as part of their duties to ensure all patient-related information was available 
to the oncologist when seeing a new patient at the DHBMCC for the first time. Once 
requested, this information would be faxed to the DHBMCC from any hospital in the 
province since no computer access to other health authorities existed at that time. 
Occasionally, the investigator would find that similar type of reports from within the 
Eastern Health district were not available on the paper chart, however the data was easily 
accessible through the hospital MediTech system. 
Though time consuming, the paper patient chart was the best source of data for 
cases diagnosed in 2013. The investigator was intimately aware of the paper chart used at 
the DHBMCC, having worked as the Primary Nurse for the Medical Oncology clinics for 
ten years. This enabled the investigator to quickly and efficiently locate the data and 
interpret the sequence of events. 
MediTech Computer System. 
Though not necessary for use in all patient cases, the Meditech system was useful 
on occasion for obtaining data from within the Eastern Health district for cases diagnosed 
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in both 2013 and 2016. This was especially true for those cases where the paper chart, or 
occasionally, the electronic record was missing some specific data from imaging, 
pathology reports or written communication between the surgeon and the family 
physician.  
 ARIA Computer System.  
The ARIA system was the single most important data source for patients diagnosed 
in 2016. The majority of information on imaging, operating room reports, pathology, 
surgeon progress notes, oncology first assessment and progress notes (both radiation and 
medical oncology) were easily accessible. The system was highly convenient since it was 
available on any work computer at the DHBMCC and the center offered the services of an 
ARIA nursing support person to aid in navigating the ARIA system, if needed.  
The ARIA system was also useful for helping to determine whether the staging 
investigations ordered by surgeons revealed the presence of metastatic disease for patient 
cases from both 2013 and 2016. The investigator was also able to track incidental findings 
on some staging investigations which later was confirmed through re-imaging to be early 
evidence of metastatic disease. The ARIA system was also helpful in determining whether 
referred patients were physically suitable for definitive surgery and/or other treatment 
modalities when surgical notes were lacking. In both cases, the information provided 
helped exclude patient cases that did not conform to the eligibility criteria. As already 
indicated, there are many data sources in this project as well as a large number of 
variables of interest. Table 1 provides a summary of the best source to access in order to 
extract the necessary data for a particular variable according to the study year.    
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Table 1  
Sources for Data Collection  
Variable Pre-Implementation (2013) Post-Implementation 
(2016) 
Cancer 
Registry 
Paper 
Chart  
OPIS Medi-
Tech 
 
Cancer 
Registry 
ARI
A 
Medi-
Tech 
Patient age X    X   
Year of 
diagnosis 
X    X   
Clinical tumor 
(T) size 
X    X   
Tumor histology  X X X  X X 
Tumor grade  X X X  X X 
Unilateral/ 
bilateral 
 X X X  X X 
Multifocal/ 
multicentric 
 X X X  X X 
Clinical nodal 
status (N) 
 X X X  X X 
Clinical/ 
pathological 
AJCC stage 
X    X   
Estrogen/ 
progesterone 
receptor status 
X    X   
HER2 receptor 
status 
X    X   
Chest wall/skin 
involvement 
X    X   
Facility location  X X X  X X 
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Data Collection Tool. 
 To extract the data in an organized and efficient manner, a paper data collection tool 
was required which in turn warranted the need for a data dictionary. The data dictionary 
defined the specific data to be collected and ensured that all  
data was accurately coded from the medical record. The purpose of these tools was to 
allow ease of data entry, maintain data accuracy, and to standardize the process. However, 
developing a new data collection tool could be a time-consuming and an unnecessary 
step, especially when many excellent tools are available online which can be modified for 
personal use. Nurse researchers, Gregory and Radovinsky (2012) have provided an 
excellent example of a data collection form, as well as a data dictionary, which the 
investigator adapted for use in this project. A copy of the adapted data collection form and 
data dictionary are located in Appendix E and F. These authors emphasized the need for 
appropriate organization or grouping of the variables in order to efficiently extract the 
data as it appears in the medical record. Therefore, all variables were grouped in the data 
collection tool to allow efficient extraction of the data from the same locations in the 
chart.  
Data Management 
  The investigator chose to create separate Excel spreadsheets by study year in 
which to house the extracted data, labeled as evaluation data and according to year. Each 
spreadsheet was constructed with suitable headings which reflected the variables of 
interest for this project. Along with the coded cancer registry dataset, the divisional 
manager of the tumor registry also provided the investigator with a copy of the 
explanation of what each of the codes represented. The coded data was used to describe 
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tumor size, lymph node status, and how to evaluate lymph node involvement of each 
patient case. A copy of these coding explanations has been included in Appendix G. Using 
the information obtained from the coded cancer registry database, the data were then 
transferred into the Evaluation Data Excel spreadsheets as indicated by study year, under 
the appropriate headings.  
The next step in the process was to extract the remaining data through a chart 
review. The ideal method for entering the data extracted from the various data sources 
would have been with the aid of a laptop computer assigned solely to the investigator, 
allowing the data to be entered directly into the Evaluation Data Excel spreadsheets. 
However, due to the financial constraints, it was difficult for the management of the 
Cancer Care Program to provide a laptop computer for each staff member. There are two 
laptops available to all staff within the program when needed. However, this raises 
concerns for the investigator on the ability to protect the privacy of patient information 
being collected. Therefore, the decision was made to develop an appropriate paper data 
collection tool to capture the required extracted data from the various sources. 
 Statistical Analysis. 
 The statistical analysis of these data was conducted using the Microsoft Excel 365 
software for Windows 10. Confidence intervals (CI) were calculated for the overall 
referral rates and the T3/T4 tumor only referral rates for both 2013 and 2016, using a 95% 
CI. It had been the intention of this investigator to perform a multivariable analysis on the 
data obtained, however the resulting sample size was too small to allow for such an 
analysis.  
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Pilot Test. 
The investigator chose the first fifteen patient cases in the 2016 dataset to pilot test 
the data collection tool. The results were instrumental in providing insight into the lack of 
consistent data required for two of the chosen variables of interest. As previously 
mentioned, the palpability of the tumor and the patients’ pre-existing co-morbidities may 
well be important variables in the surgeons’ decision-making. However, the lack of 
consistent surgeon reporting of clinical visits created a gap in the data collected and led to 
the exclusion of these two variables. In addition, the pilot test demonstrated the lack of 
synoptic pathology reporting for some hospitals in the province which made it difficult on 
occasion, to accurately record data on the tumor focality variable of interest.  
 The pilot test also helped the investigator realize the necessity for adding certain 
variables, such as the molecular subtype of the tumor and which specimen it was tested 
on, which would likely be of use for surgeons during decision-making. Recent evidence 
revealed that triple negative and HER2 positive breast cancer subtypes treated with 
neoadjuvant therapy confer a survival advantage for patients (Broglio et al., 2016; 
Houssami, Macaskill, von Minckwitz, Marinovich, & Mamounas, 2012). This would 
likely be a motivating factor for surgeons and oncologists alike, to pursue the use of 
neoadjuvant therapy in this cohort.  
It became apparent during the pilot test that some surgeons had contacted a medical 
oncologist prior to commencing surgery to discuss the case and decide a course of action. 
In each case encountered, the surgeon acted on the advice of the oncologist and the 
investigator felt that this should be acknowledged as a referral, despite the oncologist 
never having seen the patient face-to-face. Therefore, two additional headings were added 
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to the data Excel spreadsheets which included whether cases were either referred/not 
referred for neoadjuvant therapy and the final choice of treatment sequence (neoadjuvant 
or adjuvant). The utilization of a pilot test was extremely helpful in streamlining the 
quality of the data being extracted from the chart review.  
Promoting Data Quality   
Retrospective chart reviews are also associated with some commonly identified 
shortcomings such as “…incomplete or missing data within the medical record, records 
lacking specific patient information, difficulty in interpreting or verifying documented 
information, and variability in the quality of documentation among health care personnel” 
(Gregory & Radovinsky, 2012, p.109). These limitations can result in the introduction of 
systematic error and interpreter bias which can skew the outcomes and negatively affect the 
internal validity of the study (Kaji, Schriger, & Green, 2014). The investigator of this study 
also experienced incidents where certain variable data were missing (e.g., lack of reporting 
of pathological tumor focality) and had to be reported as unknown; or the variability (or 
lack thereof) of surgeons’ documentation prevented the extraction of a complete dataset 
resulting in the omission of the variable in question. Though a substantial improvement in 
documentation was noted from that of 2013 compared to 2016, the problem persisted in 
2016 with variation among hospitals and surgeons.  
The investigator took measures to help mitigate some of the limitations within control 
by improving the transparency and rigor of the process. Having an experienced certified 
cancer registrar carry out the search for potentially eligible patient cases from the provincial 
tumor registry was an important measure in which to establish the rigor of a study. A chart 
review was still necessary however, to aid in identifying patient cases which did not meet 
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the eligibility criteria and to extract the required data from both paper charts and electronic 
computer records, not available from the tumor registry database. As a primary nurse with 
several years of clinical experience working within the medical oncology discipline, the 
investigator and sole data collector had the expertise necessary to conduct the chart review 
while minimizing data collection error.  
The utilization of a well-developed data collection tool accompanied by a detailed 
data dictionary have been attributed to an increase in the interrater reliability of the chart 
review data collection process (Gregory & Radovinsky, 2012). Interrater reliability is 
basically the degree of agreement among how several data extractors collect data in a 
similar fashion. As this study has only one data extractor, it could be argued that the intra-
rater reliability was high however, a single data extractor can also introduce selection 
bias. Therefore, it was fundamentally important for the data collection process to remain 
consistent throughout to aid in reducing systematic error and investigator bias during the 
data collection process. 
Controlling all confounding factors is an impossible task during a study, however it is 
necessary to control those which can be controlled. Pre-existing co-morbidities are difficult 
to measure, and the lack of consistent surgical clinical documentation prevented its use as a 
variable of interest in this evaluation study. Nevertheless, the presence of co-morbidities in 
the sample population could be expected to have a significant confounding effect on the 
results of this study. Occasionally, in the investigators’ experience, patients with pre-
existing co-morbidities are referred to medical oncology by surgeons who are reluctant to 
perform surgery but still want to be able to offer these patients some form of treatment. 
Therefore, measures were taken to ensure that the inclusion criteria allowed only those 
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cases who were able to undergo definitive surgery and at least one other treatment option 
offered in the cancer care program (e.g., endocrine therapy, chemotherapy or radiation 
therapy).  
Ethical Considerations 
 Permission was granted from the program director of the provincial cancer care 
program to conduct this evaluation project and provided access to the provincial cancer 
registry and the various computerized electronic patient health records. The permission 
was granted on the basis that this evaluation study met the standards of the Newfoundland 
and Labrador’s Health Research Ethics Authority (HREA). The HREA has the 
responsibility for reviewing any research proposal which involves conducting research on 
living human participants. However, according to its website some studies are exempt 
from HREA approval such as “…quality assurance and quality improvement studies, 
program evaluation activities, performance reviews, and testing within normal 
educational requirements if there is no research question involved (used exclusively for 
assessment, management or improvement purposes)” (HREA website, bullet #3). A tool 
developed by the Alberta Research Ethics Community Consensus Initiative and provided 
on the HREA website was helpful in determining whether a study can be classified as 
research or a quality assurance initiative. It consists of a series of questions regarding the 
study and provided a numerical interpretation of the study’s intention, the results of which 
indicate that this evaluation project is a program evaluation activity and is exempt from 
HREA approval. A copy of the completed tool for this evaluation project has been added 
to Appendix H of this report. 
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The investigator took several measures to ensure the privacy and protection of the 
health information of patient cases in this evaluation study. The original tumor registry 
datasets have been kept on an encrypted USB flash drive and kept in a locked drawer 
within the investigator’s locked office at the DHBMCC. It will remain so for a period of 
five years until which time the data will be destroyed. The data of interest was collected 
from the tumor registry datasets and entered on separate data Excel spreadsheets designed 
by the investigator which included the patient case identifiers such as names and 
corresponding MCP numbers. Once the investigator collected the remaining data of 
interest from the chart review and completed the data entry into the newly constructed 
spreadsheet, the process of data de-identification was initiated. This process required the 
removal of all patient names and MCP numbers with each case being assigned a 
replacement unrelated number, which protected the anonymity of the patients and their 
personal health information. The new Excel spreadsheets with the de-identified data are 
being kept on a password protected work computer in the locked office of the investigator 
in a security-controlled work environment at the DHBMCC.  
Results 
A closer examination of the original tumor registry datasets revealed that many of 
the cases did not meet the eligibility criteria. In the 2013 dataset, the total number of 
patient cases in the sample was 113. However, 64 cases were excluded due to ineligibility 
leaving a total of 49 patient cases for 2013. In the 2016 dataset, the total number of 
patient cases in the sample was 133 with 77 cases excluded resulting in a total of 56 
patient cases.  
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Furthermore, during the data collection process, it became obvious that some 
patients were referred mainly because their pre-existing co-morbidities prevented primary 
surgery due to an elevated risk of death. This left the surgeon with little recourse other 
than to refer in hopes that a medical oncologist could offer some less risky means of 
treatment, which is rarely the case. At this juncture, in an attempt to create a more 
homogeneous sample population, the decision was made to only include patient cases 
who were candidates for at least two of the three main treatment options for breast cancer 
(i.e., surgery, pharmaceutical or chemical intervention, radiation therapy). Those cases 
that did not meet this stipulation were excluded and resulted in two additional patient 
cases being excluded for each study year from the locally advanced breast cancer sample 
population.  
The Figure 1 flowchart was designed in order to provide clarification of the sample 
population by year, by diagnosis, and finally whether cases were referred, not referred or 
not candidates for treatment. In 2013, of the 45 patient cases with locally advanced breast 
cancer only 10 were referred for neoadjuvant consideration, while 33 were not and two 
were ineligible. The four patient cases having inflammatory breast cancer in 2013 were 
all eligible and referred for neoadjuvant treatment. The final sample size for 2013 was 47 
patient cases.  
In 2016, of the 56 patient cases with locally advanced breast cancer only 14 were 
referred, 38 were not, and two were ineligible. The two cases with inflammatory breast 
cancer in 2016 were eligible and both were referred for neoadjuvant consideration. In 
2016, the final sample size was 54 patient cases.  
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Figure 1. Evaluation Project Study Groups Flowchart.  
Inflammatory Breast Cancer 
There were four cases of inflammatory breast cancer in 2013 and only two cases in 
2016. All six cases were referred for neoadjuvant consideration by the surgeons in 
question, which is 100% of patient cases for both years. This rate exceeds the range found 
in the literature review of 72% to 93% for neoadjuvant guideline adherence for the study 
Total # of Patient Cases 
246 
2013 
113 Patient Cases  
64 did not meet Eligibility 
Criteria N = 49 
Locally Advanced Breast 
Cancer (LABC) 
n = 45 
Received a Neoadjuvant 
Referral 
(R2013 LABC) 
n = 10 
Did not receive a 
Neoadjuvant Referral 
 (NR2013 LABC) 
n = 33 
Ineligible for Neoadjuvant 
Therapy 
(NC2013 LABC) 
n = 2 
Inflammatory Breast 
Cancer (IBC) 
n = 4 
Received a Neoadjuvant 
Referral 
 (R2013 IBC) 
n = 4 
Did not receive a 
Neoadjuvant Referral 
 (NR2013 IBC) 
n = 0 
Ineligible for Neoadjuvant 
Therapy 
(NC2013 IBC) 
n = 0 
2016 
133 Patient Cases 
77 did not meet Eligibility 
Criteria N = 56 
Locally Advanced Breast 
Cancer 
(LABC) 
n = 54 
Received a Neoadjuvant 
Referral 
 (R2016 LABC) 
n = 14 
Did not receive a 
Neoadjuvant Referral 
(NR2016 LABC) 
n = 38 
Ineligible for Neoadjuvant 
Therapy 
(NC2016 LABC) 
n = 2 
Inflammatory Breast 
Cancer 
(IBC) 
n = 2 
Received a Neoadjuvant 
Referral 
 (R2016 IBC) 
n = 2 
Did not receive a 
Neoadjuvant Referral 
(NR2016 IBC) 
n = 0 
Ineligible for Neoadjuvant 
Therapy 
(NC2016 IBC) 
n = 0 
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population with a diagnosis of inflammatory breast cancer. While the numbers were 
small, the referral rates for inflammatory breast cancer did indicate 100% compliance at 
least for the two years studied therefore, the remaining analysis will focus solely on the 
locally advanced breast cancer cohort only. 
Locally Advanced Breast Cancer 
Table 2 summarizes the comparison between the number and proportion of cases 
that were referred and not referred according to the study year of the locally advanced 
breast cancer cohort. A detailed discussion of the results has been provided below under 
the appropriate diagnostic heading. As shown in Table 2, the referral rates for those 
diagnosed with locally advanced breast cancer revealed a considerably different picture 
than that of the inflammatory breast cancer cohort. The analyses for 2016 suggests that 
only approximately 27% with a 95% CI [14.9%, 39.0%], of the eligible sample 
population of locally advanced breast cancer cases were referred to the medical oncology 
discipline. Using a confidence interval (CI) indicates that the likelihood of the true 
referral rate can be expected to be as low as 14.9% or as high as 39% for the 2016 results. 
The results for 2013 were similar with a referral rate of 23% having a 95% CI [10.6%, 
35.9%]. In this case, the likelihood is that the true referral rate could be as low as 10.6% 
or as high as 35.9%. Regardless, both referral rates for 2013 and the 2016 were much 
lower than the range of 44% to 79% adherence to neoadjuvant guidelines identified in the 
literature review. It was also clear that there was considerable overlap of the CI ranges for 
both years which indicates that there were little or no difference between the referral 
rates. A closer look at the data for all patient cases with locally advanced breast cancer 
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was warranted to determine if any of the identified variables may have influenced these 
results. 
 
Table 2  
 
Number and Proportion of Patients Diagnosed with Locally Advanced Breast Cancer 
(LABC) in 2013 and 2016 
 
 2013 
N = 43 
 
Total 
n (%) 
2016 
N = 52 
 
Total 
n (%) Referred 
n (%) 
Not 
Referred 
n (%) 
Referred 
n (%) 
Not 
Referred 
n (%) 
Locally 
Advanced 
Breast 
Cancer 
(LABC) 
 
10 
(23.3%) 
 
33 
(76.7%) 
 
43 
(100%) 
 
14 
(26.9%) 
 
38 
(73.1%) 
 
52 
(100%) 
  
 
 Patient Demographic and Facility Variables for LABC. 
 Table 3 summarizes the results of this cohort by the patient demographic of age and 
facility-related data according to the referral status and study year. The facility data gave 
information regarding the name of the facility which in turn, informed the investigator 
whether the definitive surgery had been performed in a large university-affiliated hospital 
versus moderate to small urban hospitals or a small rural community hospital. All of the 
numbers were too small or too similar in this table to reliably be able to draw conclusions. 
However, there were some instances where the investigator was able to identify some 
notable trends in the data.  
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Table 3 
Patient Age and Facility Type of LABC by Year and Referral Status 
 
Variables 2013 2016 
Referred 
n (%) 
Not Referred 
n (%) 
 
Referred 
n (%) 
Not Referred 
n (%) 
Age Range 
(years) 
 
Median Age: 58 
Range: 35 to 85 
Median Age: 61.5 
Range: 33 to 85 
≤ 40 
 
3 (100) 
 
0(0) 1(33.3) 2(66.7) 
41 – 50 
 
2(22.2) 
 
7(77.8) 5(55.6) 4(44.4) 
51 – 60 2(20) 
 
8(80) 4(33.3) 8(66.7) 
61 – 70 3(37.5) 
 
5(62.5) 2(11.1) 16(88.9) 
> 70 0(0) 13(100) 2(20.0) 8(80.0) 
Facility Type 
 
 
 
Large Urban        
(University-
affiliated) 
 
8(40.0%) 12(60.0%) 8(24.2%) 25(75.8%) 
Moderate Urban 
Community 
Hospital 
 
1(11.1%) 8(88.9%) 2(33.3%) 4(66.7%) 
Small Urban 
Community 
Hospital A 
 
0(0) 8(100) 0(0) 3(100) 
Small Urban 
Community 
Hospital B 
 
0(0) 1(100) 3(60.0) 2(40.0) 
Other (Small 
Rural Community 
Hospitals) 
1(20.0%) 4(80.0%) 1(20.0) 4(80.0) 
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 The median age and range for 2013 and 2016 was 58.0 years (35 years to 85 years) 
and 61.5 years (33 years to 85 years), respectively. One of the data  trends was related to 
the stratified age groups which indicated a higher proportion of cases aged 41 to 50 years 
were being referred in 2016 (55.6%) compared to the same age group in 2013 (22.2%). 
Interestingly, another trend that was identified in the data was a larger number of cases in 
the 61 to 70-year age group for 2016 compared to 2013 (18 cases vs. 8 cases), however a 
smaller proportion of them had been referred in 2016 (11.1% vs. 37.5%). The most 
important exception of note was regarding the facility-related data which indicated that 
despite having a larger number of patient cases receiving definitive surgery at university-
affiliated hospitals in 2016 (33) compared to 2013 (20), the proportion of cases being 
referred were lower in 2016 (24.2%) compared to 2013 (40%). 
Tumor Size, Lymph Node Status, and AJCC Staging for LABC.  
 Table 4 summarizes the locally advanced breast cancer data by tumor size, nodal 
status, and AJCC staging according to referral status and the year of study. The 2013 
results indicated that larger tumor sizes (> T2) were more likely to be referred (67%; six 
out of nine) than those ≤ T2 (13%; four out of 30) (see Appendix A for explanation of T 
sizes). This was also the case with the 2016 results which showed that 11 out of 18 (61%) 
cases with tumors > T2 were referred while only three out of 34 (9%) cases of tumors ≤ 
T2 were referred. This also held true for those with lymph node involvement, who were 
much more likely to be referred compared to those with negative lymph nodes. In 2013 
nine cases with lymph node involvement were referred compared to one with no lymph 
node involvement. In 2016, 14 cases with lymph node involvement were referred while 
there were no cases of lymph node negative disease referred. There was also a data trend 
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suggesting that there were a larger number of stage IIIA breast cancers (32) in 2016 
compared to 2013 (26), with a slightly higher proportion of these having been referred for 
neoadjuvant therapy in 2016 (31% vs. 23%).  
Table 4 
Tumor Size, Lymph Node Status, and AJCC Stage of LABC by Year and Referral Status 
 
Variables 2013 2016 
Referred 
n (%) 
Not 
Referred 
n (%) 
 
Referred 
n (%) 
Not 
Referred 
n (%) 
Clinical Tumor 
Size* 
 
 
Tx 
 
0(0) 4(100) 0(0) 4(100) 
T1b 0(0) 3(100) 0(0) 2(100) 
T1c 
 
0(0) 8(100) 1(10.0) 9(90.0%) 
T2 
 
4(21.1) 15(79.0) 2(11.1) 16(88.9) 
T3 5(62.5) 3(37.5) 9(60.0) 6(40.0) 
T4 
 
1(100) 0(0) 2(66.7) 1(33.3) 
Lymph Node 
Status 
 
 
Negative 
 
1(7.1) 13(92.9) 0(0) 4(100) 
Positive 9(31.0) 20(69.0) 14(29.2) 34(70.8) 
AJCC Stage 
(Clin/Path) 
 
 
Stage IIB 
(T3N0M0) 
1(25.0) 3(75.0) 0(0) 4(100) 
Stage IIIA 
 
6(23.1) 20(76.9) 10(31.3) 22(68.8) 
Stage IIIB 
 
1(100) 0(0) 0(0) 2(100) 
Stage IIIC 2(16.7) 10(83.3) 4(28.6) 10(71.4) 
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Other Tumor-related Variables for LABC. 
 Table 5 summarizes the analysis of the other tumor-related variables such as tumor 
histology, grade, focality, unilateral versus bilateral, and the molecular subtype of the 
disease by referral status and year of study. Ductal tumors are the most common histology 
type found in breast cancer. Therefore, it is not surprising that the majority of the patient 
cases in this cohort had been diagnosed with ductal histology for both study years. 
Though the sample size for ductal histology was the same for both years with 28 cases, 
there was a slight increase in the proportion of cases in 2016 (32%) compared to 2013 
(25%). In both 2013 and 2016, the referral rate for grade 3 tumors were virtually the same 
even though these poorly differentiated tumors are highly aggressive. However, there was 
a slight trend toward more referrals for grade 2 tumors in 2016 (27.8%) compared to 2013 
(21.7%). Grade 2 and 3 tumors were far more likely to be referred in either year 
compared to those with grade I disease (0%).  
Table 5 
Other Tumor-related Variables of LABC by Year and Referral Status 
 
Variables 2013 2016 
Referred 
n (%) 
Not Referred 
n (%) 
 
Referred 
n (%) 
Not Referred 
n (%) 
Tumor Histology 
 
 
Ductal 7(25.0) 21(75.0) 9(32.1) 19(67.9) 
Lobular 0(0) 2(100) 0(0) 4(100) 
Mixed 
 
2(22.2) 7(77.8) 4(25.0) 12(75.0) 
Other 1(25.0) 3(75.0) 1(25.0) 3(75.0) 
176 
 
Variables 2013 2016 
Tumor Grade 
 
 
Grade 1 
 
0(0) 3(100) 0(0) 0(0) 
Grade 2 
 
5(21.7) 18(78.3) 5(27.8) 13(72.2) 
Grade 3 3(21.4) 11(78.6) 7(22.6) 24(77.4) 
Unknown 2(66.7) 1(33.3) 2(66.7) 1(33.3) 
Tumor Focality 
 
 
Unifocal 
 
2(9.1) 20(90.9) 11(27.5) 29(72.5) 
Multifocal 
 
4(44.4) 5(55.6) 3(33.3) 6(66.7) 
Multifocal/ 
Multicentric 
 
0(0) 0(0) 0(0) 1(100) 
Unknown 4(33.3) 8(66.7) 0(0) 2(100) 
Laterality 
 
 
 
Unilateral 9(22.5) 31(77.5) 12(24.0) 38(76.0) 
Bilateral 1(33.3) 2(66.7) 2(100) 0(0) 
Molecular 
Subtype 
 
 
Luminal A/B 6(20.0) 24(80.0) 7(19.4) 29(80.6) 
HER2 Positive 0(0) 1(100) 0(0) 3(100) 
Triple Negative 4(33.3) 8(66.7) 7(53.8) 6(46.2) 
 
 
 Unifocal tumors are much more commonly found in the breast cancer population 
than multifocal tumors or multifocal/multicentic disease. However, unifocal tumors are 
also far less aggressive than multifocal tumors or those with multifocal/multicentic 
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disease. The numbers were really too small and too similar to determine whether 
multifocality or multifocal/multicentric disease were truly a characteristic of influence for 
both years of study. A larger sample size may be able to answer this question more 
conclusively.  
 Similar to the trends found for ductal histology and unifocal tumors, the findings of 
unilateral disease are also far more common than that of bilateral disease in breast cancer. 
In addition, the presence of bilateral tumors indicates a far more advanced and aggressive 
pathology than that of unilateral disease. The numbers for bilateral disease were too small 
to identify a trend.  
 The referral rates for luminal (approximately 19% to 20%) and HER2 positive (0%) 
breast cancers were similar for both study years. However, there was one noteworthy 
trend in the data which concerned the difference in referral rates of the triple negative 
molecular subtype. Despite the small numbers, it was evident that a higher proportion of 
triple negative cases were referred in 2016 (53.8%; seven out of 13) compared to 2013 
(33.3%; four out of 12). 
Argument for Subgroup Analysis 
 The only findings in the results which appear to provide an explanation for such a 
low referral rate for all locally advanced breast cancers would be the tumor size and 
presence of lymph node involvement. This coincides with one of the three characteristics 
used to define the locally advanced breast cancer population which were:     
• a tumor size > 5cm (T3 or T4); and/or  
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• at least N2 disease defined by the AJCC staging manual on breast cancer staging 
as “…clinically fixed/matted ipsilateral axillary lymph nodes or clinically 
imaged ipsilateral internal mammary nodes in absence of clinically evident 
axillary lymph node…” involvement (Edge et al., 2010, p.2); and/or 
• AJCC stages IIB (T3N0M0) or any stage III breast cancer. 
 The clinical assessment of the T size is frequently easily determined by 
measurement under clinical palpation or radiological measurement under imaging with a 
T size assigned according to the measurement (in mm). An exception to this would be 
tumors classified as Tx which indicates that clinical disease can be detected in the axillary 
lymph nodes however, there is no evidence of tumor clinically or radiologically detected 
in the breast. The clinical T3 or T4 tumors in any sample would unequivocally meet the 
definition of locally advanced breast cancer and routinely should have been referred for 
neoadjuvant treatment.  
 In the presence of smaller tumor sizes, such as T1 and T2 (either clinically or 
radiologically), a clinical diagnosis of N2 disease is required to confirm a locally 
advanced breast cancer diagnosis requiring a neoadjuvant referral. However, in this case 
the clinical assessment of the axillary lymph nodes to detect N2 disease can be much 
more challenging even with the aid of radiological imaging. The axillary contents are 
much denser than the breast and often requires the use of ultrasound to help detect 
enlarged lymph nodes. ‘Pathological’ lymph nodes are lymph nodes detected during 
imaging measuring at least 1cm or larger which are suspicious for the presence of a 
disease process. Lymph nodes smaller than 1 cm can sometimes be visualized on imaging 
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by the radiologist but often cannot be categorically defined as pathological. Unless there 
are at least two levels of ipsilateral pathological axillary lymph nodes, or ipsilateral 
pathological internal mammary node involvement visualized on imaging, then the N 
status cannot be classified as N2 disease. Therefore, these cases would not be eligible for 
neoadjuvant therapy when combined with a T size of 2 or smaller.  
 In some cases where imaging suggests N1 or no nodal disease, the aggressiveness 
of some breast cancers may create regional lymph nodes involvement with tumor at a N2 
level, without these lymph node(s) reaching pathological size at the time of imaging. In 
these cases, the extent of disease will only be revealed during the pathological analysis 
after definitive surgery which is too late to take advantage of the benefits of neoadjuvant 
therapy. Therefore, without the aid of a clear indication of N2 disease and in the presence 
of a T2 or smaller tumor size, the surgeon will correctly proceed with definitive surgery. 
 There were a group of patient cases within this cohort which, according to the 
definition of locally advanced breast cancer, should have been referred without question. 
The use of AJCC staging would not be helpful in identifying this group since it too would 
require detailed clinical knowledge of the nodal status. However, breast cancers having 
clear evidence of T3 and T4 tumors should automatically be candidates for neoadjuvant 
therapy and therefore, should be a suitable cohort in which to investigate a more accurate 
representation of the actual referral rate. Therefore, the remaining analysis will focus on 
the locally advanced breast cancers with T3 and T4 tumors.  
Locally Advanced Breast Cancer (T3/T4 only)  
 A comparative analysis was performed on T3 and T4 locally advanced breast 
cancers according to the study year, and the results are outlined in Table 6. The number of 
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T3 and T4 cases doubled in number for 2016 (n = 18) compared to 2013 (n = 9). 
However, the referral rate decreased from approximately 67% (95% CI: 35.9%, 97.5%) in 
2013, to approximately 61% (95% CI: 38.6%, 83.6%) in 2016. In 2013, the likelihood of 
the true referral rate can be expected to be as low as 35.9% or as high as 97.5%, while the 
true referral rate for 2016 would be between 38.6% and 83.6%. The confidence intervals 
in both study years are notably wide. Taking into consideration the sample sizes were 
small, the referral rates for both study years do fall within the range identified in the 
literature review of 44% to 79%. However, a larger sample size would allow for a more 
accurate estimate of the referral rate with a narrower confidence interval, and a clearer 
picture of the true rate.  
 Nevertheless, in 2016 nearly 40% of patient cases with clear evidence of locally 
advanced disease were not referred for neoadjuvant therapy. The question then became 
‘was there an association between the chosen variables of interest and the referral status 
of patient cases with T3 and T4 breast cancer in 2016?’ 
Table 6 
 
Number and Proportion of Patients Diagnosed with T3 and T4 Locally Advanced Breast 
Cancer (LABC) in 2013 and 2016 
 
T size of 
Breast 
Cancer 
2013 (T3 & T4) 
n = 43 
Total 
n (%) 
2016 (T3 & T4) 
n = 52 
Total 
n (%) 
Referred 
n (%) 
Not 
Referred 
n (%) 
Referred 
n (%) 
Not 
Referred 
n (%) 
T3 5(55.6%) 3(33.3%)  
9 
(20.9%) 
9(50.0%) 
 
6(33.3%)  
18 
(34.6%) T4 1(11.1%) 0(0) 2(11.1%) 
 
1(5.6%) 
Total  6(66.7%) 
 
3(33.3%) 
 
n = 43 
(100%) 
11(61.1%) 7(38.9%) n = 52 
(100%) 
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 Patient Demographic and Facility Variables (T3/T4).  
 The analysis of the T3 and T4 data for 2016 was summarized in Table 7 according 
to the patient demographic of age and facility type based on whether the patient cases had 
been referred or not. As previously was the case, the numbers are small which hinders the 
ability to draw any meaningful conclusions. The median age of the referred group was 54 
years with a range of 34 to 79 years of age, while the median age for the non-referred 
group was 55 years with a range of 33 to 85 years of age. Of the seven cases that were ≤ 
50 years of age, five were referred for neoadjuvant therapy while six of the 11 cases that 
were > than age 50 were referred which may indicate that younger patients are more 
likely to be referred than older patients. The facility-related data suggests that patient 
cases in the T3/T4 cohort, who received their definitive surgery at university-affiliated 
hospital, were more likely to be referred (six of the nine cases) compared to other 
facilities (five of the remaining nine cases) in the province. 
Table 7 
 
 Patient Age and Facility Type of Clinical T3 and T4 Tumors of LABC by Referral Status 
for 2016  
 
Variables Referred 
n = 11 
Not Referred 
n = 7 
Age Range (in years) Median Age: 54 
Range: 34 to 79 
Median Age: 55 
Range: 33 to 85 
≤ 40 
 
1 
 
1 
41 – 50 
 
4 
 
1 
 
51 – 60 
 
3 
 
2 
 
61 – 70 
 
2 
 
2 
 
> 70 
 
 
1 
 
1 
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Variables Referred 
n = 11 
Not Referred 
n = 7 
 
Facility Type 
 
 
Large Urban  
(University-affiliated) 
 
6 3 
Moderate Urban Community 
Hospital 
 
1 2 
Small Urban  
Community Hospital B 
 
3 2 
Other (Small Rural 
Community Hospitals) 
1 0 
 
Lymph Node Status and AJCC Stage (T3/T4). 
 The analysis of the lymph node status and AJCC stage in the T3 and T4 cohort has 
been provided in Table 8 by referral status. It was apparent from these data that those 
T3/T4 cases with lymph node involvement were more likely to be referred (11 of 18 
cases) than those who did not (0 of 2 cases). In addition, the AJCC stages of IIIA (seven 
of 11 cases referred) and IIIC (all four cases referred) indicated that these stages were 
more likely to be referred than stages IIB and IIIB with 0 cases referred. 
Table 8 
 
 Lymph Node Status and AJCC Staging of Clinical T3 and T4 Tumors of LABC by 
Referral Status for 2016  
 
Variables Referred 
n = 11 
Not Referred 
n = 7 
Lymph Node Status   
Negative 
 
0 
 
2 
 
Positive 
 
11 
 
5 
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Variables Referred 
n = 11 
Not Referred 
n = 7 
AJCC Stage (Clinical or 
Pathological) 
 
 
Stage IIB 
(T3N0M0) 
0 
 
2 
 
Stage IIIA 
 
7 
 
4 
 
Stage IIIB 0 
 
1 
 
Stage IIIC 
 
4 
 
0 
 
 
Other Tumor-related Variables (T3/T4). 
 Table 9 summarizes the analysis of the data from the 2016 study year of the other 
tumor-related variables for T3 and T4 tumors according to referral status. As mentioned 
previously, tumors with a ductal histology (8 out of 18), grades 2 or 3 (9 out of 18), a 
unifocal (9 out of 18) and/or unilateral distribution (9 out of 18) are not only the most 
common features but also among those most likely to be referred. Five of 11 cases with 
the luminal subtype were referred while six of the seven cases triple negative subtype 
were referred. This indicates that those with a triple negative subtype was more likely to 
be referred than any other subtype. 
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Table 9 
 
 Other Tumor-related Variables of Clinical T3 and T4 Tumors of LABC by Referral Status 
for 2016  
 
Variables Referred 
n = 11 
Not Referred 
n = 7 
Tumor Histology 
 
 
Ductal 8 1 
Lobular 0 2 
Mixed 2 3 
Other 1 1 
Tumor Grade 
 
 
Grade 2 4 4 
Grade 3 5 3 
Unknown 
 
 
2 0 
 
Tumor Focality 
 
 
Unifocal 
 
9 5 
Multifocal 
 
2 1 
Unknown 0 1 
Tumor Laterality 
 
 
Unilateral 9 7 
Bilateral 2 0 
Molecular Subtype 
 
 
Luminal A/B 5 6 
HER2 Positive 0 0 
Triple Negative 6 1 
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Discussion  
 Referral Rates and Adherence. 
 The results of the analyses indicate that the neoadjuvant referral rate for the six 
patient cases with inflammatory breast cancer in 2013 and 2016 was 100%. This suggests 
that there has been complete compliance to the recommendations for treatment of 
inflammatory breast cancer for these patients during both years of study.  
 However, the interpretation of the data regarding the referral rate for the locally 
advanced breast cancer sample appears to be much more complex. The initial results 
suggested that only approximately 27% (95% CI:14.9%, 39.0%) for all-comers in 2016 
who met the definition of locally advanced breast cancers on clinical assessment or final 
pathology were referred to medical oncology for neoadjuvant consideration. This result 
was only incrementally larger than the 2013 rate of approximately 23% (95% CI: 10.6%, 
35.9%). The observed referral rates for 2013 and 2016 were much lower than the referral 
rate identified in the literature of 44% to 79%.  
 The subgroup analyses conducted on the T3 and T4 tumors was justified since these 
patient cases conclusively met the definition of locally advanced breast cancer. These 
breast cancer cases were among the few where the surgeon was aware that these were 
locally advanced prior to making the decision to refer the patient or not. This was 
reflected in a substantial increase in the referral rates for this subset of approximately 
67% (95% CI: 35.9%, 97.5%) in 2013 and 61% (95% CI: 38.6%, 83.6%) in 2016. These 
rates did fall within the literature identified range of 44% to 79%. However, both referral 
rates have very wide confidence intervals which make it difficult to estimate the true 
referral rate and can only be narrowed by using a larger sample size. Nevertheless, the 
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most alarming result in 2016 was that approximately 40% of the patients with T3 or T4 
locally advanced breast cancer, who should have received a referral to medical oncology 
for a neoadjuvant discussion, did not. 
 Another important insight of this study has been the relatively incremental 
differences between 2013 and 2016, in terms of guideline adherence in both analyses. 
Therefore, it is reasonable to state that the study results reveal that there has been little or 
no difference in the referral rate between study years. This would also indicate that the 
dissemination of the Eastern Health BDSG neoadjuvant guideline has had little or no 
effect on the clinical practice of referring eligible cases for neoadjuvant treatment. 
Unfortunately, this result is hardly surprising since lack of adherence to clinical practice 
guidelines has been a consistent problem in Canada, as well as many other developed 
countries, as outlined in the literature (Gupta et al., 2016; Hall, Irish, Gregg, Groome, & 
Rohland, 2015). An article in the Canadian Medical Association Journal recognized time 
and resource availability among the main limitations physicians cite for the lack of use of 
clinical practice guidelines (Vogel, 2011). Other criticisms of guidelines include their 
length, complexity, and the variety of choice available from numerous sources. These 
legitimate complaints must be taken seriously, and measures taken to enhance the 
usability of the clinical practice guidelines if patient outcomes are to be constructively 
improved.  
Factors and Decision-making. 
As was the case for the referral rate analysis, the sample size was too small to allow 
firm conclusions to be drawn though the identification of trends in the data was still 
possible. Several trends in the data were identified from the analysis of the factors which 
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may influence the surgeon’s decision-making process for all locally advanced breast 
cancers and the T3 and T4 subgroup. These trends suggested that cases were more likely 
to be referred if the patient were younger (≤ 50 years), and/or had clinical lymph node 
involvement, and/or had AJCC stages IIIA, and/or had triple negative breast cancer. 
Though all cases within this subset should have been referred for neoadjuvant treatment, 
the presence of these factors did appear to aid in promoting the use of neoadjuvant 
referral. The information regarding molecular subtyping seemed especially important 
when the breast cancer in question was of the triple negative subtype. At present, receptor 
testing is not routinely performed on the needle core biopsy unless the surgeon requests it 
specifically. Therefore, unless the case is obviously a locally advanced breast cancer and 
the surgeon had the foresight to order receptor testing on the needle core biopsy, the 
surgeon cannot avail of the molecular subtype information to help with decision-making.  
It is possible of course, that out of the seven cases with T3 and T4 tumors in 2016 
which were not referred, age may have been the extenuating factor for at least one or two 
of these patients. In addition, the patient’s right to choose with regards to the sequence of 
events surrounding their individual treatment must be honored as a legitimate reason not 
to refer. However, having approximately 40% of the eligible population not being referred 
for treatment which may potentially affect their overall survival should not be an 
acceptable outcome. Therefore, more must be done to promote the use of neoadjuvant 
treatment for surgeons who need to encourage eligible patients in order to maximize the 
treatment benefit at a curable stage.    
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Recommendations  
 The results of this evaluation project have revealed some underlying issues with the 
referral program and the clinical practice guideline program, as well. The referral rates for 
the entire locally advanced breast cancer cohort are much lower than the rates found in 
the literature review. However, the referral rates for the T3/T4 subgroup does fall within 
the literature’s range for referral though a large proportion of patients (approximately 
40%) who should have been referred, were not. These results also indicate that surgeons 
have failed to adhere to clinical practice guidelines regarding neoadjuvant therapy for the 
locally advanced breast cancer population. As investigator, insight into several of these 
issues have prompted the development of some recommendations to be initiated by the 
BDSG and the administrative body which may prove to be effective in combating these 
problems with an eye to improving patient outcomes.  
 The recommendations to improve referral rates from a systems approach include: 
1. Present the results to the administrative body in the form of an executive 
summary, which highlights the issues within the healthcare system. Consulting 
those with extensive managerial expertise who are ideally positioned to offer 
advice and feedback on how to initiate change at a system level, is crucial;  
2. Present the results and issues to the Eastern Health BDSG in order to 
encourage ideas and actions that can be initiated in-house in the respective 
departments to improve the availability of certain information which may affect 
the surgeons’ decision-making ability. These include: 
o standardization of molecular subtype testing on all needle core breast 
biopsies of pathologically confirmed breast cancers; 
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o continuing to advocate for synoptic radiological and pathological 
reporting across the province;  
o synoptic reporting of the decision-making process from surgeons;  
o methods to increase the consultation and collaboration between 
surgeons and oncologists.  
3. Encourage the implementation of measures for professional development 
among the guideline users and promotion of a team approach to patient care 
which include educational approaches which incorporate team-building tactics. 
The use of local conferences or workshops where oncologists can meet face-to-
face with the province’s family physicians and surgeons can be crucial in 
promoting the team approach, while providing interpretations of the latest 
research findings which are likely to change clinical practice.            
 There would be little argument that the referral process is highly complex and is 
often influenced by various factors. However, having studied many of these factors, it 
was determined that these factors alone, do not consistently influence decision-making. 
Clinical practice guidelines are meant to provide a resource for surgeons to consult when 
treatment decision-making is complicated or problematic. Yet, the evidence provided 
earlier indicates that surgeons often complain that guidelines are too long or too complex 
to enable ease of use. In the example of the Eastern Health BDSG, some physicians have 
complained about the difficulty in accessing or knowing where to access the guidelines.  
 The recommendations for improving the clinical practice guideline process, 
dissemination and uptake are: 
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1. Carry out a survey of the province’s surgeons to determine what 
percentage are aware of or use the Eastern Health BDSG clinical practice 
guideline on neoadjuvant treatment. Also provide a summary of this 
evaluation project to engage surgeons by emphasizing the importance of 
participating in the survey and by giving them an opportunity to voice their 
opinions; 
2. Continue to provide evidence-based clinical practice guidelines for 
surgeons and family physicians to guide the care of our patients diagnosed 
with breast cancer. However, it will be crucial going forward to develop 
guidelines that will incorporate the needs of the surgeons as highlighted in the 
survey; 
3. Revise the guidelines by making them more user-friendly by clarifying the 
treatment options according to particular clinical situations. The introduction 
of treatment algorithms may be helpful to encourage family physicians and 
surgeons to utilize the guideline more frequently in the management of these 
patients. Two algorithms  designed by the investigator are in Appendix B and 
C; 
4. Examine the dissemination practices of our clinical practice guidelines in 
order to ensure that family physicians and surgeons are actually receiving 
them and are aware of, and familiar with the guidelines. Improving 
dissemination efforts may also be helpful in promoting the use of any newly 
developed treatment algorithms and potentially receiving feedback on their 
usefulness and improvement strategies. 
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Conclusion 
The chart review process for this evaluation project was the crucial final step in 
gathering the best quality data available in order to answer the questions of interest in this 
study. The procedures and protocols implemented in this endeavor were essential in 
maintaining the internal validity of this project. Despite the measures taken however, the 
final sample size was too small to draw any firm conclusions for this study. Regardless of 
the sample size, it was still important to generate recommendations from the findings of 
this study. A complete year of patient data for the province had been used in both a pre- 
and post-guideline dissemination study period, even though the sample size was not 
sufficient. Increasing the sample size would require additional years of study which 
would have been limited by the small number of years in the post-dissemination period. 
In addition, recommendations were indeed necessary now especially since the referral 
rates were clearly lower than expected.  
Nevertheless, it was possible to identify some trends in the data such as the 
presence of factors that were associated with the likelihood of referral to the medical 
oncology discipline. This project was useful in identifying the neoadjuvant referral rates 
which indicated a need for interventions which could increase the number of eligible 
patients being referred. It was also helpful in highlighting the need for a fundamental 
change in guideline development in order to make these guidelines more user-friendly, 
more accessible and more measurable for quality improvement initiatives. In addition, 
this project has provided a method which can be used as a template for evaluating other 
clinical practice guidelines developed by this group, or other groups.  
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The next steps for this project would be to develop and implement interventions as 
per the recommendations to ultimately increase the referral rate and to positively 
influence patient outcomes. 
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Appendix A: AJCC Breast Cancer Staging 
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Appendix B: Diagnostic and Treatment Algorithm for Invasive Breast Cancer 
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Legend for the Diagnostic and Treatment Algorithm for Invasive Breast Cancer 
1. Suspicious lesion:  Patients usually enter the oncology system with a suspicious breast lesion 
either through a clinical presentation (found by self or family physician), through the breast 
screening program (finding on routine screening mammogram), or through an incidental 
finding (found on imaging while being investigated for a different health issue, such as CT or 
MRI of chest).  
2. Bilateral mammogram and spot compression views: A bilateral mammogram (if not already 
completed) and a spot compression view will be performed to evaluate the suspicious lesion.   
3.  Needle core biopsy under ultrasound (or MRI) guidance: If the lesion is still considered to be 
suspicious at this stage, a needle core biopsy is performed under ultrasound-guidance (or MRI-
guidance when difficulty visualizing the lesion) in an attempt to establish whether the lesion is 
malignant or benign.   
4. Pathological confirmation of breast cancer: The family physician will often consult a surgeon 
while waiting for the results, or once a pathological diagnosis of breast cancer has been 
confirmed.  
5. CT scan and bone scan: During the first visit, the surgeon will order a CT scan of the chest, 
abdomen and pelvis as well as, a nuclear medicine bone scan to be performed to complete the 
cancer staging. The results of these tests will determine whether the patient has: 
a. No evidence of metastatic disease:  See number 6.  
b. Evidence of metastatic disease: If imaging provides evidence of distant metastatic 
spread from the breast cancer primary to the bones or other organs, the surgeon may 
proceed with a palliative simple mastectomy and/or consult with both medical and 
radiation oncologists to determine the best treatment sequence with a palliative intent to 
alleviate symptoms and extend survival. 
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6. No evidence of metastatic disease: If imaging provides no definitive evidence of metastatic 
disease, the surgeon must determine to the best of her/his ability the AJCC clinical stage of the 
cancer. This will help determine whether the patient has in situ disease only, or if the patient 
has invasive disease which is either early stage or locally advanced/inflammatory breast cancer.   
a. Early stage breast cancer: If the surgeon determines the patient has early-stage breast 
cancer, then the patient will proceed to undergo adjuvant therapy consisting of definitive 
surgery first, followed by chemotherapy and/or endocrine therapy (for 5-10 years) post-
operatively, followed by chest wall radiation therapy if indicated.  
b. Locally advanced or inflammatory breast cancer: If the surgeon determines the patient 
has locally advanced or inflammatory breast cancer, then the surgeon should refer the 
patient immediately to see a medical oncologist. If warranted, neoadjuvant 
chemotherapy or endocrine therapy will begin quickly, and the tumor will be assessed 
frequently for response. Sufficient tumor response after 4 to 6 cycles will be followed by 
definitive surgery, and then chest wall radiation therapy four week post-operatively. If 
there is little or no tumor response to the first treatment regimen after one or two cycles, 
the treatment can be altered or switched. Endocrine therapy will continue following the 
completion of radiation therapy for five to ten years, as directed.  
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Appendix C: Surgeon’s Decision to Refer Algorithm  
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Legend for Surgeon’s Decision to Refer for Non-Metastatic Invasive Breast Cancer 
1. Surgeon: The surgeon must decide from the clinical, radiological and pathological evidence 
whether the patient has early stage breast cancer or has locally advanced/inflammatory breast 
cancer.  
2a. Locally advanced breast cancer or inflammatory breast cancer: The surgeon would regard 
those patients with a clinical tumor size of ≥ 5 cm, and/or ≥ clinical N2 lymph node 
involvement, and/or a clinical AJCC stage IIB (T3N0) or any stage III breast cancer, with or 
without a HER2 positive or triple negative subtype on needle core biopsy to have locally 
advanced breast cancer. A patient with a clinical and pathological confirmation of 
inflammatory breast cancer will be regarded so by the surgeon. 
2b. Referral to Medical Oncology: If the patient has been confirmed to have locally advanced 
breast cancer or inflammatory breast cancer as stipulated, the surgeon must refer the patient to 
the medical oncology discipline for a discussion about neoadjuvant therapy. The surgeon, 
using independent medical judgement, may decide to forego the neoadjuvant referral only in 
certain circumstances. One of these circumstances include when the patient’s frailty or pre-
existing co-morbidities impose an unacceptable mortality risk. Another would be when the 
patient refuses any treatment at all or will accept only surgical intervention. The surgeon must 
advise the patient of the risks of refusing some, or all, therapy and assure the patient that 
should change his/her mind the option of referral will still be open though the outcomes may 
not be assured.  
3a. Early stage breast cancer with extenuating circumstances: The surgeon would regard patients 
to have early stage breast cancer if the patient had a clinical tumor size of < 5cm, and/or 
clinical N0 or N1 disease, and/or any clinical AJCC stage I or stage II (except T3 N0). 
However, patients with early breast cancer who have extenuating circumstances that may 
require neoadjuvant referral would include those with one or more of these clinical findings:  
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• a HER2 positive or triple negative subtype on needle core biopsy 
• patient requests breast conserving surgery (BCS) but surgeon is unsure of resectability 
• presence of any patient- or tumor-related factor(s) which may motivate the surgeon to 
refer (e.g., young age of patient, questionable clinical tumor size, grade 3 tumor, 
multifocal/multicentric disease). 
3b. Collaborate with a medical oncologist: If the patient has any of the clinical findings listed in 
3a, then the surgeon should contact a medical oncologist to present the case and come to some 
consensus of the best treatment sequence to initiate for the benefit of the patient.  
4a. Early stage breast cancer: If the patient has a clinical tumor size of < 5cm, and/or clinical N0 
or N1 disease, and/or any clinical AJCC stage I or stage II (except T3 N0) with or without a 
luminal subtype on needle core biopsy, then the surgeon must regard these cases as early stage 
breast cancer. 
4b. Proceed to primary surgery: If the patient has no clinical indications which suggest the need 
for neoadjuvant referral than the surgeon must proceed to perform surgery has the primary 
treatment modality followed by a referral for adjuvant therapy approximately 4 weeks post-
operatively. 
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Appendix D: Letter to Divisional Manager of the NL Cancer Registry 
Dr. H. Bliss Cancer Center 
300 Prince Philip Drive 
St. John’s, NL 
709-777-8840 
05/04/2018  
 
Divisional Manager 
NL Cancer Registry 
Dr. H. Bliss Murphy Cancer Center 
300 Prince Philip Drive 
St. John’s, NL 
 
Dear Divisional Manager: 
As per our discussion on March 2nd of this year, I am providing a written request 
for the specific data of interest for an evaluation project which does not require 
Health Research Ethics Authority approval. I have received permission from the 
Program Director of the Cancer Care Program to proceed with the above project. 
I am ready to begin the evaluation project on May 7th, 2018. 
 
The sample population from which I will require data are: 
• Female patients with a diagnosis of locally advanced breast cancer with the 
following clinical stages of IIB, IIIA, IIIB, IIIC, or a diagnosis of inflammatory 
breast cancer; 
• Both years of 2013 and 2016 from January 1 to December 31 for each; 
• Those who received neoadjuvant therapy as per sequence of primary surgery 
after chemotherapy or endocrine therapy. 
 
The variables of interest required for this evaluation project are: 
• Tumor size 
• Histologic grade and type 
• Unilateral versus bilateral 
• Presence of multicentric or multifocal disease 
• Estrogen and progesterone receptor status 
• HER2 receptor status 
• Clinical assessment of lymph node status 
• Clinical AJCC staging 
• Patient age 
• Received neoadjuvant therapy (where possible) 
 
Cynthia Higdon 
Clinical Practice Guideline Coordinator  
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Appendix E: Data Collection Tool 
 
Adherence to an Oncology Clinical Practice Guideline: 
An Evaluation Project 
Principal Investigator: Cynthia Higdon 
 
        Date:  
         
        Data Source:  
 
        PI Initials:  
 
1. Subject medical care plan (MCP) number 
2. Subject outpatient OPIS number (if needed)        
3. Subject name (last, first)     
4. Subject date of birth (mm/dd/yyyy)    
Patient Demographic Data 
5. Age at initial diagnosis      
6. Year of initial diagnosis      
7. Cancer diagnosis 
Tumor-related Factors 
8. Tumor size (mm)       
9. Tumor histology 
10. Tumor grade      
11. Tumor laterality 
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 Date:   
 Data Source:  
   PI Initials:    
 
12. Tumor focality and/or centricity   
13. Clinical lymph node status     
14. AJCC staging         
15. Molecular Subtyping 
a. Estrogen receptor (positive/negative, %) 
b. Progesterone receptor (positive/negative, %)      
c. Human epidermal growth factor (HER2) 
(positive/negative, rating) 
 
d. Subtype 
e. Testing specimen 
Outcomes  
16. Surgeon/family doctor referral 
17. Treatment sequencing  
Facility-related Data 
18. Hospital name 
19. Hospital type 
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Appendix F: Data Dictionary 
 
Adherence to an Oncology Clinical Practice Guideline: An Evaluation Plan 
Principal Investigator: Cynthia Higdon 
Variable Name Variable Description Variable Definition 
1. Patients’ MCP 
number 
Hospital medical record 
identifier number 
Twelve-digit medical care 
plan number 
2. Patients’ OPIS 
number 
DHBMCC 2013 medical 
chart identifier number 
Eight-digit DHBMCC 
outpatient medical chart 
number 
3. Patient name Patient identifier  First and last name 
4. Date of birth Patient identifier MM/DD/YYYY 
5. Patient age Age at initial diagnosis Actual age in years 
6. Year  Year of initial diagnosis Actual calendar year 
diagnosed (2013 or 2016) 
7. Cancer diagnosis Confirmation of cancer 
diagnosis   
Actual pathology-confirmed 
diagnosis on either needle 
core biopsy or surgically 
excised tumor (invasive 
mammary carcinoma or 
inflammatory breast cancer)  
8. Neoajuvant 
therapy referral 
Referral for neoadjuvant 
consideration 
Whether the patient was 
referred to the medical 
oncology service for 
evaluation and consideration 
of neoadjuvant therapy;  
May be referred by surgeon or 
family doctor;  
Also considered referred if 
physician discussed case with 
a medical oncologist prior to 
surgical treatment; 
This is considered as either 
referred or not referred 
9. Treatment 
sequence 
Treatment sequencing 
received by patient 
Actual treatment sequencing 
defined as either neoadjuvant 
(systemic therapy before 
definitive surgery) or adjuvant 
(definitive surgery before 
systemic therapy) 
10. Size of tumor Measurement of largest tumor 
foci  
Actual measurement in 
millimeters (mm) of largest 
on tumor foci on palpation, 
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Variable Name Variable Description Variable Definition 
imaging or surgically excised 
tumor  
11. Tumor histology Type of breast cancer cell by 
location or notable feature 
Identified as ductal, lobular, 
mixed (both ductal and 
lobular), medullary, 
mucinous, papillary, 
metaplastic, cribiform, 
sarcomatous, and 
inflammatory   
12. Tumor grade Description of the nature of 
the tumor cells 
Denotes how closely the 
tumor cells appear in 
comparison to a normal breast 
cell (grade 1: well 
differentiated, grade 2: 
moderately differentiated, 
grade 3: poorly differentiated, 
or unknown: unable to assess) 
13. Tumor laterality Tumor involvement in one or 
both breasts 
Pathological confirmation of 
tumor involvement isolated to 
one breast or in both breasts 
(unilateral or bilateral)  
14. Tumor focality 
and/or 
multicentricity 
Confirmation of number and 
location of tumor foci 
Pathological or radiological 
confirmation of one or more 
tumor foci in one quadrant of 
the breast (unifocal or 
multifocal) or more than one 
quadrant of the breast 
(multicentric) 
15. Clinical lymph 
node status 
Clinical assessment of lymph 
node involvement  
Pathological confirmation of 
surrounding lymph nodes 
which are, or radiologically 
appear to be, positive for 
tumor spread (negative or 
positive) 
16. Chest wall and/or 
skin involvement 
Tumor involvement of the 
chest wall and/or skin 
Clinical, radiological or 
pathological evidence of 
tumor invasion into the chest 
wall and/or the skin (yes or 
no) 
17. AJCC stage Staging of disease by the 
American Joint Committee on 
Cancer 
Clinical or pathological 
staging by TNM, where T is 
the tumor size in greatest 
dimension, Where N is the 
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Variable Name Variable Description Variable Definition 
level of lymph node 
involvement, and M is the 
presence or absence of distant 
metastases as per the AJCC 
staging manual in the 
appendix. 
18. Estrogen receptor 
(ER) and/or 
progesterone 
receptor (PR) 
Pathological detection of 
hormone receptors on surface 
of tumor cells 
The presence of hormone 
receptors stimulates tumor 
cell growth;  
Presented has a percentage of 
pathologically detected cells 
with hormone receptors (0 to 
100%): tumor cells with ≤ 
10% staining considered 
negative, and those with > 
10% staining considered 
positive; 
Use of antihormonal therapy 
may be warranted 
19. Human epidermal 
growth factor 
receptor 2 (HER2 
neu) 
Pathological detection of an 
over-amplification of the 
HER2 neu receptor on 
surface of tumor cells 
The presence of an over-
amplification of HER2 neu 
receptors stimulates tumor 
cell growth; 
Presented as either HER2 1+ 
as a negative result and HER2 
3+ as a positive result, while a 
HER2 2+ is an equivocal 
result which must undergo 
further testing (with FISH, 
CISH, or dual ISH tests to 
obtain one of the two initial 
results);   
Use of the monoclonal 
antibody, Herceptin may be 
warranted 
20. Molecular 
subtype 
The presence or absence of 
receptors on the cell surface 
which stimulate tumor cell 
growth; use of 
pharmaceutical intervention 
may be warranted  
There are four common 
molecular subtypes of breast 
cancer which have been 
reduced to three types for this 
study: 
• Luminal A or B (presence 
of hormone receptors on 
the surface of the tumor 
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Variable Name Variable Description Variable Definition 
cells with or without the 
presence of an over-
amplification of HER2 
neu); 
• HER2 neu Positive 
(absence of hormone 
receptors but presence of 
an over-amplification of 
HER2 neu); and  
• Triple Negative (absence 
of hormone receptors and 
HER2 neu receptor 
amplification). 
21. Molecular testing 
specimen 
Specimen used for molecular 
testing 
The tissue specimen used to 
test for ER, PR and HER2 neu 
receptors (needle core biopsy 
specimen or post surgically 
excised tumor specimen)  
22. Hospital name Hospital facility Name of hospital facility 
where definitive surgery was 
performed which provides the 
location of the facility as well 
23. Hospital type By size and affiliation Define the hospital has from a 
small, medium or large urban 
or small rural area; 
Also define has university-
affiliated or community 
hospital 
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Appendix G: Cancer Registry Coding Guides 
Breast 
CS Tumor Size 
 
• Note 1: Code the specific tumor size as documented in the medical record. If 
the only information regarding tumor size is the physician's statement of the T 
category, assign code 990 (T1mi), 991 (T1b), 992 (T1 or T1c), or 995 (T2). If 
the physician's statement of the T category is T1a with no documentation of 
tumor size, code tumor size as 005. If the physician's statement of the T 
category is T3 with no documentation of tumor size or a statement specifying 
only that the tumor size is greater than 5 cm, code tumor size as 051. 
 
• Note 2: When coding pathologic size, code the measurement of the invasive 
component. For example, if there is a large in situ component (e.g., 4 cm) and 
a small invasive component, see CS Site-Specific Factor 6 to code more 
information about the reported tumor size. If the size of invasive component is 
not given, code the size of the entire tumor and record what the size value 
represents in CS Site-Specific Factor 6. Note that some breast cancers cannot 
be sized pathologically 
 
• Note 3: Microinvasion is the extension of cancer cells beyond the basement 
membrane into the adjacent tissues with no focus more than 0.1 cm in greatest 
dimension. When there are multiple foci of microinvasion, the size of only the 
largest focus is used to classify the microinvasion. (Do not use the sum of all 
the individual foci.) 
 
Code Description 
000 No mass/tumor found 
 
001-988 001 - 988 millimeters (mm)  
(Code exact size in mm) 
 
989 989 mm or larger 
 
990 Microinvasion 
Microscopic focus or foci only and no size given 
Described as "less than 1 mm" 
 
Stated as T1mi with no other information on tumor size 
991 Described as "less than 1 centimeter (cm)" 
 
Stated as T1b with no other information on tumor size 
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List of Schemas Breast Schema Index 
 
HER 2 neu Value  ER/PR 
00 IHC1+  01 Positive 
01 IHC2+  02 Negative 
02 IHC3+    
03 IHC-  Blank 
Fields 
No data 
available 04 FISH+  
05 FISH-    
06 CISH+    
07 CISH-  T Size mm 
08 SISH+    
09 SISH-  999 unknown 
10 Dual ISH+    
 
  
992 Described as "less than 2 cm," or "greater than 1 cm," or 
"between 1 cm and 2 cm" 
 
Stated as T1 [NOS] or T1c [NOS] with no other information on 
tumor size 
993 
 
Described as "less than 3 cm," or "greater than 2 cm," or 
"between 2 cm and 3 cm" 
994 Described as "less than 4 cm," or "greater than 3 cm," or 
"between 3 cm and 4 cm" 
995 Described as "less than 5 cm," or "greater than 4 cm," or 
"between 4 cm and 5 cm" 
 
Stated as T2 with no other information on tumor size 
996 Mammographic/xerographic diagnosis only, no size given; 
clinically not palpable 
997 Paget disease of nipple with no demonstrable tumor 
998 Diffuse 
999 Unknown; size not stated 
Size of tumor cannot be assessed 
Not documented in patient record 
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Breast 
CS Lymph Nodes 
 
Note 1: Code only regional nodes and nodes, NOS, in this field. Distant nodes 
such as cervical (excluding supraclavicular) or contralateral axillary are coded in 
CS Mets at DX.  
 
Note 2: Micrometastases are defined as tumor deposits greater than 0.2 
millimeter (mm) but not greater than 2.0 mm in largest dimension. 
Macrometastases are tumor deposits greater than 2.0 mm. All nodes with at least 
micrometastases are included in the count of positive lymph nodes, but at least 
one node must contain a macrometastasis for assignment of a pathologic N 
category greater than pN1mi. 
 
Note 3: If the pathology report indicates that nodes are positive, but size of the 
metastases is not stated, assume the metastases are greater than 0.2 mm and 
code the lymph nodes as positive in this field. Use code 600 in the absence of 
other information about regional nodes.  
 
Note 4: In a physical exam if palpable nodes are not described as fixed or 
matted, assume that nodes are movable. 
 
Note 5: Codes 130-600 refer to level I and level II ipsilateral axillary lymph nodes 
and ipsilateral intramammary nodes only. Ipsilateral level Ill axillary lymph nodes, 
which are also known as infraclavicular or apical nodes, are coded 750 or higher. 
Axillary lymph nodes do not include internal mammary or ipsilateral 
supraclavicular lymph nodes.  
 
Note 6: For the breast schema, the choice of the N category is dependent on the 
CS Lymph Nodes Eval field. There are certain CS Lymph Nodes codes that can 
only be used if the nodes are evaluated clinically (CS Lymph Nodes Eval is coded 
0, 1, 5, or 9), which will be designated as "Evaluated clinically:" at the beginning 
of the code description. Similarly, there are certain CS Lymph Nodes codes that 
can only be used if the nodes are evaluated pathologically (CS Lymph Nodes 
Eval is coded 2, 3, 6, or 8), and these will be designated as "Evaluated 
pathologically:". All other codes can be used for clinical or pathologic evaluation. 
 
Note 7: Isolated tumor cells (lTC) are defined as single tumor cells or small 
clusters not greater than 0.2 mm, usually detected only by immunohistochemical 
(IHC) or molecular methods but which may be verified on hematoxylin and eosin 
(H and E) stains. ITCs do not usually show evidence of malignant activity (e.g., 
proliferation or stromal reaction). Lymph nodes with ITCs only are not considered 
positive lymph nodes. If the record only states N0(i+), code to 000 and see CS 
Site-Specific Factor 4. 
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Code Description TNM 7 
Map 
TNM 6 
Map 
SS77 Map SS2000 
Map 
000 
No regional lymph node 
involvement OR isolated 
tumor cells (ITCs) detected 
by 
immunohistochemistry/ 
immunohistochemical: 
(IHC) methods or 
molecular methods 
ONLY. 
(See Note 7 and CS Site-
Specific Factors 4 and 5) 
^ . * NONE NONE 
050 
Evaluated pathologically: 
None; no regional lymph node 
involvement 
 
BUT ITCs detected on routine 
hematoxylin and eosin (H and 
E) stains. 
(See Note 7) 
N0(i+) N0(i+) NONE NONE 
130 
Evaluated pathologically: 
 
Axillary lymph node(s), 
ipsilateral,              
micrometastasis ONLY 
detected by IHC ONLY 
 
(At least one micrometastasis 
greater than 
0.2 mm or more than 200 cells 
AND all micrometastases less 
than or equal to 2 mm) 
N1mi N1mi RN RN 
150 
Evaluated pathologically: 
Axillary lymph node(s), 
ipsilateral, 
micrometastasis ONLY 
detected or verified 
on H&E 
(At least one micrometastasis 
greater than 
0.2 mm or more than 200 cells ' 
AND all micrometastases less 
than or 
equal to 2 mm) 
 
Micrometastasis, NOS 
N1mi N1mi RN RN 
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Code Description TNM 7 
Map 
TNM 6 
Map 
SS77 Map SS2000 
Map 
155 
Evaluated pathologically: 
 
Stated as N1mi with no other 
information on regional lymph 
nodes 
N1mi N1mi RN RN 
250 
Evaluated pathologically: 
 
Movable axillary lymph 
node(s), ipsilateral, positive 
with more than 
micrometastasis 
(At least one metastasis 
greater than 2 mm) 
(See Note 4) 
 
 
^^ 
 
 
** 
 
 
RN 
 
 
RN 
255 
Evaluated pathologically: 
 
Clinically movable axillary 
lymph node(s), ipsilateral, 
positive 
(Clinical assessment because 
of 
neoadjuvant therapy or no 
pathology) 
(See Note 4) 
N1 N1 RN RN 
257 
Evaluated pathologically: 
 
Clinically stated only as N1 
(Clinical assessment because 
of neoadjuvant therapy or no 
pathology) 
N1 N1 RN RN 
258 
Evaluated pathologically: 
 
Pathologically stated only as 
N1 [NOS], no 
information on which nodes 
were involved 
^^ ** RN RN 
260 
Stated as N1 [NOS] with no 
other information on regional 
lymph nodes 
^^ ** RN RN 
280 
OBSOLETE DATA RETAINED 
V0104 
 
Stated as N2, NOS 
ERROR ** RN RN 
290 
OBSOLETE DATA 
CONVERTED V0203 
See code 610 
 
Clinically stated only as N2, 
ERROR ERROR ERROR ERROR 
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Code Description TNM 7 
Map 
TNM 6 
Map 
SS77 Map SS2000 
Map 
NOS (clinical 
assessment because of 
neoadjuvant 
therapy or no pathology) 
300 
OBSOLETE DATA 
CONVERTED V0203 
See code 620 
 
Pathologically stated only as 
N2, NOS; no 
information on which nodes 
were involved 
ERROR ERROR ERROR ERROR 
500 
OBSOLETE DATA RETAINED 
V0104 
 
Fixed/matted ipsilateral axillary 
nodes, 
positive with more than 
micrometastasis  
(i.e., at least one metastasis 
greater than 2 mm) 
 
Fixed/matted ipsilateral axillary 
nodes, 
NOS 
ERROR  ** RN RN 
510 
Evaluated clinically: 
 
Fixed/matted ipsilateral axillary 
nodes 
Clinically 
(Clinical assessment because 
of neoadjuvant therapy or no 
pathology) 
 
Stated clinically as N2a 
(Clinical 
assessment because of 
neoadjuvant 
therapy or no pathology) 
^^ ** RN RN 
520 
Evaluated pathologically: 
 
Fixed/matted ipsilateral axillary 
nodes clinically with pathologic 
involvement of lymph nodes 
WITH at least one metastasis 
greater than 2mm 
 
^^ ** RN RN 
600 Axillary/regional lymph ^^ ** RN RN 
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Code Description TNM 7 
Map 
TNM 6 
Map 
SS77 Map SS2000 
Map 
node(s), NOS 
Lymph nodes, NOS 
610 
Evaluated clinically: 
 
Clinically stated only as N2 
[NOS] 
(Clinical assessment because 
of 
neoadjuvant therapy or no 
pathology) 
^^ ** RN RN 
620 
Evaluated path0l0gically: 
 
Pathologically stated only as 
N2 [NOS]; no information on 
which nodes were involved 
^^ ** RN RN 
630 
Stated as N2 [NOS] with no 
other 
information on regional lymph 
nodes 
 
^^ ** RN RN 
710 
Evaluated pathologically: 
 
Internal mammary node(s), 
ipsilateral, positive on sentinel 
nodes but not clinically 
apparent 
(No positive imaging or clinical 
exam) 
WITHOUT axillary lymph 
node(s), ipsilateral 
N1b N1b RN RN 
720 
Evaluated pathologically: 
 
Internal mammary node(s), 
ipsilateral, positive ·on sentinel 
nodes but not clinically 
apparent 
(No positive imaging or clinical 
exam) 
WITH axillary lymph node(s), 
ipsilateral 
 
^^ ** RN RN 
730 
Evaluated pathologically: 
 
Internal mammary node(s), 
ipsilateral, positive on sentinel 
nodes but not clinically 
apparent (No positive imaging 
or clinical exam) 
N1b N1b RN RN 
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Code Description TNM 7 
Map 
TNM 6 
Map 
SS77 Map SS2000 
Map 
UNKNOWN if positive axillary 
lymph node 
(s), ipsilateral 
 
735 
Evaluated clinically: 
 
Internal mammary node(s), 
ipsilateral, positive on sentinel 
nodes but primary not resected 
WITHOUT axillary lymph 
node(s), ipsilateral OR 
UNKNOWN if positive axillary 
lymph node(s) 
N2b N2b RN RN 
740 
Internal mammary node(s), 
ipsilateral, clinically apparent 
(On imaging or clinical exam) 
WITHOUT axillary lymph 
node(s), ipsilateral 
N2b N2b RN RN 
745 
Internal mammary node(s), 
ipsilateral, 
clinically apparent 
(On imaging or clinical 
exam) 
UNKNOWN if positive 
axillary lymph node 
(s), ipsilateral 
N2b N2b RN RN 
748 
Stated as N2b with no 
other information on 
regional lymph nodes 
^^ ** RN RN 
750 
Infraclavicular lymph 
node(s) 
(subclavicular) (level Ill 
axillary nodes) (apical), 
ipsilateral  
WITH or WITHOUT axillary 
nodes(s) 
WITHOUT internal 
mammary node(s) 
 
N3a N3a D RN 
755 
Stated as N3a with no 
other information on 
regional lymph nodes 
N3a N3a D RN 
760 OBSOLETE DATA RETAINED AND N3b N3b RN RN 
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Code Description TNM 7 
Map 
TNM 6 
Map 
SS77 Map SS2000 
Map 
REVIEWED V0203 
See codes 763 and765 
Internal mammary node(s), 
ipsilateral, clinically 
apparent (on imaging or 
clinical exam) 
WITH axillary lymph 
node(s), ipsilateral, codes 
150 to 600 
WITH or WITHOUT 
infraclavicular (Ievel III 
axillary nodes) (apical) 
lymph nodes 
 
763 
Internal mammary node(s), 
ipsilateral, 
clinically apparent 
(On imaging or clinical 
exam). 
WITH axillary lymph 
node(s), ipsilateral, codes 
150 to 600  
WITHOUT infraclavicular 
(level Ill axillary 
nodes) (apical) lymph 
nodes or unknown if 
infraclavicular (level Ill 
axillary nodes) ;' 
(apical) lymph nodes 
involved 
 
N3b N3b RN RN 
764 
Internal mammary node(s), 
ipsilateral, clinically 
apparent 
(On imaging or clinical 
exam)  
WITHOUT axillary lymph 
node(s), ipsilateral 
WITH infraclavicular (level 
Ill axillary 
nodes) (apical) lymph 
nodes involved 
N3b N3b D RN 
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Code Description TNM 7 
Map 
TNM 6 
Map 
SS77 Map SS2000 
Map 
765 
Internal mammary node(s), 
ipsilateral, 
clinically apparent 
(On imaging or clinical 
exam) 
WITH axillary lymph 
node(s), ipsilateral WITH 
infraclavicular (level Ill 
axillary 
nodes) (apical) lymph 
nodes involved 
N3b N3b D RN 
768 
Stated as N3b with no 
other information on 
regional lymph nodes 
N3b N3b RN RN 
770 
OBSOLETE DATA 
RETAINED V0200 
Internal mammary node(s), 
ipsilateral, clinically 
apparent (on imaging or 
clinical exam) 
UNKNOWN if positive 
axillary lymph node 
(s), ipsilateral 
ERROR N2b RN RN 
780 
OBSOLETE DATA 
RETAINED V0200 
 
(750) + (770) 
ERROR N3a D RN 
790 
OBSOLETE DATA 
CONVERTED V0203 
See code 820 
 
Stated as N3, NOS 
ERROR ERROR ERROR ERROR 
800 Supraclavicular node(s), ipsilateral N3c N3c D D 
805 
Stated as N3c with no 
other information on 
regional lymph nodes 
N3c N3c D D 
810 
Evaluated clinically: 
 
Clinically stated only as N3 
[NOS] (Clinical 
assessment because of 
N3NOS N3NOS RN RN 
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Code Description TNM 7 
Map 
TNM 6 
Map 
SS77 Map SS2000 
Map 
neoadjuvant therapy or no 
pathology) 
815 
Evaluated pathologically: 
 
Pathologically stated only 
as N3 [NOS]; no 
information on which 
nodes were involved 
N3NOS N3NOS RN RN 
820 
Stated as N3, NOS with no 
other information on 
regional lymph nodes 
N3NOS N3NOS RN RN 
999 
Unknown; regional lymph 
nodes not stated 
Regional lymph node(s) 
cannot be assessed Not 
documented in patient 
record 
NX NX U U 
 
^For CS Lymph Nodes code 000 ONLY, the N category is assigned based on the 
coding of CS Site-Specific Factors 4 and 5 using the IHC MOL Table for this 
schema. 
 
^^For CS Lymph Nodes codes 250, 258, 260, 510, 520, 600, 610, 620, 630, 720, 
and 748 ONLY, the N category is assigned based on the values of CS Lymph 
Nodes Eval and CS Site-Specific Factor 3 (Number of Positive Ipsilateral Axillary 
Lymph Nodes). If the CS Lymph Nodes Eval code is 2(p), 3(p), 6(yp), or 8(a), the 
N category is determined by reference to the Lymph Nodes Pathologic Evaluation 
Table. If the CS Lymph Nodes Eval code is 0(c), 1(c), 5(c), or 9(c), the N category 
is determined by reference to the Lymph Nodes Clinical Evaluation Table. If the 
CS Lymph Nodes Eval field is not coded, the N category is determined by 
reference to the Lymph Nodes Positive Axillary Node Table. 
 
*For CS Lymph Nodes code 000 ONLY, the N category is assigned based on the 
coding of CS Site-Specific Factors 4 and 5 using the IHC MOL Table for this 
schema. 
 
**For CS Lymph Nodes codes 250, 258, 260, 280, 500, 510, 520, 600, 610, 620, 
630, 720, and 748 ONLY, the N category is assigned based on the values of CS 
Lymph Nodes Eval and CS Site-Specific Factor 3 (Number of Positive Ipsilateral 
Axillary Lymph Nodes). If the CS Lymph Nodes Eval code is 2(p), 3(p), 6(yp), or 
8(a), the N category is determined by reference to the Lymph Nodes Pathologic 
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Evaluation Table. If the CS Lymph Nodes Eval code is 0(c), 1(c), 5(c), or 9(c), the 
N category is determined by reference to the Lymph Nodes Clinical Evaluation 
Table. If the CS Lymph Nodes Eval field is not coded, the N category is 
determined by reference to the Lymph Nodes Positive Axillary Node Table. 
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Breast 
CS Lymph Nodes Eval 
 
• Note 1: This field is used primarily to derive the staging basis for the N category 
in the TNM system. It records how the code for the item "CS Lymph Nodes" 
was determined based on the diagnostic methods employed and their intent.   
 
• Note 2: In the 7th edition of the AJCC manual, the clinical and pathologic 
classification rules for the N category were changed to reflect current medical 
practice. The N is designated as clinical or pathologic based on the intent 
(workup versus treatment) matching with the assessment of the T classification. 
When the intent is workup, the staging basis is clinical, and when the intent is 
treatment, the staging basis is pathologic.  
 
A. Microscopic assessment including biopsy of regional nodes or sentinel 
nodes if being performed as part of the workup to choose the treatment 
plan, is therefore part of the clinical staging. When it is part of the 
workup, the T category is clinical, and there has not been a resection of 
the primary site adequate for pathologic T classification (which would be 
part of the treatment). 
 
B. Microscopic assessment of regional nodes if being performed as part of 
the treatment is therefore part of the pathologic staging. When it is part 
of the treatment, the T category is pathologic, and there has been a 
resection of the primary site adequate for pathologic T classification (all 
part of the treatment).  
 
• Note 3: Microscopic assessment of the highest N category is always pathologic 
(code 3).  
 
• Note 4: If lymph node dissection is not performed after neoadjuvant therapy, 
use code 0 or 1. 
 
• Note 5: Only codes 5 and 6 are used if the node assessment is performed after 
neoadjuvant therapy. 
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Code Description Staging Basis 
0 
Does not meet criteria for AJCC ·pathologic 
staging: 
 
No regional lymph nodes removed for examination. Evidence 
based on physical examination, imaging examination, or other 
non-invasive 
clinical evidence. No autopsy evidence used. 
c 
1 
Does not meet criteria for AJCC pathologic staging based on at 
least one of the following criteria: 
 
No regional lymph nodes removed for examination. Evidence 
based on endoscopic examination, or other invasive techniques 
including surgical observation, without biopsy. No autopsy 
evidence used. 
OR 
Fine needle aspiration, incisional core needle biopsy, or 
excisional biopsy of regional lymph nodes or sentinel nodes as 
part of the diagnostic workup, WITHOUT removal of the primary 
site adequate for pathologic T classification (treatment). 
c 
2 
Meets criteria for AJCC pathologic staging: 
 
No regional lymph nodes removed for examination, but 
evidence derived from autopsy (tumor was suspected or 
diagnosed prior to autopsy). 
p 
3 
Meets criteria for AJCC pathologic staging based 
on at least one of the following criteria: 
 
Any microscopic assessment of regional nodes 
(including FNA, incisional core needle bx, 
excisional bx, sentinel node bx or node resection),  
WITH removal of the primary site adequate for pathologic T 
classification·(treatment) or biopsy assessment of the highest T 
category. 
OR 
Any microscopic assessment of a regional node in the highest 
N category, regardless of the T category information. 
 
p 
5 
Does not meet criteria for AJCC y-pathologic (yp) 
staging: 
 
Regional lymph nodes removed for examination 
AFTER neoadjuvant therapy AND lymph node evaluation based 
c 
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Code Description Staging Basis 
on clinical evidence, unless the pathologic evidence at surgery 
(AFTER neoadjuvant) is more extensive (see code 6). 
6 
Meets criteria for AJCC y-pathologic (yp) staging: 
 
Regional lymph nodes removed for examination AFTER 
neoadjuvant therapy AND lymph node evaluation based on 
pathologic evidence, because the pathologic evidence at 
surgery is more extensive than clinical evidence before 
treatment. 
yp 
8 
Meets criteria for AJCC autopsy (a) staging:  
 
Evidence from autopsy; tumor was unsuspected 
or undiagnosed prior to autopsy. 
a 
9 
Unknown if lymph nodes removed for examination 
 
Not assessed; cannot be assessed 
Unknown if assessed 
Not documented in patient record  
c 
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Appendix H: Health Research Ethics Authority Screening Tool  
 Question Yes   No 
1. Is the project funded by, or being submitted to, a research funding 
agency for a research grant or award that requires research ethics 
review? 
    
2. Are there any local policies which require this project to undergo 
review by a Research Ethics Board? 
    
 IF YES to either of the above, the project should be submitted to a 
Research Ethics Board. 
IF NO to both questions, continue to complete the checklist. 
 
    
3. Is the primary purpose of the project to contribute to the growing body 
of knowledge regarding health and/or health systems that are generally 
accessible through academic literature? 
 
    
4. Is the project designed to answer a specific research question or to test 
an explicit hypothesis? 
    
5. Does the project involve a comparison of multiple sites, control sites, 
and/or control groups? 
    
6. Is the project design and methodology adequate to support 
generalizations that go beyond the particular population the sample is 
being drawn from? 
    
7. Does the project impose any additional burdens on participants beyond 
what would be expected through a typically expected course of care or 
role expectations? 
 
    
LINE A: SUBTOTAL Questions 3 through 7 = (Count the # of Yes responses) 0 7 
8. Are many of the participants in the project also likely to be among those 
who might potentially benefit from the result of the project as it 
proceeds? 
  
 
 
 9. Is the project intended to define a best practice within your organization 
or practice? 
   
  10. Would the project still be done at your site, even if there were no 
opportunity to publish the results or if the results might not be 
applicable anywhere else? 
   
  11. Does the statement of purpose of the project refer explicitly to the 
features of a particular program, organization, or region, rather than 
using more general terminology such as rural vs. urban populations? 
   
12
. 
Is the current project part of a continuous process of gathering or 
monitoring data within an organization? 
  
LINE B: SUBTOTAL Questions 8 through 12 = (Count the # of Yes responses) 4 1 
 SUMMARY 
See Interpretation Below:  Line B = 4   >  Line A = 0  Quality/Evaluation 
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• If the sum of Line A is greater than Line B, the most probable purpose is research. The 
project should be submitted to an REB. 
• If the sum of Line B is greater than Line A, the most probable purpose is 
quality/evaluation. Proceed with locally relevant process for ethics review (may not 
necessarily involve an REB). 
• If the sums are equal, seek a second opinion to further explore whether the project should be 
classified as Research or as Quality and Evaluation. 
These guidelines are used at Memorial University of Newfoundland and were 
adapted from ALBERTA RESEARCH ETHICS COMMUNITY CONSENSUS 
INITIATIVE (ARECCI).  Further information can be found 
at: http://www.hrea.ca/Ethics-Review-Required.aspx. 
NOTE: Since the YES answers are greater in Line B (4) than those in Line A (0), 
this indicates that this practicum project is likely to be a Quality Initiative or 
Evaluation Project.  
 
 
NOTE: Since the YES answers are greater in Line B (4) than those in Line A 
(0), this indicates that this practicum project is likely to be a Quality Initiative or 
Evaluation Project. 
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ADHERENCE TO AN EASTERN HEALTH NEOADJUVANT 
BREAST CANCER CLINICAL PRACTICE GUIDELINE 
 
Background 
In the fall of 2017 during a regularly scheduled monthly meeting, concerns were being 
raised by some members of the Eastern Health Breast Disease Site Group (BDSG). The 
concerns brought forth were regarding whether breast cancer patients, eligible for 
neoadjuvant therapy, were being appropriately referred to the medical oncology discipline 
by their surgeons. Neoadjuvant therapy is the standard of care for patients diagnosed with 
locally advanced breast cancer (LABC) or inflammatory breast cancer (IBC), and is 
recommended by the Eastern Health BDSG clinical practice guideline “Neoadjuvant 
Treatment of Primary Breast Cancer”. This clinical practice guideline was approved in 
July 2014 and disseminated to all surgeons who perform breast surgery in the province of 
Newfoundland and Labrador (NL). 
 
An active member of the BDSG, I am presently employed in the position of Clinical 
Practice Guideline Coordinator at the Dr. H. Bliss Murphy Cancer Center (DHBMCC). 
As part of the fulfillment of the requirements of the Master of Nursing Program at the 
Graduate School of Nursing, I had offered the BDSG the opportunity to use my practicum 
as a means with which to assess adherence to an Eastern Health pre-existing clinical 
practice guideline. The membership decided that a study should be conducted to evaluate 
the proportion of patients, eligible for neoadjuvant therapy, who received a referral to 
medical oncology and whether any change had occurred since the dissemination of 
guideline. 
 
Three approaches were used to gather the information required to carry out this program 
evaluation. A comprehensive literature review was conducted, consultations were carried 
out with key individuals with expertise in their fields, and an extensive retrospective chart 
review was performed. The full report prepared for this evaluation project is available in 
the Memorial University Health Sciences Library research repository.  
 
The program director of the NL Cancer Care Program granted permission for conducting 
this program evaluation project and access to patient information from the medical charts 
of the DHBMCC and the NL Cancer Registry database.  
 
Literature Review 
A comprehensive literature review was performed to obtain research evidence on the use 
of neoadjuvant therapy, adherence to clinical practice guidelines and factors that may 
affect the surgeons’ decision to refer. Four research studies related specifically to 
neoadjuvant therapy and guideline adherence, as well as 35 general breast cancer-related 
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studies about guideline adherence, were obtained. The four neoadjuvant studies provided 
the evidence for a range of neoadjuvant referral rates for both cohorts of interest. The 
evidence suggested that the rate of neoadjuvant referrals for those with LABC was in the 
range of 44% to 79%, while the rate for those with IBC was in the range of 72% to 
93%.1,2,3,4  
 
Additional information acquired from these literature reviews included strategies to 
improve the rigor and internal validity of this evaluation project; variables of interest 
which may influence the decision-making process including patient demographics, tumor 
characteristics, and facility type and location; and suggestions for variable measurement. 
Though a preliminary list of variables of interest were identified at this stage, adjustments 
were made to the list to accommodate data availability during the chart review process.   
 
The outcomes of interest were the referral rates pre and post guideline dissemination 
according to diagnosis and study period and which patient/tumor/facility-related variables 
impacted the surgeons’ decision to pursue a medical oncology referral.  
            
Consultations 
An interview with two medical oncologists provided necessary information to finalize the 
eligibility criteria for the study, which were based on the definitions used in the BDSG 
guideline. The IBC cohort is a T4 subtype of LABC and is reported separately due to its 
distinct aggressive biology and clinical presentation. The LABC cohort were categorized 
as having at least one of three characteristics:  
 
• at least one tumor having a size greater than 5cm;  
• the presence of clinically palpable, or radiological imaging, of ipsilateral axillary 
lymph nodes or ipsilateral internal mammary nodes in keeping with at least level II 
lymph nodes (N2); or 
• breast cancer stages of either IIB (T3 N0 M0 only), or any stage III.  
 
An interview with a surgeon provided additional information on the various factors or 
variables which can affect the decision to refer the patient for neoadjuvant consideration 
or proceed to primary surgical options. Some of these variables included patient 
demographics such as age, health status and co-morbidities, interest in breast 
conservation therapy; several tumor characteristics such as tumor size, histology, grade 
and molecular subtype; and the type of facility, either a university-affiliated hospital or 
community-based hospital. 
 
After the consultation with the director of the NL Cancer Registry, the study time periods 
of interest were defined as the full calendar year of 2013 and 2016, representing the pre 
and post dissemination phases. The interview also provided beneficial information on the 
identification of the various data sources required depending on the study year. The 
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interview with the ARIA computer support person was helpful in providing the necessary 
training for collecting the data from this system. 
     
Chart Review 
Methods 
 
The patient data were extracted from the NL Cancer Registry by the registry director and 
I extracted any remaining data of interest from the chart review. All data were 
documented into Excel spreadsheets and any analysis was conducted in Excel. This 
project was determined to be a program evaluation for quality improvement purposes and 
therefore exempt from Health Research Ethics Board review.  
  
Results and Discussion 
 
The Cancer Registry provided data on 113 patient cases in 2013 and 133 in 2016. Sixty-
six cases were ineligible in the 2013 sample and 79 were ineligible in the 2016 sample. 
The reasons for ineligibility included cases with metastatic disease, inappropriate cancer 
stages, and male cases. In 2013, the final sample consisted of four cases of IBC and 43 
cases of LABC while in 2016, there were two cases of IBC and 52 cases of LABC.  
 
All six cases of IBC in 2013 and 2016 were referred to medical oncology for neoadjuvant 
therapy. Though the sample numbers were very small, these results suggest that surgeons 
referred 100% of the IBC cases for neoadjuvant treatment at least for the two years 
studied. 
         
The referral rates were calculated for all patient cases diagnosed with LABC and an 
additional analysis was conducted for a subset of the LABC sample, the patient cases 
with T3 and T4 tumors. The T3/T4 subgroup, by definition, automatically should have 
been referred by their surgeon for neoadjuvant therapy and therefore was felt to reflect a 
more meaningful referral rate than that obtained for all LABC cases. Table 1 summarizes 
the referral rates for both the LABC group and T3/T4 subgroup. The referral rate for all 
LABC patient cases was 23.3% in 2013 and 26.9% in 2016 while the referral rate for the 
T3/T4 subset was 66.7% in 2013 and 61.1% in 2016. The referral rate for all LABC cases 
was much lower than the range identified from the literature of 44% to 79% while the rate 
for the T3/T4 tumors falls within it. Nevertheless, nearly 40% of the eligible T3/T4 
patient cases of the LABC population were not referred to medical oncology for a 
discussion regarding neoadjuvant therapy in 2016.   
 
These results also indicated that there was little or no difference in referral rates between 
pre- and post-guideline dissemination which indicates that the BDSG guideline has had 
little effect on the number of patients being referred for neoadjuvant consideration. 
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Table 1: Number and Proportion of All Patients with T3/T4 Tumors and All Locally 
Advanced Breast Cancers (LABC) According to Referral Status in 2013 and 2016  
 
Locally 
Advanced  
Breast Cancer 
2013 
N = 43 
Total 
n (%) 
2016 
N = 52 
Total 
n (%) 
Referred 
n (%) 
Not 
Referred 
n (%) 
Referred 
n (%) 
Not 
Referred 
n (%) 
All 10 
(23.3%) 
33 
(76.7%) 
43 
(100%) 
14 
(26.9%) 
38 
(73.1%) 
52 
(100%) 
 T3 5(55.6%) 3(33.3%)  
9 
(20.9%
) 
9(50.0%) 
 
6(33.3%)  
18 
(34.6%) T4 1(11.1%) 0(0) 2(11.1%) 
 
1(5.6%) 
                                    
                                                                                                                                                                                                
A final analysis was conducted on the T3/T4 subgroup in 2016 to investigate whether any 
of the variables studied appear to have influenced the surgeons’ decision to refer. The 
small sample size prevented the use of multivariable analysis to determine whether any of 
the chosen independent variables were positively associated with the likelihood of being 
referred. However, several trends were identified in the data which indicated that certain 
subsets of the T3/T4 subgroup seemed more likely to be referred for neoadjuvant 
consideration. Table 2 summarizes only those variables which appeared to demonstrate 
trends in the T3/T4 data. These subsets consisted of younger patients, those surgically 
treated at university-affiliated hospitals, positive lymph node involvement, a clinical 
diagnosis of Stage IIIA and IIIC breast cancers, and triple negative subtype.  
 
 
Table 2: Patient/Tumor/Facility-related Variables of Clinical T3/T4 Tumors of LABC by 
Referral Status for 2016  
 
Variables Referred 
n = 11 
Not Referred 
n = 7 
Age Range (in years) Median Age: 54 
Range: 34 to 79 
Median Age: 55 
Range: 33 to 85 
41 – 50 
 
4 
 
1 
 
Facility Type  
Large Urban  
(University-affiliated) 
6 3 
Lymph Node Status   
Positive 11 
 
5 
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Variables Referred 
n = 11 
Not Referred 
n = 7 
AJCC Stage (Clinical or 
Pathological) 
 
Stage IIIA 
 
7 
 
4 
 
Stage IIIC 4 0 
Molecular Subtype  
Triple Negative 6 1 
 
Recommendations 
There is an obvious need to implement measures which are intended to improve the rates 
of neoadjuvant referral and improve outcomes for our eligible patients with LABC, 
especially for those with HER2 positive and tripe negative subtypes. The following are a 
list of recommendations that are for discussion to bring about a positive change in 
compliance rates for surgeons. The recommendations are:  
 
1. Determine measures that can be taken in-house to improve the neoadjuvant referral 
rates such as: 
a. encourage more opportunities for consultation and collaboration;  
b. improve the advertisement regarding tumor boards and how to access them for 
presentation of patient cases;  
c. improve accessibility to a medical oncologist; and 
d. promote receptor testing on needle core biopsy specimens so the surgeon has this 
information at the time of decision-making. 
 
2. Implement measures for professional development and promote a team approach 
among oncologists, surgeons and family physicians to ultimately improve patient care, 
for example: 
a. educational events such as conferences, workshops or written updates of new 
research findings requiring changes in practice; 
b. encourage surgeons to participate in efforts to improve the rate of neoadjuvant 
referral for eligible patients; and 
c. maintain focus on team-building efforts to build consensus and encourage 
collaboration on the appropriate approach.  
 
3. Implement measures to improve the usability and use of the BDSG neoadjuvant 
guideline such as: 
a. conduct a survey for surgeons and family doctors about the BDSG clinical practice 
guidelines;  
b. shorten and simplify the guidelines and use algorithms to clarify decision-making 
options, examples of which are provided in Appendix A and B; and 
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c. re-examine the methods for dissemination of the BDSG guidelines to determine if 
surgeons and family physicians are receiving them.  
 
Conclusion 
 
This practicum project has been successful in evaluating the state of neoadjuvant referrals 
by surgeons in this province. Although the results were less than desirable, it has provided 
the opportunity for the BDSG and the administrative body to help initiate measures which 
can bring about change. It is also clear that measures must be taken to improve the 
effectiveness of our clinical practice guidelines. It will require the input from and 
collaboration between all key stakeholders to create the change needed to improve 
outcomes for our locally advanced and inflammatory breast cancer patients.  
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Appendix A: Diagnostic and Treatment Algorithm for Invasive Breast 
Cancer 
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Legend for the Diagnostic and Treatment Algorithm for Invasive Breast Cancer 
1. Suspicious lesion:  Patients usually enter the oncology system with a suspicious breast 
lesion either through a clinical presentation (found by self or family physician), 
through the breast screening program (finding on routine screening mammogram), or 
through an incidental finding (found on imaging while being investigated for a 
different health issue, such as CT or MRI of chest).  
2. Bilateral mammogram and spot compression views: A bilateral mammogram (if not 
already completed) and a spot compression view will be performed to evaluate the 
suspicious lesion.   
3.  Needle core biopsy under ultrasound (or MRI) guidance: If the lesion is still 
considered to be suspicious at this stage, a needle core biopsy is performed under 
ultrasound-guidance (or MRI-guidance when difficulty visualizing the lesion) in an 
attempt to establish whether the lesion is malignant or benign.   
4. Pathological confirmation of breast cancer: The family physician will often consult a 
surgeon while waiting for the results, or once a pathological diagnosis of breast cancer 
has been confirmed.  
5. CT scan and bone scan: During the first visit, the surgeon will order a CT scan of the 
chest, abdomen and pelvis as well as, a nuclear medicine bone scan to be performed to 
complete the cancer staging. The results of these tests will determine whether the 
patient has: 
6. No evidence of metastatic disease:  See number 6.  
7. Evidence of metastatic disease: If imaging provides evidence of distant metastatic 
spread from the breast cancer primary to the bones or other organs, the surgeon may 
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proceed with a palliative simple mastectomy and/or consult with both medical and 
radiation oncologists to determine the best treatment sequence with a palliative intent 
to alleviate symptoms and extend survival. 
8. No evidence of metastatic disease: If imaging provides no definitive evidence of 
metastatic disease, the surgeon must determine to the best of her/his ability the AJCC 
clinical stage of the cancer. This will help determine whether the patient has in situ 
disease only, or if the patient has invasive disease which is either early stage or locally 
advanced/inflammatory breast cancer.   
a. Early stage breast cancer: If the surgeon determines the patient has early-stage breast 
cancer, then the patient will proceed to undergo adjuvant therapy consisting of 
definitive surgery first, followed by chemotherapy and/or endocrine therapy (for 5-10 
years) post-operatively, followed by chest wall radiation therapy if indicated.  
b. Locally advanced or inflammatory breast cancer: If the surgeon determines the patient 
has locally advanced or inflammatory breast cancer, then the surgeon should refer the 
patient immediately to see a medical oncologist. If warranted, neoadjuvant 
chemotherapy or endocrine therapy will begin quickly, and the tumor will be assessed 
frequently for response. Sufficient tumor response after 4 to 6 cycles will be followed 
by definitive surgery, and then chest wall radiation therapy four week post-operatively. 
If there is little or no tumor response to the first treatment regimen after one or two 
cycles, the treatment can be altered or switched. Endocrine therapy will continue 
following the completion of radiation therapy for five to ten years, as directed.  
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Appendix B: Surgeon’s Decision to Refer Algorithm 
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Legend for Surgeon’s Decision to Refer for Non-Metastatic Invasive Breast Cancer 
1. Surgeon: The surgeon must decide from the clinical, radiological and pathological 
evidence whether the patient has early stage breast cancer or has locally 
advanced/inflammatory breast cancer.  
2a.  Locally advanced breast cancer or inflammatory breast cancer: The surgeon would 
regard those patients with a clinical tumor size of ≥ 5 cm, and/or ≥ clinical N2 lymph 
node involvement, and/or a clinical AJCC stage IIB (T3N0) or any stage III breast 
cancer, with or without a HER2 positive or triple negative subtype on needle core 
biopsy to have locally advanced breast cancer. A patient with a clinical and 
pathological confirmation of inflammatory breast cancer will be regarded so by the 
surgeon. 
2b.  Referral to Medical Oncology: If the patient has been confirmed to have locally 
advanced breast cancer or inflammatory breast cancer as stipulated, the surgeon must 
refer the patient to the medical oncology discipline for a discussion about neoadjuvant 
therapy. The surgeon, using independent medical judgement, may decide to forego the 
neoadjuvant referral only in certain circumstances. One of these circumstances include 
when the patient’s frailty or pre-existing co-morbidities impose an unacceptable 
mortality risk. Another would be when the patient refuses any treatment at all or will 
accept only surgical intervention. The surgeon must advise the patient of the risks of 
refusing some, or all, therapy and assure the patient that should change his/her mind 
the option of referral will still be open though the outcomes may not be assured.  
3a.  Early stage breast cancer with extenuating circumstances: The surgeon would regard 
patients to have early stage breast cancer if the patient had a clinical tumor size of < 
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5cm, and/or clinical N0 or N1 disease, and/or any clinical AJCC stage I or stage II 
(except T3 N0). However, patients with early breast cancer who have extenuating 
circumstances that may require neoadjuvant referral would include those with one or 
more of these clinical findings:  
• a HER2 positive or triple negative subtype on needle core biopsy 
• patient requests breast conserving surgery (BCS) but surgeon is unsure of 
resectability 
• presence of any patient- or tumor-related factor(s) which may motivate the 
surgeon to refer (e.g., young age of patient, questionable clinical tumor size, 
grade 3 tumor, multifocal/multicentric disease). 
3b.  Collaborate with a medical oncologist: If the patient has any of the clinical findings 
listed in 3a, then the surgeon should contact a medical oncologist to present the case 
and come to some consensus of the best treatment sequence to initiate for the benefit 
of the patient.  
4a.  Early stage breast cancer: If the patient has a clinical tumor size of < 5cm, and/or 
clinical N0 or N1 disease, and/or any clinical AJCC stage I or stage II (except T3 N0) 
with or without a luminal subtype on needle core biopsy, then the surgeon must regard 
these cases as early stage breast cancer. 
4b.  Proceed to primary surgery: If the patient has no clinical indications which suggest the 
need for neoadjuvant referral than the surgeon must proceed to perform surgery has the 
primary treatment modality followed by a referral for adjuvant therapy approximately 
4 weeks post-operatively 
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